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Abstract 
Lung cancer is the second common malignancy in both men and women and the leading 
cause of cancer-related deaths worldwide. More than 220,000 individuals are diagnosed 
with a form of lung cancer and over 150,000 patients will die of the disease each year. One 
of the most challenging aspects of lung cancer therapy is the development of multidrug 
resistance and metastatic dissemination to other parts of the body. 
RNA interference has emerged as a powerful strategy in cancer therapy to down-regulate 
specific genes associated with tumor progression and resistance. Mad2 is an essential 
mitotic checkpoint component required for accurate chromosome segregation during 
mitosis, and its complete abolition leads to cell death. However, intracellular delivery of 
small interfering RNA (siRNA) to specific tumor site is a major challenge that needs to be 
overcome before this experimental technique can be routinely used as a clinically viable 
therapeutic strategy. 
 We have developed an epidermal growth factor receptor (EGFR)-targeted chitosan system 
for silencing the Mad2 gene as a strategy to efficiently induce cell death in EGFR 
overexpressing human A549 non-small cell lung cancer cells (NSCLC). EGFR-targeted 
nanoparticles were formulated and characterized for size, charge, morphology, and 
encapsulation efficiency. Qualitative and quantitative intracellular uptake studies by 
confocal imaging and flow cytometry, respectively, showed time-dependent enhanced and 
selective intracellular internalization of EGFR-targeted nanoparticles compared to non-
targeted system. Targeted nanoparticles showed nearly complete depletion of Mad2 
expression in A549 cells contrasting with the partial depletion in the non-targeted system. 
Accordingly, Mad2-silencing induced apoptotic cell death was confirmed by cytotoxicity 
assay and flow cytometry.  
Additionally, the biodistribution of the nanoparticles was assessed qualitatively and 
quantitatively in cisplatin (DDP) sensitive and resistant lung cancer xenograft model. The 
targeted nanoparticles showed a consistent and preferential tumor targeting ability with 
rapid clearance from the plasma to infiltrate and sustain within the tumor up to 96 h. They 
exhibited a 6-fold higher tumor targeting efficiency compared to the non-targeted 
nanoparticles.  
Furthermore, we investigated the in vivo gene knockdown, therapeutic efficacy, and safety 
profile of the targeted and non-targeted formulations. This system was tested as a single 
therapy and in combination with cisplatin in drug sensitive (A549-WT) and resistant (A549-
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DDP) subcutaneous tumor models of NSCLC. We verified that the combination treatment 
of cisplatin with siMad2-loaded EGFR-targeted CS nanoparticles delayed the tumor growth 
significantly in cisplatin-resistant tumors. In addition, this treatment was found to be devoid 
of toxic effects, as confirmed by the results of the following parameters: body weight gain; 
biochemical markers of hepatic and renal function; histopathology of liver/kidney/spleen 
tissues. Collectively, our results highlight the noteworthy potential that this strategy holds 
promise for the treatment of aggressive cancers. 
We believe that the development of efficient and versatile drug delivery platforms to 
overcome the physical and biological obstacles in cancer therapeutics is an area of great 
concern, and novel materials are actively sought for such applications. For these reasons, 
we have designed a nanoparticle system with different functional blocks with that can be 
“mixed and matched” to attain desired characteristics in a delivery vector. We have applied 
the combinatorial design to chitosan (CS), where the polymer backbone has been modified 
with (i) polyethylene glycol, (ii) EGFR-binding peptide, and (iii) lipid derivatives of varying 
chain length to encapsulate hydrophobic drugs. Cisplatin is one of the most potent 
chemotherapy drugs broadly administered for cancer treatment. Cisplatin is a hydrophilic 
drug, and in order for it to be encapsulated in the developed nanosystems, it was modified 
with lipids of varying chain length. The library of four CS derivatives and six platinum 
derivatives was self-assembled in aqueous medium and evaluated for physicochemical 
characteristics and cytotoxic effects in platinum-sensitive and resistant lung cancer cells. 
The results show that the lipid-modified platinate encapsulation into CS nanoparticles 
significantly improved cellular cytotoxicity of the drug. In this work, we have also reinforced 
the idea that CS is a multifaceted system that can be as successful in delivering small 
molecules as it has been as a nucleic acids carrier. 
 
Keywords: Chitosan nanoparticles, Epidermal Growth Factor Receptor, mad2 gene, RNA 
interference, cisplatin, Non-Small Cell Lung Cancer 
, 
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Resumo 
O cancro do pulmão é o segundo tumor maligno mais comum em homens e mulheres e a 
principal causa de mortes relacionadas com cancro em todo o mundo. Mais de 220.000 
pessoas são diagnosticadas com uma forma de cancro de pulmão e mais de 150.000 
pacientes morrem da doença a cada ano. Um dos aspetos mais desafiadores da terapia 
contra o cancro de pulmão é o desenvolvimento de resistência a múltiplas drogas e 
disseminação metastática para outras partes do corpo. 
O RNA de interferência tem emergido como uma poderosa estratégia na terapia contra o 
cancro para regular negativamente genes específicos associados com a progressão do 
tumor e resistência. Mad2 é um componente essencial do checkpoint mitótico, necessário 
para a segregação cromossómica durante a mitose, e sua completa abolição leva à morte 
celular. No entanto, a entrega intracelular de small interfering RNA (siRNA) ao local 
específico do tumor consiste num grande desafio que necessita de ser ultrapassado antes 
desta técnica experimental poder ser rotineiramente utilizada como uma estratégia 
terapêutica viável clinicamente. 
Desenvolvemos um sistema de quitosano (CS) direcionado para o recetor do fator de 
crescimento epidérmico (EGFR) para o silenciamento do gene mad2 como uma estratégia 
para induzir eficientemente a morte celular em células humanas de cancro do pulmão de 
não-pequenas células (NSCLC), A549 que sobre-expressam EGFR. Nanopartículas 
EGFR-dirigidas foram formulados e caracterizadas em termos de tamanho, carga, 
morfologia e eficiência de encapsulação. Estudos de internalização intracelular qualitativos 
e quantitativos, por microscopia confocal e citometria de fluxo, respetivamente, 
demonstraram em função do tempo, uma internalização melhorada e seletiva das 
nanopartículas EGFR-dirigidas em relação às partículas alvo não-dirigidas. As 
nanopartículas alvo dirigidas demonstraram depleção quase completa da expressão de 
Mad2 em células A549 contrastando com a depleção parcial no sistema não-dirigido. 
Consequentemente, a morte celular por apoptose, induzida pelo silenciamento de Mad2 foi 
confirmada por ensaio de citotoxicidade e citometria de fluxo. 
Adicionalmente, a biodistribuição das nanopartículas foi avaliada qualitativamente e 
quantitativamente em modelos de cancro do pulmão sensíveis e resistentes à cisplatina 
(DDP). As nanopartículas alvo dirigidas demonstraram uma capacidade de direcionamento 
específico e acumulação consistente preferencial pelo tumor com rápida remoção do 
plasma para o tumor até 96 h. Estas exibiram uma eficiência de direcionamento para o 
tumor de 6 vezes mais elevada que nanopartículas alvo não-dirigidas. 
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Além disso, investigou-se o silenciamento genómico in vivo, a eficácia terapêutica e o perfil 
de segurança das formulações alvo e não-alvo dirigidas. Este sistema foi testado como 
terapia única e em combinação com cisplatina em modelos de tumores subcutâneos de 
NSCLC sensíveis (A549-WT) e resistentes (A549-DDP) a cisplatina. Verificou-se que o 
tratamento de combinação de cisplatina com nanopartículas de CS EGFR-dirigidas 
contendo siMad2 atrasou significativamente o crescimento de tumores resistentes à 
cisplatina. Além disso, este tratamento demonstrou ser desprovido de efeitos tóxicos, tal 
como confirmado pelos resultados dos seguintes parâmetros: monotorização do peso 
corporal; marcadores bioquímicos da função hepática e renal; histopatologia dos tecidos 
do fígado / rim / baço. Coletivamente, os nossos resultados destacaram o potencial desta 
estratégia e o facto de que esta consiste numa possível terapêutica promissora no 
tratamento de cancros agressivos e resistentes. 
Acreditamos que o desenvolvimento de plataformas eficientes e versáteis para a entrega 
de fármacos para superar os obstáculos físicos e biológicos na terapêutica contra o cancro 
é uma área de grande preocupação, e novos materiais são ativamente procurados para 
tais aplicações. Por estas razões, projetamos um sistema de nanopartículas com diferentes 
blocos funcionais para que pudessem ser "misturados e combinados" para atingir as 
características desejadas como vetor de entrega. Aplicou-se o desenho combinatório ao 
quitosano, em que a espinha dorsal do polímero foi modificada com (i) polietilenoglicol, (ii) 
péptido de ligação ao EGFR e (iii) derivados de lípidos de cadeia de comprimento variável 
para encapsular fármacos hidrofóbicos. A cisplatina, é um dos quimioterápicos mais 
potentes e amplamente administrados no tratamento do cancro. A cisplatina é um fármaco 
hidrofílico, e para que ele a ser encapsulado nos nanosistemas desenvolvidos, esta 
molécula foi modificada com lípidos de cadeia de comprimento variável. A biblioteca de 
quatro derivados de CS e seis derivados de cisplatina foi quanto às características físico-
químicas e os efeitos citotóxicos em células sensíveis e resistentes à cisplatina de cancro 
do pulmão. Os resultados demonstram que o encapsulamento de cisplatina modificada 
com lípidos em nanopartículas de CS melhorou significativamente a citotoxicidade celular 
do fármaco. Neste trabalho, queremos também reforçaram a ideia de que o CS é um 
sistema multifacetado que pode ser tão bem sucedido na entrega de pequenas moléculas 
como tem sido como de ácidos nucleicos. 
 
Palavras-chave: Nanopartículas de quitosano, recetor do fator de crescimento epidérmico, 
gene mad2, RNA de interferência, cisplatina, cancro do pulmão das não pequenas células 
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Thesis outline and organization 
This thesis is organized in 5 chapters reflecting the progression of research objectives.  
 Chapter 1 consists in a bibliographic review centered on recent knowledge of 
targeted therapies for NSCLC treatment, such as targeting mitotic components. A 
particular emphasis has been put on RNA interference technology as an anti-cancer 
therapy and the contribution of nanocarriers in dramatic improvement of RNAi 
efficacy.  
 The project aims and goals are described in detail in Chapter 2. 
 Chapter 3 reflects the optimization of chitosan-based nanoparticle formulation to 
encapsulate siRNA targeting the mitotic protein Mad2; and subsequently, the study 
of its in vitro efficiency 
 Chapter 4 describes the biodistribution and pharmacokinetics analysis of EGFR-
targeted chitosan nanoparticles in drug sensitive and resistant NCSLC models 
 Chapter 5 reproduces the in vivo efficacy and safety studies towards NSCLC 
therapy when administered in combination with cisplatin. 
 Chapter 6 describes a parallel project that was focused on exploring chitosan as a 
carrier for hydrophobic drugs by modifying it with lipid chains where lipid-modified 
cisplatin was chosen as the model hydrophobic drug to critically study effect of lipid 
chain length on drug formulation and subsequent in vitro activity in drug-sensitive 
and resistant NSCLC cells. 
 The overall conclusions are presented on Chapter 7. 
Most information presented in the 5 chapters that constitute this thesis has been 
already submitted to international peer review, via publication in scientific journals - 
according to the following list: 
 Nascimento AV, Bousbaa H, Ferreira D, Sarmento B. Non-small cell lung 
carcinoma: an overview on targeted therapy. Current drug targets. 2015 Dec 
1;16(13):1448-63. 
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Non-Small Cell Lung Cancer (NSCLC) 
1. INTRODUCTION 
Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths (around 
13% of all deaths) in 2008 (1). Lung cancer is the most frequently occurring cancer in the 
world and has a very low 5-year survival rates, and for these reasons, lung cancer should 
be considered as a major public health problem. In Europe, lung cancer is the second most 
common cancer in men and the third most common cancer in women (Figure 1) (1). In terms 
of mortality, lung cancer is the third leading cause of death in high-income countries and 
the most deadly type of cancer, with 1.38 million deaths (18.2% of the total) (2). Worldwide, 
it is the leading cause of death in smokers and accounts for more deaths than any other 
cancer in both men and women (3). Lung cancer is related with a poor overall prognosis 
but, across all ages and irrespective of histologic subtype, women tend to live longer than 
men for reasons that are not yet understood.  
The classification of lung cancers is based on pathologic features visible on light microscopy 
and it provides a basis for epidemiology, prognosis and therapeutic approach. The most 
recent classification of the World Health Organization (WHO) has been widely accepted 
and it divides lung cancers into two major groups, small cell (SCLC) and NSCLC (4). The 
non-small cell cancer group is subdivided in adenocarcinoma, squamous cell carcinoma, 
large cell carcinoma, and variants. Approximately 40% of all lung cancer cases are 
adenocarcinomas and 25-30% are squamous cell carcinomas (5). Large cell cancer makes 
up 10% of all cases, while SCLC accounts for 20% of all cases.  
In the last 30 years, many attempts have been made to unravel the genetic bases of lung 
cancer. Tumor suppressors, including Rb and p53, were shown to be frequently inactivated 
in lung cancer (6), mostly due to deletion or hypermethylation (7). Several oncogenes are 
found activated in lung cancer, including K-ras, c-myc, N-myc, and L-myc, with a crucial 
role in cancer establishment (8). Finally, autocrine growth factors have been implicated in 
the onset of lung cancer, with the epidermal growth factor receptor (EGFR) playing a pivotal 
role in the development of the disease. 
With the available therapeutics, the 5-year relative survival rate for patients with lung cancer 
is less than 15% (9). This instigates a huge demand for new and more potent therapies 
focusing on molecular mechanisms that offer great promise in this regard.  
A promising strategy is to use RNA interference (RNAi). RNAi is a sequence-specific and 
post-transcriptional gene silencing mechanism, capable of the elucidating molecular 
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mechanisms that underpin both normal biology and human disease. The application of 
RNAi technology both in vitro and in vivo has tremendous potential as a therapy for various 
diseases especially since it allows to switch off the causative genes. Although substantial 
obstacles still exist for RNAi-based cancer therapeutics, several RNAi studies have 
successfully reached clinical stage. In this review, we will highlight the current 
understanding of molecular targets and latest advances in therapies for lung cancer, and 
will also address the current status of RNAi-based cancer therapeutics. 
 
Figure 1: Distribution of the expected cases and deaths for the 5 most common cancers in Europe 2012 in males 
(a) and females (b). For each sex, the area of the segment of the pie chart reflects the proportion of the total 
number of cases or deaths (1). 
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2. CURRENT MOLECULAR TARGETS FOR NSCLC THERAPY 
The best treatment option to NSCLC continues to be the complete surgical resection, which 
offers a 40% 5-year survival rate. However, 75% of patients have an advanced or metastatic 
form of lung cancer at the time of diagnosis and are unsuitable for surgery (8). In these 
cases, platinum-based chemotherapy drugs are the standard therapy but they imply severe 
toxicity and can result in multi-drug resistance (MDR) of NSCLC cells (10). In the search for 
new therapies, molecularly targeted drugs have appeared as an emerging platform for lung 
cancer therapy in the last decade (Figure 2).  
 
Figure 2: Signaling pathways and tyrosine kinase receptors involved in the tumorigenesis of NSCLC. Akt, protein 
kinase B; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; HB, heparin binding; IGF-1R, 
insulin-like growth factor 1 receptor; MAPK, mitogen-activated protein kinase; NRG, neuregulin; NSCLC, non-
small cell lung cancer; P, phosphate; PI3K, phosphatidylinositol-3-kinase; Raf, v-raf 1 murine leukemia viral 
oncogene homolog 1; Ras, retrovirus-associated DNA sequences; RTK, receptor tyrosine kinase; SOS, Son of 
sevenless; TGF, transforming growth factor. (11) 
Accordingly with National Cancer Institute Dictionary of Cancer Terms, these targeted drugs 
or other substances are able to block the growth and spread of cancer by interfering with 
specific molecules involved in tumor growth and progression (12). Patients selected for such 
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treatment on the basis of specific features of their tumor are currently benefiting from such 
agents. Although targeted drugs may block important pathways, lung cancer is a 
heterogeneous disease with multiple mutations and, as such, it is highly unlikely for 
neoplasic establishment and development to be dependent on a single signaling pathway 
(13). Consequently, several targeted therapies have been introduced into clinical trials, both 
as single and multiple agents or combined with other conventional treatment modalities 
(13). Continuous advances in our understanding of the molecular biology of cancer and 
mechanisms of tumorigenesis have empowered a constant discovery of potential molecular 
targets and the development of novel ‘targeted therapies’.  
2.1 Receptor Tyrosine Kinase Signalling 
Epidermal Growth Factor Receptor 
EGFR, also known as human epidermal receptor 1 (HER1) or ErbB1, is the founding 
member of the ErbB family of four structurally related receptor tyrosine kinases (RTKs): 
EGFR (ErbB-1), HER2/c-neu (ErbB-2), HER3 (ErbB-3), and HER4 (ErbB-4) (14). EGFR 
signaling activates two of the most important pathways in solid tumors, the 
RAS/RAF/MEK/MAPK pathway and the PI3K/AKT/mTOR pathway, which jointly endorse 
cancer cell proliferation, cell growth, invasion, apoptosis, and tumor angiogenesis. 
Overexpression of EGFR is very common in NSCLC patients (40%-80%), and is associated 
with advanced tumor stage, resistance to standard therapies, and poor patient prognosis 
(15). Enhanced ligand production by cancerous cells, EGFR overexpression on cancer cell 
membranes and activating mutations on EGFR and related genes, represent different ways 
by which EGFR can be deregulated (16). EGFR has revealed to be one of the most relevant 
targets for NSCLC treatment (17). Strategies to block such pathway include tyrosine kinase 
inhibitors (TKIs) and monoclonal antibodies. 
TKIs are small molecules that inhibit the phosphorylation and activation of EGFR and the 
downstream signaling pathway by blocking ATP assembly to the EGFR intracellular tyrosine 
kinase domain (18). EGFR TKIs have a narrow efficacy in unselected patients but are very 
effective in EGFR-mutated patients who frequently have certain clinical characteristics 
(adenocarcinoma, non-smoking history, Asian ethnicity, female gender) (8). In 2003 and 
2004, the first generation of TKIs, gefitinib (AstraZeneca, London, UK) and 
erlotinib(Genzyme, Boston, MA, USA), were approved for the treatment of NSCLC (19). 
They are orally bioavailable synthetic anilinoquinazolines which selectively and reversibly 
inhibit the kinase activity of EGFR (20). Somatic activating mutations between EGFR gene 
exons 18 and 24, which code for tyrosine kinase (TK) domain, frame deletions in exon 19 
(45%-50% of all somatic EGFR mutations), and the L858R missense mutations in exon 21 
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are positively associated with a strong patient response to erlotinib and gefitinib (21, 22). 
The use of EGFR TKIs as the favorite option for a first-line situation in metastatic EGFR 
mutation-positive patients with NSCLC has been supported by large phase III studies (23). 
Actually, gefitinib frontline use on patients with activating EGFR mutations has been 
recommended by the American Society of Clinical Oncology (ASCO) Clinical Practice 
Guidelines 2009. For those cases where EGFR mutation is absent or unknown, cytotoxic 
chemotherapy is recommended (24). Despite the success of first-generation TKIs, novel 
second-generation TKIs are urgently required, as new mutations have emerged (e.g. 
T790M, exon 20) and shown to be treatment resistant (25).  
A number of second-generation agents have been developed and are currently undergoing 
clinical trials and include compounds that irreversibly inhibit both EGFR and HER2 ((11). 
One of those agents is afatinib (BIBW 2992; Boehringer Ingelheim; Ingelheim, Germany), 
a novel anilinoquinazoline derivative that irreversibly and powerfully targets the intrinsic 
kinase activity of all active ErbB receptor family members (26). A phase II LUX-Lung 2 trial 
was done in patients with the activating EGFR driver mutations (deletion 19 and L858R) 
that failed to respond to first-line chemotherapy (27). The trial showed that afatinib had a 
positive activity and 66% of the patients had an objective (complete or partial) response. 
The results were more disappointing, with an objective response seen in 39% of the 
patients, with other EGFR mutations, including T790M. Two different clinical trials are being 
conducted: one where afatinib is being compared with cisplatin/pemetrexed in the first-line 
treatment of advanced NSCLC patients with activating EGFR mutations; the other one also 
encloses advanced NSCLC population with EGFR mutations but aims to compare afatinib 
to cisplatin/gemcitabine (11). Dacomitinib (PF-00299804, Pfizer, New London, CT, USA) is 
a HER inhibitor with affinity for EGFR, HER2, and HER4, that has also shown activity in 
NSCLC (28). A phase III clinical trial comparing Dacomitinib with placebo in patients who 
did not respond to chemotherapy in currently under progress (11).  
The efficacy of tumor-aimed monoclonal antibodies has been associated with the number 
of copies of the corresponding gene in the tumor in question, while the sensitivity to small 
molecules has been primarily correlated with mutations altering the receptor's catalytic 
domain (29). Cetuximab (IMC-C225, Erbitux, ImClone Systems Inc, New York City, NY, 
USA) is a human-mouse chimeric immunoglobulin G1 class monoclonal antibody that 
targets EGFR extracellular domain in the ligand-binding region (30). Cetuximab was initially 
registered for clinical practice for the treatment of advanced colorectal cancer and then for 
head and neck cancer. While being investigated as a first-line treatment of patients with 
advanced NSCLC, cetuximab was able to inhibit the growth of human NSCLC cell lines 
(31). The use of cetuximab has been also analyzed in advanced NSCLC patients as a 
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monotherapy or in combination with chemotherapy (32). The response rate to cetuximab in 
a single-agent regime was approximately 4.5% in recurrent EGFR-expressing NSCLC, 
while it increased to 25-35% when administered in combination with platinum-based 
chemotherapy (33). National Comprehensive Cancer Network practice guidelines for 
advanced/metastatic NSCLC recommend cetuximab in combination with platinum-based 
chemotherapy (32). Future patient selection based on predictive biomarkers will enhance 
the emerging clinical profile of this agent. Other HER family-targeted antibodies (e.g. 
trastuzumab ) have failed to demonstrate clinical benefit in NSCLC, either as a 
monotherapy or in combination with chemotherapy (28).  
Angiogenesis pathway 
Angiogenesis is a hallmark of cancer and is crucial for tumor growth and metastasis. Cancer 
cells have the ability to induce blood vessel formation by secreting pro-angiogenic factors, 
such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) 
and fibroblast growth factor (FGF). Cell activation, proliferation, migration, and survival are 
intimately related to several signaling cascades, including RAF-MEK-ERK and PI3K 
pathways, which are activated through the recognition of VEGF by its receptor (29). 
Increased VEGF expression is found in a variety of human tumors, including NSCLC (34). 
One way to block angiogenesis pathways is by inhibiting VEGF receptor with ligand 
antibodies (e.g. bevacizumab) or TKI (e.g. sunitinib, sorafenib and valatinib).  
Bevacizumab (Genentech, San Francisco, CA, United States), a recombinant humanized 
anti-VEGF monoclonal antibody, recognizes all isoforms of VEGF ligands and was the first 
commercially available angiogenesis inhibitor (35). In Europe, first line therapy includes the 
combination of bevacizumab with carboplatin plus paclitaxel or in addition to platinum based 
chemotherapy (22). A recent meta-analysis of four randomized phase II and III studies 
evaluating the effectiveness of adding bevacizumab to platinum-doublets in the treatment 
of NSCLS has demonstrated an improved outcome. Platinum-doublets consist in a 
combination of platinum-based (cisplatin, carboplatin) chemotherapy with a second agent 
like docetaxel, paclitaxel, vinorelbine, gemcitabine, etc. The safety of bevacizumab was also 
demonstrated through several studies aiming the treatment of NSCLC patients with treated 
central nervous system metastases, as results confirmed a favorable drug safety profile 
(36).  
Sunitinib (SUGEN, Redwood City, CA, USA) is an oral, small-molecule, multi-targeted RTK 
inhibitor (37). Sunitinib has shown an 11.1% overall response rate in phase II studies but, 
when tested with other chemotherapeutic agents, its toxicity was fairly undesirable (38). 
Phase III trials tested sunitinib as single treatment or in conjugation with erlotinib (39). 
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Sunitinib plus erlotinib did not improve overall survival compared with erlotinib 
alone.Treatment-related toxicities were severe in combination therapy including 
rash/dermatitis, diarrhea, and asthenia/fatigue (39). Similar to sunitinib, sorafenib targets a 
spectrum of membrane receptors, including VEGFR-1 and -2. In contrast to its successful 
phase II trials, phase III studies on sorafenib conjugated with other chemotherapeutic 
agents showed no clinical benefit (37, 40).  
Up-regulation of other angiogenesis pathways has been suggested as a resistance 
mechanism of tumor cells. Through alternative expression of another angiogenic factor, 
tumors may circumvent the inhibition of a single angiogenic protein (41). Therefore, TKIs 
that can block several receptors, such as PDGFR and FGFR, may be more effective. Having 
that in consideration, several agents have been developed such as axitinib, a TKI of 
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR and c-kit (Pfizer, New York City, NY, USA), and 
BIBF 1120, an inhibitor of VEGFR, FGFR, and PDGFR (Boehringer Ingelheim, Ingelheim, 
Germany) (42, 43). Axitinib, a small molecule indazole derivative is an oral, potent, and 
selective kinase inhibitor and is currently being studied in multiple solid tumors. A phase II 
trial tested axitinib in monotherapy, aiming the treatment of advanced NSCLC. Results 
showed a median overall survival of 14.8 months and a progression-free survival of 4.9 
months, which represent better outcomes than those obtained with other TKIs in 
monotherapy. Moreover, the treatment was well tolerated, being fatigue, hypertension, and 
hyponatremia the only frequent adverse effects registered (43). BIBF 1120 is an indolinone 
derivative that inhibits mitogen-activated protein kinase (MAPK) and Akt signaling 
pathways, resulting in the inhibition of cell proliferation and apoptosis (44). Phase I/II trials 
with BIBF 1120 indicates promising efficacy and a favorable safety profile in patients with 
advanced NSCLC (42). Phase I clinical trials investigated the effects of BIBF 1120 when 
combined with paclitaxel and carboplatin in first-line patients with advanced NSCLC and 
have demonstrated an acceptable safety profile (45). The novel generation of cancer 
therapies is now composed of multi-targeting agents, and several approaches aiming the 
inhibition of both EGFR and VEGF in the treatment of NSCLC are taking place (46). 
Other receptor tyrosine kinases  
The Insulin-like growth factor (IGF) pathway is a multicomponent cellular network that 
mediates growth, differentiation and developmental processes, and is also implicated in 
numerous metabolic events. It comprises two main receptors (IGF-1R and insulin receptor 
[IR]) and three main ligands (IGF-1, IGF-2 and insulin) (47). Growth deficits and cancer 
development are examples of pathologies interrelated with the deregulation of the IGF 
pathway, which leads to activation of major intracellular signaling cascades, including the 
RAS/RAF/MAP kinase and the PI3K pathway (48). Similar to other RTK, the main 
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categories of targeted therapy to inhibit IGF-1R signaling are small molecules and 
monoclonal antibodies. Deterioration of glucose metabolism can result from indiscriminate 
blocking of this receptor family, since its kinase domain has approximately 85% homology 
to the IR (49). Although it was initially a concern, it was later accepted that targeting both 
IGF-1R and IR may actually be beneficial in order to prevent adaptive resistance (50). 
Several small molecules and antibodies against IGF-1R are currently under preclinical and 
early clinical stages, such as ganitumab (Amgen, Thousand Oaks, CA, USA), AVE1642 
(ImmunoGen Inc., Waltham, MA, USA) and BIIB022 (Biogen Idec., Weston, MA, USA) (51-
53).  
An emerging molecular target being tested in clinical trials is the RTK MET. C-Met is a proto-
oncogene that encodes for a heterodimeric transmembrane RTK, known as MET or 
hepatocyte growth factor (HGF) receptor (HGFR). When binding to its ligand, HGF, MET 
activation leads to cell growth, survival, motility, invasion and angiogenesis (54). Despite 
multiple controls, pathway deregulation occurs in a variety of neoplasms. Many NSCLC 
patients (60-80%) overexpress c-MET, whereas only 20% display c-MET mutations (55). 
Since MET hyperactivation initiates the PI3K/Akt pathway independently of EGFR 
activation, EGFR inhibitors are ineffective for the treatment of c-MET amplification derived 
cancers (55). Therefore, designing therapeutic solutions aiming MET itself could become 
clinically relevant for patients unable to positively respond to gefitinib or erlotinib. NSCLC 
cell lines overexpressing MET showed to be very sensitive to PHA665752 (Pfizer, New York 
City, NY, USA), a selective inhibitor of MET kinase (56). Subsequent studies in patients with 
lung cancer, both resistant to EGFR TKIs and with MET amplification, demonstrated that 
treatment with PHA665752 could restore gefitinib sensitivity.  
SCH 900105 (AVEO Pharmaceuticals, Cambridge, MA, USA), a humanized anti-HGF 
antibody with specificity for free HGF; cabozantinib (Exelixis Inc., South San Francisco, CA, 
USA), a MET and VEGFR2 inhibitor; tivantinib (Arqule Inc., Woburn, MA, USA), selective 
cMET inhibitor; and BMS-777607 (Bristol-Myers Squibb, New York City, NY, USA), a small-
molecule MET kinase inhibitor, are currently under investigation and represent some 
strategies to prevent MET signaling (57-60). 
2.2 RAS/RAF/MEK/MAPK Pathway  
Ras is a protein superfamily of inner-membrane associated small GTPases, related to the 
Ras protein subfamily the members of which are H-Ras, K-Ras, and N-Ras. By acting as 
molecular switches connecting extracellular signals with nuclear transcription factors, they 
regulate key signaling pathways involved in normal cell differentiation, proliferation, and 
survival (61). The Ras oncogenes are often aberrantly activated in lung cancer due to Ras 
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mutations or growth factor receptor (GFR) overexpression, playing a crucial role in 
tumorigenesis (62, 63). Mutations on the K-Ras gene have been found in 20%-30% of 
NSCLC, pre-dominantly in smokers who have adenocarcinoma, and are believed to play a 
key role in this malignancy (64). Most of these mutations (90%) occur on exon 12 or exon 
13 and are related with decreased sensitivity to EGFR TKI therapy (65).  
Additionally to TKIs, several novel targeted drugs for this pathway are currently in pre-
clinical and clinical tests in different types of cancer, such as GSK1120212 
(GlaxoSmithKline, Brentford, UK), a selective inhibitor of MEK1; AS703026 (Merk Serono, 
Darmstadt, Germany), a selective inhibitor of MEK1/2; selumetinib (AstraZeneca, London, 
UK), a selective inhibitor of MEK1/2; and salirasib (Kadmon Corporation, New York City, 
NY, USA), a Ras inhibitor (66-71). A phase II study of the Ras-MAPK signaling pathway 
inhibitor TLN-4601 (Thallion, Dorval, QC, Canada) was conducted in patients with 
glioblastoma, but it showed to be ineffective when administered as monotherapy (72).  
2.3 PI3K/AKT/Mtor Pathway 
The serine/threonine kinase Akt has a critical regulatory role in diverse cellular processes, 
including cell growth, cell proliferation, angiogenesis, and protein synthesis. Akt cascade is 
activated by RTKs, integrins, B and T cell receptors, cytokine receptors, G protein coupled 
receptors, and other stimuli. PI3K/Akt/mTOR pathway activation in human cancers has 
been associated with resistance to anti-EGFR drugs, which has increased the interest in 
describing alterations in this pathway to optimize EGFR therapy (73). Several occurrences 
can contribute to this event: activation of upstream RTKs (including EGFR and PDGFR); 
constitutively activation of Akt; mutations in PIK3CA, which expresses the catalytic subunit 
of PI3K; altered expression of PTEN protein, which inhibits the PI3K/Akt pathway; among 
others (74, 75). Due to the potential to shut down survival pathways while targeting this 
pathway, therapeutic agents are being explored to determine pathway-activating mutations 
and to restore sensitivity to upstream signaling targeted agents (73, 76). First generation 
mTOR inhibitors (e.g., rapamycin) have essentially cytostatic anti-tumor activity and can 
only inhibit mTORC1, but second generation agents being tested can inhibit mTORC1 and 
mTORC2. These agents have shown promising antitumor activity in clinical trials (77, 78). 
Inhibition of mTORC2 will also affect the activation of Akt (55). RNA interference technology 
(see below) has also been tested against this pathway, leading to promising results (79). 
Small interfering RNA (siRNA) oligonucleotides that specifically inhibit mTOR have been 
evaluated in vitro and resulted in increased apoptosis and in the inhibition of 
proliferation/migration in NSCLC cells. Inhibition of PI3K enhances sensitivity of NSCLC 
cells to radio- and chemotherapy, as shown by preclinical studies with the PI3K inhibitor 
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LY294002 (Semafore Pharmaceuticals; Westfield, IN, USA), which is currently being tested 
in phase I trials (80). 
2.4 Eml4-Alk 
The anaplastic lymphoma kinase (ALK) is a member of the insulin superfamily of RTKs and 
acts as a dominant oncogenic driver following chromosomal rearrangements. It has been 
shown, in a specific subset of NSCLC patients, that ALK translocations instigate aberrant 
activation of downstream oncogenic signaling pathways such as MAP kinase, PI3-kinase, 
and signal transducers leading to cell proliferation, invasion, and inhibition of apoptosis (81, 
82). EML4-ALK translocation consists of ALK fusion with echinoderm microtubule-
associated protein-like 4 (EML4), is found in 3%-6% of all NSCLC cases, and is associated 
with resistance and poor response to EGFR TKIs (83). Crizotinib (PF02341066, Xalkori, 
Pfizer, New York City, NY, USA) has shown promising activity in phase I/II trials and was 
recently approved for the treatment of ALK-positive NSCLC (84). 
2.5 Apoptotic Pathway 
In recent years, apoptosis has become an appealing target for lung cancer therapy. This 
pathway is mainly structured by a balance between proapoptotic (Bax, Bak, Bad, and Bim) 
and antiapoptotic (Bcl-2, Bcl-xL, Bcl-w, and Mcl-1) factors (85). In 10%-35% of NSCLCs 
and 75%-95% of SCLCs, B-cell lymphoma 2 (Bcl-2) is overexpressed, conferring resistance 
to cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies (86, 87). Clinical 
studies have shown that Oblimersen sodium (Genasense), an antisense oligonucleotide 
targeting Bcl-2, reduces Bcl-2 production in lung cancer cells, thereby increasing cell 
sensitivity to standard anticancer treatments. Small molecule inhibitors of antiapoptotic 
proteins as ABT-737 (ABBOTT, ABBOTT park, IL, USA), an inhibitor of the Bcl-2, Bcl-xL, 
and Bcl-w proteins, and AT-101 (Ascenta Pharmaceuticals Inc., San Diego, CA, USA), a 
Bcl-2 inhibitor, have demonstrated single-agent preclinical activity against NSCLC (88, 89). 
Survivin, an antiapoptotic protein that regulates both programmed cell death and mitosis, 
has prognostic value for NSCLC patients since its expression and subcellular localization 
is associated with an increase in the risk of disease recurrence, resistance to radiotherapy 
and death (90, 91). YM155 (Astellas Pharma, Chūō, TKY, Japan), a novel small-molecule 
suppressor of Survivin has been evaluated in a monotherapy phase II trial in advanced 
NSCLC and showed reasonable antitumor activity, stabilizing the disease in 37.8% of 
patients (92). Data obtained from this trial suggests that YM155 may not be effective in 
monotherapy. Still, it could be useful if conjugated with other chemotherapeutic agents. 
Therefore, further multimodality studies should be performed. siRNA against Survivin has 
also demonstrated therapeutic potential by increasing apoptosis of H460 and A549 lung 
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cancer cells after radiotherapy and suppressing the growth of the transplanted lung cancer 
in mice (93, 94). 
2.6 Histone Deacetylase and Heat Shock Proteins 
Histone deacetylase are a class of enzyme responsible for removing acetyl groups on lysine 
residues from histones allowing tighter interaction between these and the DNA (95). These 
enzymes are believed to be involved in the repression of tumor suppressor genes and in 
the activation of transcriptional factors involved in tumorigenesis at different stages of 
cancer development (96). Histone deacetylase inhibitors cause cell cycle arrest and 
apoptosis by upregulating the intrinsic apoptotic pathway (97). Additionally, they can also 
enhance the cytotoxic effects of radiation and synergistically promote the effects of 
chemotherapy (98, 99). Suberoylanilide hydroxamic acid and trichostatin A, two histone 
deacetylase inhibitors, have recently proved to be able to sensitize NSCLC cancer cells to 
ionizing radiation (100). Vorinostat, another compound that inhibits histone deacetylases, 
has also been evaluated in combination with the novel proteasome inhibitor marizomib in a 
Phase I trial in lung cancer patients, resulting in a highly synergistic antitumor activity (101). 
Heat shock proteins (Hsp), or stress proteins, are another class of proteins with therapeutic 
interest. Hsp are involved in essential cellular mechanisms as protein assembly, cell 
division, apoptosis, protein trafficking, cell signaling, prevention of unwanted protein 
aggregation, etc. (102). Hsp90 inhibitors have emerged as a class of promising drugs to 
target multiple oncogenic pathways. Hsp90 is upregulated in response to stress and also 
maintains the activity and stability of key oncogenic signaling proteins (103). Geldanamycin 
(Synta Pharmaceuticals, Lexington, MA, USA), an Hsp90 inhibitor, has shown promising 
effects in clinical trials, although its extremely low water solubility and severe hepatotoxicity 
have hindered its development as effective therapeutics (104, 105). Therefore, some 
improved analogues have been developed, including Tanespimycin (Kosan Biosciences 
INC, Bay Center Place Hayward, CA, USA)and Retaspimycin hydrochloride (Infinity 
Pharmaceuticals, Cambridge, MA, USA) (106). 
2.7 Mitotic Inhibitors 
Cell cycle deregulation is a common hallmark of cancer cells, and targeting the cell division 
cycle in cancer cells has been the aim of several therapeutic strategies. Antimitotic 
chemotherapy remains the most effective approach in the clinical treatment of a variety of 
human cancers. Cytotoxic platinum-doublet chemotherapy that includes antimitotic agents 
is a current standard therapy in advanced NSCLC. Traditional anti-mitotic agents include 
the microtubule toxins such as taxol, other taxanes and the vinca alkaloids, all of which 
have proven to be successful, but with significant toxicity (107). These drugs avert a 
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functional spindle leading to spindle assembly checkpoint (see below) activation and 
anaphase delay (108). After mitotic arrest, cells may undergo two different pathways, cell 
death or mitotic slippage (109). Slippage refers to a process where cells exit mitosis and 
begin a new cycle with twice the DNA content (110). These cells can arrest in G1 phase, 
undergo cell death, or continue cell cycle progression increasing the potential for 
tumorigenesis (111). However, severe side effects, like myelosuppression and neurotoxicity 
and the frequent development of resistance to these drugs have limited their use and 
motivate the search for alternative antimitotic drugs (112). Innovative targeted strategies 
are now evaluating the inhibition of critical activities, such as cyclin-dependent kinase 1, 
Aurora, spindle kinesins or polo kinases (113, 114).  
Aurora kinases and Polo-like kinase 1 
Mitotic kinases are deregulated in a multiplicity of tumor cells, suggesting their potential role 
in tumorigenesis and making them a tempting target for molecular therapies(115). Plk1 
(polo-like kinase 1) and Aurora kinases represent a highly conserved family of 
serine/threonine kinases that ensures a correct spindle assembly during mitosis, heading 
to an accurate segregation of the chromosomes into daughter cells. Due to their recognition 
as potential targets for cancer chemotherapy, around thirty Aurora kinase inhibitors have 
reached different stages of pre-clinical and clinical development (116). Inhibiting Aurora B 
kinase in combination with radiation has recently proven to be a promising strategy in 
NSCLC cell lines (113). Concerning Plk1 activity, small-molecules and phosphopeptide 
inhibitors have been recently developed due to their potency and specificity against Plk1 
(117). Blocking these targets’ activity might not necessarily end in cell death; instead, cells 
can undergo mitotic slippage and exit mitosis without proper segregation of sister 
chromatids and cytokinesis, exhibiting multiple nuclei and polyploidy (118). Several 
inhibitors have been developed against this protein family and, recently, administration of 
siRNA against PLK-1 has shown promising results and demonstrated that PLK-1 is a 
suitable target for advanced NSCLC therapy (117-119). 
CENP-E 
Inhibitors of kinesin motor proteins, which are vital for spindle assembly and 
chromosomes movement during mitosis, have showed to be promising mitosis-specific 
agents to treat a variety of human neoplasm (114). CENP-E (centromere protein E) is an 
essential plus end-directed microtubule motor, present only in cells undergoing mitosis, and 
is a fundamental protein for the congression and alignment of chromosomes by moving 
unattached kinetochores towards the metaphase plate along kinetochore microtubule 
bundles, termed K-fibers (120). Cell cycle arrest and apoptosis are two consequences of 
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the inhibition of CENP-E activity, which can act as tumor suppressor and represent an 
attractive antimitotic target (121). Several CENP-E inhibitors, such as GSK923295A and 
GSK923295 (GlaxoSmithKline, Brentford, UK) have reached clinical trial stage (122, 123). 
Eg5 Kinesin 
Eg5 is a member of the kinesin superfamily of microtubule-based motors, and plays an 
essential role in the proper separation of centrosome and bipolar spindle assembly and 
maintenance, being upregulated in many tumor cells (124). Among patients with advanced 
NSCLC, Eg5 overexpression tended to be associated with a poorer outcome in terms of 
overall survival (125). A cell cycle arrest at mitosis is achieved through the inhibition of Eg5, 
which leads to the establishment of monoastral microtube arrays, followed by apoptosis 
(126). Mayer et al. discovered monastrol, the first small molecule able to inhibit Eg5, but 
since then several other inhibitors have been reported and some are being tested in clinical 
trials, both as single and in combination with other agents, although none in NSCLC (127, 
128). 
Ubiquitin-proteasome system 
The ubiquitin-proteasome system is an intracellular multicatalytic complex that plays a 
central role in regulating the degradation of proteins involved in the cell cycle, DNA 
transcription and repair, apoptosis, angiogenesis and cell growth. Proteasome inhibition is 
a focus of intense research and therapeutic development since it is a critical pathway for 
the proliferation and survival of cancer cells. Clinical trials in advanced NSCLC have being 
investigating the use of bortezomib (Millennium Pharmaceuticals, Inc., Cambridge, MA, 
USA), a proteasome inhibitor, in combination with pemetrexed (Princeton University, 
Princeton, NJ, USA), ainhibitor of precursor purine and pyrimidine nucleotide synthesis, and 
cetuximab (13). Bortezomib causes downregulation of the antiapoptotic protein Bcl-2 in 
NSCLC and induces apoptosis in SCLC. In current phases I and II studies, bortezomib has 
shown very encouraging results in combination with chemotherapy (129). An extensive 
diversity of natural and synthetic proteasome inhibitors have been described and grouped 
into five groups: peptide aldehydes, peptide vinyl sulfones, peptide boronates, peptide 
epoxyketones, and β-lactones (lactacystin and its derivatives). From those only the ones 
that have shown chymotrypsin-like activity, similar to bortezomib, have reached clinical trials 
state (130).  
Spindle assembly checkpoint pathway 
The spindle assembly checkpoint (SAC) is a surveillance mechanism that assures the 
accurate segregation of chromosomes during mitosis, by ensuring proper bipolar 
attachment of each chromosome to the mitotic spindle (131). A deregulated SAC pathway 
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has been frequently described in different cancers, including NSCLC, in association with 
chromosome instability (CIN) (132). A weak SAC activity has been associated with 
aneuploidy and tumorigenesis, while complete SAC abrogation culminates in massive 
chromosome missegregation and cell death (133). Strategy to eliminate SAC activity has 
not been applied to lung cancer, not even with other mitotic proteins. Many genetic 
alterations have been associated with tumorigenesis and tumor progression in NSCLC, but 
the precise mechanisms behind these alterations remain unknown. One of those 
alterations, CIN, suggests improper allocation of the two chromatids of a chromosome to 
the two daughter cells during mitosis (134). Up to 40% of lung cancer cell lines have been 
shown to have SAC defects and are viable. Killing these cells by completely abolishing SAC 
could be a promising anti-cancer strategy. Studies conducted in colon carcinoma cells, 
showed that knockdown of MAD2 in vivo was associated with acute chromosome 
missegregation and resulted in a reduced tumor growth (135). Monopolar spindle 1 kinase 
(MPS1) intervenes in the chromosome alignment and kinetochore-microtubule interaction 
and due to its critical role in SAC signaling it could represent a promising therapeutic target. 
Colombo et al. have identified a MPS1 small-molecule inhibitor causing massive 
aneuploidization leading to cell death and tumor growth inhibition in xenograft models (136). 
Targeting SAC proteins in NSCLC, as well in other types of cancer appears as an 
unexplored promising new concept for cancer therapy.  
MITOSIS 
1. CELL CYCLE 
Cell reproduction occurs by an evolutionarily conserved process named cell cycle. The cell 
division cycle is an orderly sequence of events terminating in mitosis and the production of 
two daughter cells, governed by a complex network of regulatory proteins . The somatic cell 
cycle may be divided into two main stages: the M (Mitosis) phase and the interphase, which 
corresponds to the period between two M phases. Interphase encompasses three phases: 
G1 (gap 1), S (synthesis) and G2 (gap 2). In G1 phase cell increases the size and DNA and 
RNA might be synthesised in order to prepare DNA replication in the next phase. In S phase, 
DNA synthesis takes place, increasing its content, and the cell becomes tetraploid (4n), 
instead of diploid (2n). After chromosome replication, the cell enters the G2 phase. In this 
phase, a rapid cell growth and protein synthesis occurs in order to prepare the cell for 
mitosis. In the M phase, the cell originates two new identical daughter cells, each of them 
owning a diploid set of chromosomes. This second major phase of the cell cycle is divided 
in two fundamental events: nuclear division (mitosis) and cytoplasmic division (cytokinesis). 
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Afterwards, each daughter cell immediately enters G1, having the opportunity to repeat the 
cycle or, alternatively, to pull out from the cycle into the G0 phase, a quiescence state, for 
an indefinite or permanent period of time (e.g., when nutrient supply is not favorable). In a 
developed multicellular organism, most cells are in G0 phase (Non-dividing cells), although 
retaining the opportunity to reactivate and re-enter the cell cycle in G1 phase at any time. 
Cell cycle progression is regulated by, the protein family of Cyclins that interact with and 
activate the Cyclin-dependent kinases (Cdk), a family of serine/threonine protein kinases 
(137, 138). Each Cdk associates in a complex with a specific Cyclin and this association 
determines which proteins will be phosphorylated by the complex (Figure 3). Each phase 
of the cycle begins with a progressive increase in a specific Cyclin concentration, and 
terminates with its protease-mediated degradation. This degradation of Cyclin terminates 
its action and imprints a one-way direction to the cell cycle.  
2. MITOSIS 
Mitosis is an elaborated and highly regulated process by which a cell gives rise to two 
genetically identical daughter cells. Mitosis is a continuous event that occurs through five 
different stages that reflect general changes in cytoplasmic and chromosome structure: 
Prophase, Prometaphase, Metaphase, Anaphase and Telophase. Early mitosis initiates 
with Prophase which is marked by chromatin condensation, originating recognizable 
chromosomes. The classic four arm structure resides in a pair of sister chromatids held 
together by restricted area attached to each other at the centromere, where specific proteins 
bind and form the kinetochore - the structure at which spindle microtubules attach. It is also 
during this phase that previously duplicated centrosomes, the MTOCs (Microtubule 
Organizing Centres), begin to separate to opposite sites and define the future poles of the 
mitotic spindle. In the next stage, Prometaphase, the nuclear envelope breaks down and 
consequently, microtubules from opposite poles overcome all the cytoplasmic space, fully 
organize the mitotic spindle and start to attach to kinetochores of dispersed chromosomes, 
done by a ‘search and capture’ process.  
Metaphase is achieved when kinetochore pairs of all chromosomes are bound to 
microtubules from opposite poles, assuming a bipolar orientation and an equatorial 
localization. Sister chromatid cohesion is then swiftly lost as they migrate to opposite poles 
of the spindle which marks the transition from metaphase to anaphase. At anaphase, it is 
possible to distinguish two periods, anaphase A, characterized by chromosome migration 
towards the poles, and anaphase B, characterized by the spindle poles moving apart as a 
result of spindle elongation. In the last stage, Telophase, chromatin decondenses, the 
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nuclear envelope is reconstituted into two identical nuclei and a contractile ring, which is 
composed of actomyosin fibers that extend around the equator of the dividing cell and then 
grips inward until they contact a group of microtubules that run between the poles, resulting 
in a structure connecting the future two daughter cells - the midbody. 
  
Figure 3: The cell cycle engine of mammalian cells. The cell cycle is driven by the sequential association of 
Cdks and cyclins: in G1 (growth phase): cyclin D, Cdk 4 and 6; in S (DNA synthesis phase): cyclin A, Cdk 1 and 
2; in G2 (gap phase): cyclin A, Cdk 1; in M (mitosis phase): cyclin B, Cdk 1. Each Cdk-cyclin complex is thus 
specific of a phase of the cycle. The decision to enter a new cycle, or to arrest proliferation, is taken in G1. 
Prolonged, or “terminal”, exit from the cycle is often denoted as G0 (Adapted from 139). 
3. KINETOCHORE TO MICROTUBULE ATTACHMENT 
After nuclear envelope break-down at the prophase to prometaphase transition, 
microtubules of the mitotic spindle initiate attachment to chromosomes at kinetochores. This 
specialized chromatin structure is the major site of microtubule-chromosome attachment by 
linking the centromere to the plus ends of microtubules originating from a spindle pole. This 
approximately 75-100 nm multiprotein structure has been exhaustively studied in the past 
few years in terms of its components and structural organization (140). An overall 
description of kinetochore structure and protein composition is given in Figure 4. 
Microtubules are polymers of α/β-tubulin dimers composed of 12-15 filaments arranged in 
hollow 25-nm diameter cylinders. Their length is variable as it alternates between growth 
and shrinkage phases, in a phenomenon generally known as "dynamic instability". Since 
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tubulin dimers are arranged in a fixed determined orientation, microtubules exhibit structural 
polarity, which influences movements along the spindle (132). 
Chromosome attachment begins with the binding of a kinetochore to the lateral surface of 
a microtubule aided by the “search and capture” mechanism. This interaction initiates the 
movement of attached chromosomes towards one spindle pole where conversion from 
lateral to end-on attachment occurs (141, 142). The interaction with microtubules from the 
opposite pole (bi-orientation) allows chromosomes to localize near the spindle equator and 
to form a dynamic arrangement referred to as the metaphase plate.  
During the process of chromosome bi-orientation, four possible kinetochore-microtubule 
attachments can be occur: monotelic attachment when one kinetochore is attached to 
microtubules from one spindle pole and its sister unattached; syntelic attachment when both 
kinetochores of a chromosome are attached to microtubules from the same spindle pole; 
merotelic attachment when a kinetochore is attached to both poles; and amphitelic 
attachment or bi-orientation, when each of the two opposing sister kinetochores is 
associated to microtubules originating from the proximal pole (Figure 5). Bi-orientation 
attachment is the only configuration that ensures accurate chromosome segregation at 
anaphase. 
4. MITOTIC REGULATION 
The control of mitosis is crucial and is mainly coordinated by two post-translational and 
intimately connected mechanisms: protein phosphorylation and proteolysis (143). Many of 
the major morphological changes that define mitosis are under the regulation of protein 
phosphorylation by serine/threonine kinases such as the Cdk1 (previously known as Cdc2) 
in association with Cyclin A and Cyclin B (144). Expression of Cyclin B peaks late in S phase 
and remains high during G2 and mitosis, establishing a complex with Cdk1 named Mitosis-
Promoting Factor (MPF). Cyclin B-Cdk1 activation is fundamental to initiate the M phase 
and is also continuously required to trigger key mitotic events such as Nuclear Envelope 
Breakdown, centrosome separation, chromosome condensation, spindle assembly, APC/C 
(Anaphase-Promoting Complex or Cyclosome) activation and anaphase spindle elongation 
(145). The Ubiquitin-mediated proteolysis of Cyclin B, and consequently the inactivation of 
MPF, marks mitotic exit and cytokinesis (143). Besides these regulatory mechanisms of 
mitosis, cells have also developed a control mechanism that guarantees accurate 
chromosome segregation by preventing mitotic exit until each and every chromosome is 
attached in a bipolar fashion to the mitotic spindle. This machinery is called mitotic 
checkpoint or Spindle Assembly Checkpoint (SAC).  
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Figure 4 : Overview of protein complexes that build the kinetochore in animal cells. The kinetochore is built on 
the centromere as a trilaminar protein-rich structure: the inner kinetochore, the outer kinetochore and the fibrous 
corona. Proteins that compose each kinetochore layer are grouped by function (APC/C, anaphase promoting 
complex/Cyclosome; Bub1-BubR1-Bub3, budding uninhibited by benzimidazole; Cdc20, cell division cycle 20; 
CENP, centromere protein; CLASP, CLIP-associating protein; CLIP170, cytoplasmic linker protein-170; CPC, 
chromosome passenger complex; EB1, end-binding protein-1; INCENP, inner centromere protein; kMTs, 
kinetochore microtubules; LIS1, lissencephaly-1; Mad1-Mad2, mitotic-arrest deficient; MCAK, mitotic 
centromere-associated kinesin; MPS1, monopolar spindle-1; MT, microtubules; NPC, nuclear pore complex; 
PLK1, polo-like kinase-1; RanBP2, Ran-binding protein 2; RanGAP, Ran-GTPase-activating protein; RZZ, Rod 
(rough deal); SAC, spindle assembly checkpoint; Ska1-3, spindle and kinetochore-associated proteins; Zw10, 
zeste white 10 - Zwilch complex; Zwint, Zw10 interactor (132). 
 
Figure 5: Bi-orientation and kinetochore attachment errors. (A) In amphitelic attachment, sister kinetochores are 
correctly attached to microtubules emanating from opposite poles of the spindle, leading to chromosome bi-
orientation. (B) In monotelic attachment, the chromo-some is mono-oriented as one kinetochore is attached to 
the microtubules from one spindle pole, while its sister is unattached. (C) In syntelic attachment, the 
chromosome is mono-oriented but, in this case, both sister kinetochores are attached to microtubules from the 
same spindle pole. (D) In merotelic attachment, one sister kinetochore is attached to microtubules from both 
spindle poles, the chromosome is improperly bi-oriented and, if left uncorrected, can produce an anaphase 
lagging chromosome. (132). 
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4.1 Spindle Assembly Checkpoint 
Key components and mechanism of action 
The SAC is a surveillance mechanism that delays the onset of anaphase until all 
chromosomes are properly attached and bi-oriented on the microtubule spindle (146). 
Although there is still many discussion concerning which parameter is monitored by the 
mitotic checkpoint, the most accepted theory is the one that states that this mechanism 
senses either kinetochore- microtubule attachment and tension across sister kinetochores. 
This theory is reinforced by the fact that tension is generated by forces upon kinetochore-
microtubules attachment and that this attachment needs tension to promote stable 
connections (147-149). SAC maintains cells in mitosis by preventing Cyclin B and securin 
from being targeted by the E3 ubiquitin ligase APC/C and degraded in the proteasome. 
Several conserved components of the SAC are involved, such as the core SAC components 
Mad1, Mad2, BubR1 (Mad3 in yeast, worms and plants), Bub1 and Bub3 (Table 1) (150, 
151).  
Mps1 protein also plays a significant role in SAC activity, besides its initially identified role 
as a requirement for the proper assembly of bipolar spindles (152, 153). Mps1 activity rises 
during mitosis and dynamically localizes to kinetochores, having the ability to dimerize and 
is autoactivated by cross-phosphorylation (154, 155). Mps1 directly phosphorylates the 
inner centromere protein Borealin and, subsequently, increases Aurora B activity. Its activity 
directs a number of checkpoint proteins including Mad1 to unattached kinetochores (156). 
The unattached kinetochores rapidly promote the association of Bub1, BubR1, Bub3, Mad1 
and Mad2 to the kinetochore. Mad2 is a conserved mitotic checkpoint protein that is thought 
to monitor microtubule attachment at the kinetochore, and can adopt two distinct 
conformations, open (O) and closed (C) (Figure 6) (157-159).  
During interphase, most Mad2 exists in the O-conformation, although, localizing at the 
nuclear envelope, a small amount assumes the C-conformation assembled with Mad1 (159, 
160). At prometaphase, Mad1:C-Mad2 complexes are found in unattached kinetochores 
and are believed to act as an instigator of conversion into C-Mad2 (161). C-Mad2 bounds 
to Cdc20, leaves the kinetochores and it is thought to catalyse O-Mad2/C-Mad2 conversion 
in the cytoplasm leading to signal transduction and amplification (162). Mad2 and Cdc20 
together with the subcomplex BubR1:Bub3 promote a “wait anaphase” signal by generating 
the mitotic checkpoint complex (MCC), which prevents APC/C activation by sequestering 
Cdc20 (163, 164). The Bub family is believed to sense spindle tension.  
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Table 1. Mitotic checkpoint core proteins and their most significant properties, 
interactions and functions 
Protein Characteristics 
Known 
ligands 
Role in the SAC Ref. 
Bub1 
122 kDa 
mitotic kinase 
Bub3, SV40 T-
large antigen, 
Blinkin 
Part of the MCC complex. Localizes to 
Kinetochores. Inhibits Cdc20 by 
phosphorylation. Required for recruiting 
other checkpoint proteins. Kinase activity 
is not required for checkpoint arrest. 
(165-167) 
BubR1 
120 kDa 
mitotic kinase 
CENP-E, 
Bub3, Cdc20, 
Blinkin 
Part of the MCC complex. Localizes to 
Kinetochores. Part of APC/C inhibitory 
complex. Directly binds to Cdc20 and 
inhibits APC/C activity. Yeast Mad3, the 
functional equivalent of BubR1. 
(165, 166, 
168) 
Bub3 37 kDa Bub1, BubR1 
Part of the MCC complex. Localizes to 
Kinetochores. Part of APC/C inhibitory 
complex. Localizes Bub1 and BubR1 to 
kinetochores. 
(169, 170) 
Mad1 83 kDa Mad2 
Directly recruits Mad2 to unattached 
kinetochores. Localizes to nuclear pores 
and unattached kinetochores. Binds to 
Bub1 and Bub3 upon checkpoint 
activation in budding yeast. 
(171) 
Mad2 23 kDa 
Mad1, Cdc20, 
CMT2/p31comet 
Inhibits APC/C by binding to Cdc20. Part 
of the MCC complex. Occurs in two 
conformations (‘closed’ C-Mad2 on 
binding Mad1 or Cdc20, or ‘open’ O-
Mad2 when unbound). Localizes to 
nuclear pores and unattached 
kinetochores 
(157, 159) 
Mps1 
97 kDa 
mitotic kinase 
Mad1, 
Proteins SPB  
Essential to centrosome duplication. 
Required for recruitment of Mad1, Mad2 
and CENP-E to the kinetochore. 
Localizes to nuclear pores, centrosomes 
and Kinetochores 
(153, 156) 
 
Although it is widely accepted that Bub1 contributes to the communication between the 
mitotic checkpoint pathway and the kinetochore-microtubule network, its role in SAC is still 
very controversial the actual mechanism (165, 172).  
As soon as chromosomes undergo bipolar attachment and are fully align at the metaphase 
plate, the mitotic checkpoint is quickly silenced. Regarding SAC silencing, a few 
mechanisms have been suggested, including: removal of checkpoint components from the 
attached kinetochore towards spindle poles by the microtubule motor complex dynein to 
cease MCC action; p31comet binding to Mad2, leading to Cdc20 dissociation from Mad2; 
Cdc20 multi-ubiquitination in a APC- or UbcH10-dependent way; and, more recently, a 
distinct regulatory network that includes the protein phosphatases PP1 and PP2A (173-
182). In either case, SAC silencing leads to APC/C activation that in turn, targets Securin 
and Cyclin B for proteolysis. Securin is an inhibitor of a protease known as Separase, which 
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is mandatory to cleave the Cohesin complex that embraces sister chromatids together, and 
ultimately, Cohesin ring break is necessary to accomplish anaphase. In regard to Cyclin B, 
its degradation inactivates Cyclin B-Cdk1 complexes and consequently leads to mitotic exit. 
 
Figure 6: Model of spindle assembly checkpoint signalling. (A) Unattached kinetochore serves as a platform for 
SAC proteins BubR1, Bub3, and Mad2 to generate the mitotic checkpoint complex that binds to Cdc20 
preventing it from activating APC⁄ C, the E3 ubiquitin ligase that targets Securin and Cyclin B for degradation by 
the 26S proteasome, thereby inhibiting anaphase onset. (B) According to the Mad2 template model, a 
constitutively closed conformation of Mad2 (C-M2) bound to Mad1 serves as receptor at the unattached 
kinetochore for cytosolic open form of Mad2 (O-M2) to switch this latter to C-Mad2 bound to Cdc20. C-Mad2⁄ 
Cdc20 complex acts as a structural equivalent of Mad1⁄ Mad2 to convert more O-Mad2 into Cdc20 bound C-
Mad2 in the cytosol, leading to signal amplification (132). 
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5. MITOTIC CHECKPOINT AND CANCER 
Disordered mitotic passage frequently results in chromosome missegregation, essentially 
irreversible, which at high rates describes a phenomenon called chromosomal instability 
(CIN). CIN is a common feature of many cancers and it correlates with poor patient 
prognosis and drug resistance (183). CIN can lead to an abnormal number of 
chromosomes, termed aneuploidy, but not all aneuploid cells display CIN as some cells are 
aneuploid with a stable karyotype. The high frequency of aneuploidy in cancer and the 
awareness of aneuploidy as a possible cause of tumorigenesis were reinforced by analyses 
of the Mitelman Database, a major repository of cytogenetic information on human cancers, 
with results from over 60,000 cases (184, 185).  
The impaired functioning of several cellular pathways has been associated with the 
increasing rate of chromosome gains and losses upon mitosis. Such pathways include: SAC 
dysfunction, centrosome abnormalities, defects in the attachment of chromosomes to 
spindle microtubules and chromosome cohesion defects (131, 186, 187). In this review, we 
will focus on how a defective SAC may contribute to chromosome missegregation. 
The spindle assembly checkpoint is a key signaling pathway that should prevent cells from 
prematurely segregating their chromosomes and, as a result, preclude CIN. A single 
unattached kinetochore was proven to be enough to postpone anaphase onset until the last 
kinetochore is attached to the spindle. On the other hand, a complete silencing of the mitotic 
checkpoint results in massive chromosome loss, cell death and embryonic lethality (112, 
188). However, a weakened mechanism, largely widespread among tumor cells, can cause 
premature anaphase, chromosome instability and aneuploidy (Figure 7) (189, 190). These 
effects have been studied in mice heterozygous for Mad1, Mad2, Bub3, Bub1 or BubR1, 
conditions which led to subtle rates of chromosome instability, compatible with cell viability 
(191-196). In agreement, is the case of patients with the premature chromatid separation 
(PCS) syndrome, also referred to as mosaic variegated aneuploidy (MVA) (197). This rare 
genetic disorder has been linked to mutations in the BUB1B locus and a high rate of cancer 
development, frequently within the first 3 years of life.  
As a result, many studies have been conducted in order to find mutations on checkpoint 
components in human cancers that could explain SAC deregulation, and, although somatic 
mutations were detected and proven to be associated with chromosome segregation and 
cancer progression, it does not seem to be a common contributor for aneuploidy (189, 190). 
However, altered expression levels of SAC genes appear to be much more recurrent, and 
both under and overexpression were reported (190). A lower expression can be explained 
by the results obtained in mice heterozygous for SAC components (191, 193, 195, 196). On 
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the contrary, how an increased expression can be related to aneuploidy remains unknown. 
Nevertheless, some theories have been proposed; for instance, it is possible that 
overexpression could represent a cellular compensation for deficiencies in other molecular 
components of the SAC (198). Regardless the controversy surrounding SAC contribution 
to tumorigenesis and cancer, the involvement of SAC molecular elements in diverse cellular 
processes beyond chromosome congression, should be taken into account (160, 199, 200) 
How post-translational modifications of SAC elements could contribute to chromosome 
instability should also provide important information (201), especially when concerning CIN 
cancer cell lines that appear to have normally functioning checkpoints (202). 
5.1 Therapeutic Targeting of the Mitotic Checkpoint Pathway 
Antimitotic chemotherapy remains the most effective approach in the clinical treatment of a 
variety of human cancers. The most commonly used drugs are microtubule-targeting 
agents, which are classified in two main groups: microtubule-destabilizing drugs, that 
restrain microtubule polymerization (ex: vinca alkaloids); and microtubule-stabilizing 
agents, that intensify microtubule polymerization (ex: taxanes) Figure 8) (112). Vinka 
alkaloids such as vincristine, vinblastine, and vinorelbine, are often used for solid and 
haematological malignancies, such as NSCLC and Hodgkin and non-Hodgkin lymphoma 
(112, 124). Taxanes such as docetaxel and paclitaxel are frequently used as adjuvant on 
advanced breast, ovarian and head and neck cancer (124). On both classes these drugs 
avert a functional spindle leading to SAC activation and anaphase delay (108). After mitotic 
arrest, cells may undergo two different pathways, cell death or mitotic slippage (109). 
Slippage refers to a process where cells exit mitosis and begin a new cycle with twice the 
DNA content (110). These cells can arrest in G1 phase, undergo cell death or continue cell 
cycle progression increasing the potential for tumorigenesis (111). Apart from that, severe 
side effects, like myelosuppression and neurotoxicity and the frequent development of 
resistance to these drugs have limited their use and motivate the search for different 
antimitotic drugs (112).  
SAC is an essential cell cycle checkpoint for cell survival and inducing lethal instability by 
targeting this mechanism is an innovative strategy in cancer therapy (203). Inhibitors of 
kinesin motor proteins, which are vital for spindle assembly and chromosomes movement 
during mitosis, show to be promising in this regard (114). CENP-E is an essential plus end-
directed microtubule motor, present only in cells undergoing mitosis and is a fundamental 
protein for the alignment of chromosomes by moving unattached kinetochores towards the 
metaphase plate along kinetochore microtubule bundles, termed K-fibers (120).  
 
  
P a g e  26 
 
Figure 7: Defects in SAC activity can contribute to aneuploidy and tumorigenesis. Chromosome missegregation 
is prevented in cells with a fully functional SAC. In cells with weakened SAC activity, the residual checkpoint 
activity can still ensure the accuracy of chromosome segregation. However, occasional missegregations may 
escape from SAC control and lead to aneuploidy, which may contribute to tumorigenesis (131). 
 
Figure 8: Models for targeting mitosis as an anticancer strategy. Treatment with mitotic entry inhibitors or spindle 
poisons leads to G2 or prometaphase arrest that eventually may end up in apoptosis during interphase or 
mitosis. However, cells may escape entering into a new cell cycle. Depending of the status of genes such as 
p53, pRb or p38, these cells may arrest before entering S phase, die or continue proliferating. Targeting mitotic 
checkpoint regulators, such as BubR1, Mps1 or Mad2, leads to severe levels of aneuploidy. Cells containing 
numerical chromosome aberrations can similarly either arrest in the subsequent G1 phase, progress through 
the cell cycle or undergo cell death. Inhibiting mitotic exit (e.g., by targeting APC/C-Cdc20) causes a permanent 
metaphase arrest by preventing cyclin B1 degradation, thus irreversibly leading to mitotic cell death (133) 
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CENP-E provides a link between chromosome/microtubule attachments and SAC by 
modulating BubR1 function (204). Cell cycle arrest and apoptosis are two consequences of 
the inhibition of CENP-E activity, which can act as tumor suppressor and represent an 
attractive antimitotic target (121). Several CENP-E inhibitors have been studied and a few 
have reached phase I of clinical trials (122, 205, 206). 
In addition to CENP-E, Eg5 is a plus-end-directed kinesin 5-family protein, essential for the 
assembly and organization of the mitotic spindle and thought to bind antiparallel 
microtubules and slid them apart. Eg5 suppression results in the formation of characteristic 
monoaster spindles followed by mitotic arrest and apoptosis (207). The first small-molecule 
inhibitor being identified was monastrol, a cell-permeable molecule that arrests cells in 
mitosis, but since then, several Eg5 inhibitors have been analyzed and reached clinical trials 
(208). In spite of the initial expectation and the limited toxicity profile, only partial responses 
have been observed, suggesting that these agents should be used in combination with other 
cytotoxic drugs (114). 
Mitotic kinases are deregulated in a multiplicity of tumor cells, suggesting their potential role 
in tumorigenesis and making them a tempting target for molecular therapies(115). PLK1 
(polo-like kinase 1) and Aurora kinases represent a highly conserved family of 
serine/threonine kinases that ensures a correct spindle assembly heading to an accurate 
segregation of the chromosomes into daughter cells. There are three human Aurora 
kinases, Aurora A, B and C. Aurora A is the most extensively studied member and is 
required for bipolar spindle formation. Its suppression leads to cell cycle arrest and 
monopolar mitotic spindles, as it happens in Plk1 inhibition. Aurora B is required for 
chromosome segregation and cytokinesis and, thus, its inhibition culminates in a premature 
exit from mitosis, leading to polyploidization (209). In addition, inhibition of Aurora B kinase 
activity prevents BubR1 kinetochore localization after a reduction in centromeric tension. 
Aurora C is the less extensively investigated member and it appears to be important during 
mitosis, where it assumes a centrossomal localization and functions very similarly to Aurora 
B (210). An association between Aurora C and cancer has not been established until now. 
Due to their recognition as potential targets for cancer chemotherapy, around 30 Aurora 
kinase inhibitors have reached different stages of pre-clinical and clinical development 
(116). Concerning Plk1 activity, small-molecules and phosphopeptide inhibitors have been 
recently developed due to their potency and specificity against Plk1 (117). Blocking these 
targets’ activity might not necessarily end in cell death; instead, cells can undergo mitotic 
slippage and exit mitosis without proper segregation of sister chromatids and cytokinesis, 
exhibiting multiple nuclei and polyploidy. 
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Another important mitotic kinase is Mps1, which is required for proper chromosome 
segregation during mitosis. Due to its function in mitosis, Mps1 is an appealing target for 
anti-cancer therapies. Mps1 reduced levels have showed to increase tumor cells, but not 
normal cell, sensitivity to paclitaxel, resulting in severe chromosome segregation errors and 
subsequently, in cell death (156). Although several chemical inhibitors of human Mps1 
kinase activity led to promising results, none has fulfilled clinical premise (136, 211). 
Mitotic slippage and its consequences occurs in the presence of an active SAC and it’s 
thought to be trigger by cyclin B destruction (109). Considering the interest in stabilizing 
cyclin B concentrations in order to prevent mitotic exit, the E3 ubiquitin ligase APC/C has 
also been evaluated as potential cancer drug target. APC/C depletion, by RNA interference 
(RNAi), results in a prolonged mitotic arrest and increases cell sensitivity to 
chemotherapeutics (212). A small molecule called TAME was discovered, which prevents 
APC/C activation but still allows cyclin B degradation (213). This reflects the difficulties in 
targeting ubiquitin ligases. With the same purpose, experiments have been made in order 
to promote Cdc20 inhibition by RNA interference or genetic elimination (214). Mitotic arrest, 
vast apoptotic cell death and tumor regression resulted from Cdc20 removal (215). These 
results reinforce that targeting mitotic exit may be an excellent adjuvant for other mitotic 
drugs. 
The SAC core proteins Mad2 and BubR1 bear the potential to be successful targets of 
several therapeutic strategies since their abnormal expression has been reported in 
countless types of malignancies (216-218). When downregulated, these proteins showed 
to increase cell proliferation and drug resistance although the responsible mechanism has 
not been fully evaluated (131, 219). On the contrary, their knockdown is consistently lethal, 
due to colossal chromosome loss, culminating in the inhibition of tumor progression (188, 
191). A more recent work has described a natural diterpenoid, Pharicin A, capable of 
inhibiting BubR1 (220). During the last decade, a regulatory mechanism for gene expression 
in eukaryotic cells has gained particular attention. RNA interference has emerged as a 
powerful tool for modulating gene expression, including Mad2 and BubR1 expression (221, 
222). A new class of anti-mitotic compounds has been emerging and continues to highlight 
the importance of increasing our knowledge on these pathways, so that it can be reflected 
in cancer drug development. 
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RNA INTERFERENCE 
1. INTRODUCTION 
RNA interference (RNAi) is a well characterized mechanism of eukaryotic gene regulation 
but also a defense mechanism to foreign RNA like from viruses and transposable elements 
(223). It has been a major focus of research since it allows to determining and dissecting 
the function of specific proteins and treatment of diseases caused by overexpression of 
specific genes (224, 225). The main advantage of RNAi when compared to approaches 
based on small molecules, antibodies or proteins, is that this approach can focus in any 
target, including the ones that do not fit into the so-called "drugable target classes", provided 
that the nucleotide sequence of the target gene of interest is known. Other benefits on using 
RNAi include high degrees of efficiency, specificity and efficacy, uncomplicated synthesis 
and manufacture, and high cross species reactivity (224).  
RNAi, with its valuable advantages, has provided an enormous potential as a therapeutic 
tool given the ability to target and silence specific genes. As most of diseases embroil some 
sort of deregulated gene, including cancer, metabolic and genetic disorders, virus 
infections, they all become a possible target for RNAi-based therapeutics.  
2. RNAI MECHANISM 
RNA interference is mediated by the RNA-induced silencing complex (RISC) and by short 
double stranded RNA molecules that have about 20-30 nucleotides and can be found 
naturally in organisms or synthetically produced to target a specific gene (  
Figure 9) (226). RNAi mainly occurs via two types of RNA molecules: small interfering RNAs 
(siRNAs) and microRNA (miRNA). miRNAs are endogenous non-coding single-stranded 
RNAs that mediate post-transcriptional gene silencing from endogenous transcripts. 
siRNAs can be produced from a long double-stranded RNA, of endogenous or exogenous 
origin, by the enzymatic activity of the RNase III enzyme Dicer. Synthetic siRNAs have a 2-
nucleotide 3’ overhangs that copycats Dicer products. siRNAs produced by Dicer-mediated 
cleavage are incorporated into the RISC. The RISC complex is a multi-protein complex with 
nuclease activity that uses the antisense strand of the siRNA to target complementary 
mRNA for subsequent site-specific cleavage and degradation (227). The RISC complex is 
then recovered for further cleavage/degradation cycles. The mRNA cleavage is the result 
of the endoribonuclease activity of the RISC subunit, Argonaute 2 (228). Although there are 
additional RISC components, their roles in RNAi are not clearly known.  
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Figure 9: Small regulatory RNAs are non-coding RNA molecules that silence target RNAs in a sequence-specific 
manner. siRNAs, mediate RNAi by downregulating target RNAs through slicing; that is, by endonucleolytic 
cleavage These small RNAs are derived from long double-stranded RNA (dsRNA) molecules that result from 
RNA virus replication, convergent transcription of cellular genes or mobile genetic elements, self-annealing 
transcripts or experimental transfection. The endonuclease Dicer functions as a molecular ruler to cleave the 
dsRNA at 21-25-nucleotide intervals. After Dicer-mediated cleavage, one strand of the siRNA duplex (the guide 
strand) is loaded onto an Argonaute protein at the core of an RNA-induced silencing complex (RISC). (For 
simplicity, in the figure, the RISC is represented just by an Argonaute protein.) Argonaute loading takes place 
in the RISC-loading complex, a ternary complex that consists of an Argonaute protein, Dicer and a dsRNA-
binding protein (known as TRBP in humans). During loading, the non-guide (passenger) strand is cleaved by 
an Argonaute protein and ejected. The Argonaute protein then uses the guide siRNA to associate with target 
RNAs that contain perfectly complementary sequence and then catalyses the slicing of these targets. After 
slicing, the cleaved target RNA is released, and the RISC is recycled for another round of slicing. (Adapted from 
229). 
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3. RNAI VERSUS ANTISENSE APPROACH 
The use of antisense oligonucleotides is another method of gene knockdown; however it 
relies on ribonuclease H (RNAse H)-dependent cleavage of mRNA. Antisense 
oligonucleotides refers to short, single-stranded DNA or RNA sequences that are designed 
to be synthetic analogues of natural nucleic acids that specifically bind to a target mRNA. 
Similar to RNAi technology, antisense approach works reducing translation of target protein 
using the cell machinery leading to a greatly potent down-regulation of gene expression. 
Since their first applications in 1978, several chemical modifications have been proposed in 
order to improve antisense oligonucleotides stability in vitro and in vivo, but still maintaining 
their activity (230). Two of the most common modifications include the addition of 
phosphorothioate bonds and 2′‐O‐methyl‐modified nucleotides (231).  
This last modification has successfully been used in clinical trials (232). Small antisense 
RNA may culminate on the same effect though it displays a much lower efficiency 
comparing to RNAi. Due to their charge and nature, generally both kind of molecules do not 
cross cell membranes efficiently on their own and therefore need to be specially formulated 
for most applications. 
4. SIRNA VS. SHRNA 
siRNAs are the most frequently used oligonucleotides in RNAi-based therapeutics, although 
there are two more different classes, miRNAs and short hairpin RNAs (shRNAs) (233). 
These three have different efficiencies and specificities, but all share the intervention of 
RISC in their RNAi pathways in mammals. siRNA and shRNA are originated from 
exogenous molecules. While siRNAs are delivered to target cells as 20-30 base duplexes 
using a RNA-based strategy, shRNAs are expressed from plasmids or viral vectors in a 
DNA-based approach, originating longer RNA hairpin transcripts that are intracellularly 
converted into siRNA (234). shRNAs are more frequently used in laboratory studies since 
they allow permanent gene silencing. shRNAs have a higher potential of being a successful 
therapeutic strategy since they result in a permanent potent gene silencing in a single 
treatment (235). However, shRNAs lose their main advantage to RNA-based approach 
when cell death is the main result of target gene knockdown. Another disadvantage of 
shRNA consists on the potential sequence-specific off-target effects due to structural 
similarities with miRNAs (236). 
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5. RNAI-BASED ANTI-CANCER THERAPY 
The discovery of RNAi has prompted many innovations in the medical field. RNAi has been 
extensively analyzed aiming at two main purposes: elucidation of gene functions and as 
therapeutics. By knocking down a single gene at a time and studying the outcome, RNAi 
technology allows us to identify the genes responsible for the loss of that specific function 
or a particular disease, but also to detect synthetic interactions between genes due to 
redundancy of gene function in complex organisms (237). These can point out important 
targets for therapeutics. Theoretically, RNAi could be applied to treat or stop progression of 
any disease, including brain disorders such as Huntington’s and Alzheimer’s, hereditary 
maladies, genetic and viral diseases, and cancer. In fact, several of them have already 
progressed from bench to bedside with several RNAi-based drugs undergone through 
clinical trials (238). From now on, we will focus on the therapeutic potential of RNAi in cancer 
treatment. 
RNAi therapeutics can be used to concurrently target multiple genes in different cellular 
pathways involved in tumor development and also be manipulated as an individually 
personalized anticancer drug (239). siRNA and shRNA have been extensively employed, 
with favorable outcomes in silencing key targets like oncogenes, proteins with different 
functions, including enzymes, cell cycle regulators, cytokines, etc., and that are critical for 
tumor cell growth, metastasis, angiogenesis and chemoresistance (240, 241). On the basis 
of their effectiveness, the most promising ones have been presented in a large number of 
preclinical studies involving mouse xenograft models. Tumor cell proliferation is one of the 
most significant predictor of prognosis for different types of cancer. Tumor necrosis factor 
ligand (TNF) superfamily member 13, also known as a proliferation-inducing ligand (APRIL) 
is a member of the TNF ligand family. This protein has been shown to be capable of inducing 
the tumor proliferation (242). In the in vivo study of Wang and co-workers, after intratumoral 
injection of APRIL siRNA, the grafted human colorectal tumor had its growth and metastasis 
inhibited as well as increased apoptosis and necrosis (243).  
Signal transducer and activator of transcription (STAT) proteins are activated by many 
cytokines and growth factors and play a key role in cell survival, proliferation, and 
differentiation. Constitutively activated STAT leads to induction of an anti-apoptotic pathway 
and has been reported in a number of malignant cell lines and human cancers (244). 
STAT3, a member of this family, is a point of convergence for many oncogenic pathways 
directly contributing to tumorigenesis, invasion, and metastasis (245). For these reasons, 
STAT3 has been seriously considered as a silencing target in hepatocarcinoma, prostate 
cancer, T-cell lymphomas, melanoma, lung cancer and ovarian cancer (246-249). Yang and 
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co-workers have obtained consistent in vitro and in vivo results showing that STAT3 siRNA 
can effectively inhibit the growth of breast cancer cell and the development of human tumor 
xenografts in mice (250). 
A promising strategy against cancer is to use RNAi as a tool to silence oncogenes, turning 
off major MDR mechanisms as increased drug efflux, decreased drug influx, activation of 
detoxifying systems, activation of DNA repair and blocked apoptosis (251). Overexpression 
of ATP-binding cassette (ABC) transporters, as MDR1 (ABCB1), MRP1 (ABCC1) and 
ABCG2, is one of those mechanisms and several attempts have been made to co-deliver 
siRNA targeting MDR1. Li et al. developed a MDR1 siRNA and Dox co-delivery system 
using drug resistant HeLa/Dox cells which culminated in reduced levels of MDR1 gene 
expression, enhanced intra-cellular Dox accumulation and an increased toxicity of Dox 
(252). 
RNA interference has been very helpful as an adjuvant for chemotherapy and radiotherapy 
as it can increase cell sensitivity. Bcl-2 and nuclear factor erythoid-2-related factor 2 (Nrf2) 
siRNAs are two examples that illustrate such occurrence (253, 254). Cancer cell resistance 
to chemotherapy depends on two main components: nonpump resistance and pump 
resistance. Apoptosis regulator Bcl-2 plays a vital role in nonpump resistance by activating 
cellular anti-apoptotic defense and preventing cell death (255). Chen and collaborators 
deliver doxorubicin and Bcl-2-targeted siRNA simultaneously into multidrug resistant human 
ovarian cancer cells. Their results showed that Bcl-2 siRNA can effectively decrease the 
Bcl-2 mRNA by 80%, significantly suppress the nonpump resistance, and substantially 
enhance the anticancer action of doxorubicin (253). 
One example of pump resistance is Nrf2, a transcription factor that play a physiological role 
in the regulation of oxidative stress and is involved in a cellular protective response that 
defends cells against toxic insults from a broad spectrum of chemicals (256). Nrf2 and its 
downstream genes are overexpressed in resistant cancer cells and human cancer tissues, 
which is thought to underlie acquired chemoresistance, providing cancer cells with an 
advantage for survival and growth (257). Activation of Nrf2 results in the induction of 
multidrug resistance-associated proteins (Mrps), membrane multidrug efflux transporters. 
Ma and collaborators used a cervical cancer mouse xenograft model transfected with 
plasmids containing Nrf2-shRNA and were able to decrease Nrf2 mediated-target genes 
expression levels (258). Nrf-2 siRNA in combination with cisplatin treatment had the ability 
to significantly inhibit tumor growth. Bcl-2 and Nrf-2 might therefore constitute promising 
therapeutic targets to enhance the efficacy of anticancer drugs. SiRNA and shRNA 
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therapeutics have been explored in numerous preclinical studies but only six RNAi-based 
drugs for cancer are currently being evaluated in clinical trials (Table 2). 
Table 2: RNA interference based therapeutics in clinical trials a 
Diseases Target Drug name Phase 
Sponsor/ 
Collaborators 
Advanced or Metastatic 
Pancreatic Cancer 
Protein Kinase N3 Atu027 1/2 
Silence Therapeutics AG;  
Granzer Regulatory 
Consulting and Services;  
FGK Clinical Research 
GmbH 
Pancreatic Cancer KRASG12D siG12D LODER 2 Silenseed Ltd 
Solid Tumor Cancers 
M2 subunit of 
ribonucleotide 
reductase 
CALAA-01 1 Calando Pharmaceuticals 
Advanced solid tumors EphA2 
siRNA-EphA2-
DOPC 
1 
M.D. Anderson Cancer  
Center; Ovarian Cancer  
Research Fund 
Solid Tumors; NSCLC;  
Renal Cell Carcinoma;   
Hepatocellular 
Carcinoma; Ewing's 
Sarcoma 
furin FANG™ Vaccine 1 Gradalis, Inc. 
Advanced Cancer; 
Metastatic Cancer;  
Solid Tumors 
STMN1 
pbi-
shRNA™STMN1 
1 Gradalis, Inc. 
Stage III Ovarian  
Cancer; Stage IV 
Ovarian Cancer 
furin FANG™ Vaccine 2 Gradalis, Inc. 
a http://www.clinicaltrials.gov.  
One of those is Atu027, which consists of a cationic lipoplex formulation with siRNAs 
targeting protein kinase N3 (PKN3) (259). Previous studies have shown that the depletion 
of this kinase resulted in the inhibition of lymph node metastasis in orthotopic prostate 
cancer mouse models (260). Aleku and co-workers evaluated the effect of siRNA molecules 
formulated into siRNA-lipoplexes that consisted of a mixture of cationic and fusogenic lipids 
complexed with the negatively charged siRNA. They were successful in the in vivo 
downregulation of the corresponding mRNA and protein levels, with significant inhibition of 
tumor growth and lymph node metastasis. Atu-027 is presently in Phase I clinical trials and 
has early exhibited signs of efficacy (259). 
A transferrin receptor-targeted nanoparticle has been introduced by Calando 
Pharmaceuticals for siRNA delivery (261). This targeted siRNA nanoparticle formulation, 
denoted as CALAA-01, aims to inhibit the expression of M2 subunit of ribonucleotide 
reductase (RRM2), a gene involved in DNA replication, and to prevent the proliferation of 
tumor cells. RRM2 is a therapeutic target for DNA replication-dependent diseases such as 
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cancer and, when downregulated, exhibits significant antiproliferative activity (262). Taking 
into account that transferrin receptors are typically upregulated on cancer cells, human 
transferrin was used as a targeting ligand in the surface of the nanoparticle that consisted 
of a cyclodextrin-containing polymer and PEG as a steric stabilization agent. On phase I 
clinical trials, CALAA-01 was systemically administrated to patients with solid tumors and 
was able to silence the cancer-associated gene in specifically-targeted tumor cells (261). 
The local microenvironment, or niche, plays important roles in tumor growth through central 
processes as angiogenesis and inflammation. The VEGF family of ligands and receptors 
are key regulators of these processes (263). Alnylam Pharmaceuticals has taken that in 
consideration and has developed ALN-VSP02, a lipid nanoparticle formulation 
encapsulating two modified siRNAs targeting either the VEGF or Eg5 kinesin. Eg5 is a 
member of the kinesin superfamily of microtubule-based motors and mediates centrosome 
separation and bipolar spindle assembly and maintenance (264). Its depletion in pre-clinical 
studies has led to cell cycle arrest at mitosis and ultimately, to cell death, while VEGF 
knockdown was associated with decreased tumor growth and microvessel density (265). 
ALN-VSP02 has shown the same effects in preliminary clinical data on phase I clinical trial, 
along with the potential to sensitize liver cancer to chemotherapy.  
RNAi possesses high specificity and high efficiency in down regulating gene expression, it 
consists on a potential therapeutic strategy against many diseases. siRNA technology is 
therefore expected to be an invaluable treatment for number of diseases including cancer, 
although the future success of this approach will depend on the development of effective, 
specific and safe delivery systems. 
6. CHALLENGES OF RNAI AS THERAPEUTIC PLATFORM 
RNAi has shown immense potential in the treatment of cancer, viral, and genetic disorders. 
However, there are some disadvantages and limitations (266). RNAi can be more toxic than 
traditional drugs as they might affect the functions of undesired targets by non-specifically 
targeting other RNAs (the so-called off-target effects) (240). siRNAs may also activate 
components of the immune system in some cases, leading to non-specific 
consequences/phenotype. The most critical factor limiting the utility of siRNA as 
therapeutics is delivering siRNA to its intracellular target site (233). Delivery of these 
molecules into the desired organs, tissues and cell sites in the body is still minimally 
understood at this time and has known major obstacles as kidney filtration, degradation by 
endonucleases, aggregation with serum proteins, and uptake by phagocytes (Table 3) 
(240). Because of these reasons, the development of novel nano-sized carriers, viral and 
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non-viral, capable of delivering siRNA, will be critical for the systemic delivery of siRNA 
therapeutics.  
Table 3: Major obstacles for therapeutic 
efficacy of siRNA without modifications 
Stability 
Specific targeting to diseased cells 
Saturation of RNAi/miRNA 
machinery 
Immune response stimulation 
Off-target effects 
Delivery: 
• Renal filtration 
• Serum protein aggregation 
• Phagocytes uptake 
• Vascular endothelium 
• ECM 
• Cellular uptake 
• Endosome degradation 
• RISC loading 
 
First, the system should be preferably biocompatible, biodegradable and non-immunogenic; 
second, the system should be able to efficiently deliver siRNA to target cells without being 
attacked by serum nucleases; next, the delivery system should provide target specific 
distribution/ penetration, avoiding rapid hepatic or renal clearance; and finally, after delivery, 
the system should help the efficient endosome release of siRNA into cytoplasm allowing 
the interaction of siRNA with the endogenous RISC (224, 238). Although the viral vectors 
are very efficient delivery vehicles, due to the toxicity associated with this delivery, the non-
viral/synthetic nanoparticle system has become an increasingly popular alternative for 
siRNA delivery. Some of the commonly used delivery systems include lipid based carriers, 
polymer systems, peptides/proteins and conjugates(240). These are known to passively 
accumulate in the tumor site due to their leaky vasculature and lack of the lymphatic 
drainage system.  
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7. CHITOSAN-BASED NANOSYSTEMS  
In recent decades, gene delivery research has developed very quickly due to its vast 
potential as a therapeutic approach for clinical applications. However, as mentioned before, 
these naked therapeutic genes present major challenges and therefore, the improvement 
of safe and efficient delivery systems is essential for the success of gene therapy (267). In 
recent years, chitosan(CS)-based carriers have emerged as a powerful tool and gained 
increasing importance as a safe delivery system for nucleic acids (268). Due to its 
mucoadhesion, high positive charge density, low toxicity, low immunogenicity, 
biocompatibility, CS potential in the medical field is broadly promising (269). Reports 
indicate its application in very distinct areas such as microbiology, tissue engineering 
applications, dental implants, cosmetics, food industry, etc. (270, 271). 
CS is a linear copolymer polysaccharide consisting of beta-(1-4)-linked 2-amino-2-deoxy-
D-glucose (Dglucosamine) and 2-acetamido-2-deoxy-D-glucose (N-acetyl-D-glucosamine) 
units (Figure 10) (272).  
 
Figure 10: Chitin and Chitosan structure (272) 
It is obtained by deacetylation of chitin, which is the structurally present in the exoskeleton 
of crustaceans and cell walls of fungi which makes it biodegradable and inexpensive (273). 
From the biopharmaceutical point of view, CS has very appealing characteristics such as 
pH sensitivity, biocompatibility, biodegradability, mucoadhesivity, very low toxicity (an LD50 
in rats of 16 g/kg) and low immunogenicity (274).  
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CS is believed to be one of the most commonly exploited natural polymers for nanoparticles 
preparation because of its unique structural attributes. This polymer is poorly soluble in 
water and organic solvents, but soluble in most dilute aqueous acidic solution (pH < 6.5) 
(275). This property confers positive charges to CS that allow it to establish electrostatic 
interaction with the negative charges from the nucleic acids but also negatively charged 
molecules, such as phosphates, sulfates and citrates ions, to form hydrogels (276). The 
number of positive charges are directly related to the presence of the protonable amino 
group along D-glucosamine residues, which defines CS’s deacetylation degree (DD). By 
definition, DD is calculated as the ratio of D-glucosamine to the sum of D-glucosamine and 
N-acetyl D-glucosamine. When chitin becomes deacetylated on its D-glucosamine residues 
above 60%, the polymer is now designated as CS (277). DD and molecular weight are the 
two parameters that usually characterize CS and directly dictate its properties. DD typically 
ranges between 60 and 100% while its molecular weight greatly varies from 5 to 1000 kDA, 
and together these two parameters can greatly influence properties such as 
biodegradability, drug release profile, cellular uptake, etc. (278). A high DD will imply a high 
density of positive charges enabling a greater loading capacity of nucleic acids. Also, the 
ratio between the charges in the final complex will be of extreme importance because it will 
ultimately determine the transport of siRNA across cellular membranes and endocytosis 
into the cells but also its release inside the cell(278).  However, there are still some 
disagreement in which molecular weight is related to a higher transfection efficiency, the 
high or the low molecular weight. Some authors report that low molecular weight is not 
sufficient to create a stable interaction with siRNA, but in contrast, another paper showed 
that efficient silencing (279, 280). However, the molecular weight is an important factor that 
influences physicochemical properties (size, surface charge, morphology and complex 
stability) and gene silencing of chitosan/siRNA nanoparticles (270). 
Meanwhile, CS is a versatile biomaterial with a relatively simple chemical structure that 
allows CS to be further modified to create a wide range of possible drug delivery carriers. 
Also, specific chemical modifications can be done to ideally achieve a sustained/controlled 
release of a drug into a specific environment creating an optimal response, with minimum 
side-effects and prolonged efficacy (281). An increasing number of studies are focusing on 
modification of CS that are characterized by pH sensitivity, thermosensitivity, targeting 
accuracy and hydrophobic modification (279, 282, 283). In this study CS functional blocks 
have been made to self-assemble and encapsulate a modified hydrophobic small molecule, 
and ultimately to deliver them to the target cells efficiently (282). One of the most common 
passive targeting modifications consists in adding a polyethylene glycol (PEG) chains (284, 
285). PEG surface, in particular has the main advantage of providing a longer blood-
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circulating half-life by blocking and delaying the opsonization process and so, protecting 
nanocarriers from the reticulo-endothelial system, thus minimizing their removal at the liver 
site (286). Active targeting can also be achieved by simple processes as chemical 
modiﬁcation of nanoparticles surface or more complex processes such as particle 
conjugation with specific ligands or antibodies (287, 288). These systems allow the dosages 
frequency to be reduced which culminates in lesser side effects and fluctuation on drug 
levels and also a more stable effect of the drug. 
In this context, CS in vitro and pre-clinical application have contribute with a large amount 
of knowledge supporting its large potential as tumor-targeted siRNA-delivery carrier for 
cancer therapy.  
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Objective and Specific Aims 
The main goal of this dissertation project was to develop and evaluate a novel CS based 
nanoparticle system that efficiently encapsulates siRNA against the mitotic gene mad2 to 
be used as a therapeutic strategy in lung cancer cells/ tumors.  
The specific aims undertaken in the present thesis were: 
i) Development, optimization and selection of EGFR-targeted and non-targeted CS 
nanoparticles for Mad2 siRNA delivery.  
ii) In vitro evaluation of the biological activity and biocompatibility of the selected 
formulation. 
iii) Investigation of the qualitative and quantitative biodistribution profile and 
assessment of pharmacokinetics parameters of the targeted and nontargeted 
nanoparticles in mice bearing subcutaneous, cisplatin sensitive or resistant, human 
lung adenocarcinoma xenograft tumors. 
iv) Evaluation of the in vivo efficacy and safety of the different formulations as a single 
therapy and in combination with cisplatin in drug sensitive (A549-WT) and cisplatin-
resistant (A549-DDP) subcutaneous tumor models of NSCLC. 
v) Development of CS-based combinatorially designed nanoparticles platform 
technology that generates self-assembled nanoparticle constructs to encapsulate 
hydrophobic small molecules.  
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1. INTRODUCTION 
Lung cancer is the most common cause of cancer related deaths worldwide, and NSCLC 
alone accounts for nearly 80% of the fatalities (289). One of the major causes of poor clinical 
outcomes in NSCLC is the development of multidrug resistance and metastatic 
dissemination to other parts of the body. Refractory disease is the major contributor to the 
failure of chemotherapy in NSCLC and it often develops due to poor drug availability, 
reduced residence time in tumor, ineffective intracellular penetration, dynamic tumor 
microenvironment, and other molecular mechanisms adapted by cancer cells (290, 291). 
Alternative approach to develop new targets to overcome multidrug resistance and augment 
the therapeutic effects of existing drugs has therefore gained central interest in scientific 
community. RNA interference (RNAi) has emerged as a powerful strategy for overcoming 
drug resistance in NSCLC, since it allows silencing of specific genes that could be 
associated with multidrug resistance (292). Small interfering ribonucleic acids (siRNAs) 
allows the possible targeting of vital genes in tumor cells, adapting it to specific tumor types 
and customizing it to personalized therapy for subtle genotypic and phenotypic variations. 
Molecular therapy using siRNA has shown therefore great potential in the treatment of 
diseases such as cancer, by silencing crucial genes (292-294). 
The mitotic checkpoint thoroughly ensures that each new cell receives one copy of each 
chromosome from a dividing cell (131, 132). Many cancer cells have a weaker mitotic 
checkpoint which accelerates the rate of chromosome losses and gains, thereby acting as 
a driving force for carcinogenesis (131, 132). However, total suppression of the mitotic 
checkpoint activity is lethal, thus making it an attractive therapeutic target for siRNA 
mediated intervention (131). In fact, several small molecules targeting the mitotic checkpoint 
are already under clinical trials. Mad2 is one of the key mitotic checkpoint regulators that 
sequester Cdc20, thereby inactivating anaphase-promoting complex/cyclosome (APC/C), 
the complex responsible for trigging anaphase (132). Mad2 overexpression has been 
associated with aneuploidy and tumorigenesis and reported in various carcinomas such as 
such as liver cancer, breast cancer, soft-tissue sarcoma, B-cell lymphoma and NSCLC 
(218, 295-297). Decreased expression, but not complete obliteration of mitotic checkpoint 
genes has been associated with resistance to antimicrotubule drugs and DNA damaging 
agents (217, 298). In addition, low levels of Mad2 have been correlated with cisplatin 
resistance and high levels with sensitivity to the same drug (299, 300) Nonetheless, Mad2 
knockdown has been shown to be catastrophic and incompatible with cell viability (191, 
221). RNAi-mediated knockdown of Mad2 causes massive chromosome mis-segregation 
during mitosis and its null mutation in mice embryo causes early death during 
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embryogenesis (133). The selectivity and the catastrophic impact of Mad2 gene silencing 
on cancer cells, therefore, would be a highly attractive alternative therapy for cancer.  
The most challenging obstacle in siRNA therapeutics is their efficient delivery to the target 
cells. Some of the major difficulties includes poor pharmacokinetic property, enzymatic 
degradation, cellular permeability restrictions, endosomal trapping, off-target effects, and 
systemic interferon responses (267). Careful choice of a suitable delivery vector, however, 
can aid in circumventing many of these challenges and imparting significant benefit to RNAi 
as a clinically viable therapeutic option (301) An ideal delivery vector should fulfill certain 
criteria before it can be used for therapeutic applications. Biocompatibility, biodegradability 
and non-immunogenicity are some of the key consideration while designing a delivery 
system. We have recently demonstrated hyaluronic acid (HA) derivative-based self-
assembling vectors for delivery of siRNA targeting anti-apoptotic genes, survivin and Bcl2, 
in NSCLC (302). HA is a natural polymer with backbone that imparts CD44 receptor 
targeting ability to the nanoparticles and could also be used for synthesis of different 
derivatives by easy chemical coupling reactions. A detailed in vitro study demonstrated 
efficient delivery of the payload to the A549 human NSCLC cells and subsequent 
knockdown of the target gene. In vivo studies in subcutaneous A549 (wild-type, drug 
sensitive) and A549-DDP (cisplatin-resistant) NSCLC tumor-bearing mice further 
demonstrated that this delivery approach could be used in combination with cisplatin to get 
synergy of antitumor activity and overcome multidrug resistance (303, 304). 
CS is a similar natural polymer that has been extensively studied for nucleic acids delivery 
in vitro and in vivo (273, 305, 306) CS presents several advantages such as 
mucoadhesivity, biocompatibility, biodegradability and low cost of production. Most 
importantly, chitosan can bind with polyanionic molecules such as DNA or siRNA by 
electrostatic interaction due to the presence of protonated amine groups in the backbone, 
leading to the formation of nano-sized particles (268). Besides, the amine backbone of CS 
allows for chemical modifications such as attachment of PEG to impart stealth property or 
functionalization with ligands to target specific cancer cell type. Although there are no 
chitosan-based vectors for in vivo administration of nucleic acids at clinical level, there are 
numerous publications that report their use as a vaccine adjuvant for oral and intranasal 
peptide/vaccine delivery (269, 307, 308). Similarly, chitosan has been extensively used as 
a delivery vector for anticancer therapeutic small molecules and nucleic acid and therefore 
it serves as a promising candidate for siRNA administration in vitro and in vivo (309, 310).  
In the present study, we have designed EGFR-targeted CS vector for delivery of siRNA to 
selectively silence Mad2 gene, thereby depleting the corresponding protein expression and 
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study its impact in A549 cells. PEG and EGFR binding peptide derivatives of CS were 
synthesized, characterized and used for assembling CS-siMad2 complexes of the size 
below 250 nm and a net positive surface charge (Figure 11). In vitro transfection efficiency 
was evaluated as a function of dose and time and subsequent silencing activity of the siRNA 
was confirmed by qRT-PCR at gene level and flow cytometry at the protein level. Time-
dependent cytotoxicity and apoptosis assessments were also carried out to confirm the 
impact of Mad2 gene silencing on the cells.  
 
Figure 11: Schematic diagram 
2. EXPERIMENTAL METHODS 
2.1 Materials 
Two types of chitosan were used in this study. The low molecular weight chitosan (LMW 
CS) had a viscosity-average molecular weight of 50 kDa and the degree of deacetylation 
was 75-85% and a higher molecular weight chitosan (HMW CS) had a viscosity-average 
molecular weight of 60-120 kDa and the degree of deacetylation was 80%. LMW CS and 
acetic acid glacial were purchase from Sigma-Aldrich Inc. (St. Louis, MO) while HMW CS 
was a kindly provided by KitoZyme S.A. (Belgium). Fluorescent dye DyLight-488 NHS ester 
as well as succinimidyl-([N-maleimidopropionamido]-ethyleneglycol) ester (NHS-PEG-
MAL) were purchased from Thermo Scientific (Rockford, IL, USA). Double-stranded siRNAs 
against Mad2 and non-targeting (NT) siRNA sequence was purchased from Santa Cruz 
Biotechnology Inc. Amine-reactive Alexa Fluor 488 was purchased from Invitrogen/Life 
Technologies (Carlsbad, CA) and Label IT siRNA Tracker Kit was procured from Mirus 
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Corporation (Madison, WI). Pico-Green fluorescence reagent for quantification of double 
stranded nucleic acid constructs was purchased from Invitrogen/Life Technologies 
(Carlsbad, CA). For Mad2 protein quantification by flow cytometer, the antibody monoclonal 
anti-Mad2 clone 17D10 was obtained from Sigma (Sigma-Aldrich, St. Louis, MO and the 
secondary antibody goat anti-mouse conjugated with Alexa Fluor® 568 from Abcam 
(Abcam, Cambridge, UK).  
2.2 Synthesis of Chitosan Derivatives 
Both types of chitosan were dissolved in a 2% acetic acid solution, at 2mg/ml and reacted 
overnight with 10% molar equivalent of maleimide-p(ethylene glycol)-N-hydroxysuccinimide 
(Mal-PEG2000-NHS) to achieve CS-PEG-Mal. Next day, the solution was purified by dialysis 
(molecular weight cutoff - 10 kDa) in water and half the amount of chitosan-PEG-Mal was 
used for EGFR-binding peptide modification. This peptide with the following sequence, 
YHWYGYTPQWVI-GGGG-C, was originally synthesized by Zonghai Li and coworkers, and 
has been demonstrated to be most efficient in targeting the EGFR receptor (311). We have 
extensively used this peptide previously to successfully demonstrate its targeting capability 
in vitro as well as in vivo in various EGFR over-expressing tumor cells (312-318). The 
peptide was obtained from Tufts University. A 2-fold molar excess of 17-amino acid EGFR 
binding peptide was added to the nanoparticle solution at 4°C in nitrogen atmosphere 
overnight to allow cysteine group of peptide to react with maleimide group. The solution was 
purified by dialysis (molecular weight cutoff - 10 kDa) in water. Glacial acetic acid was added 
to the dialyzed nanoparticle solution in order to achieve a 5% concentration and then freeze-
dried and stored at -20 °C until further use. Non-targeted chitosan derivative was similarly 
prepared by reaction with mPEG2000-NHS followed by acetic acid addition, dialysis and 
freeze drying. The degree of substitution value of PEG on chitosan was estimated by NMR 
analysis. For each sample, 4 mg of the lyophilized product were dissolved in 0.7 ml D2O 
and characterized by 400 MHz 1H NMR spectroscopy (Varian, Inc. CA) 
2.3. Preparation and Characterization of siRNA-Encapsulated Chitosan 
Nanoparticles  
Mad-2 and scrambled siRNA duplexes were encapsulated in CS-PEG derivatives in a molar 
ratio between nitrogen residues from chitosan per nucleic acid phosphate (N/P ratio) of 
25/1, 50/1, 75/1 and 100/1 CS-PEG was dissolved in water (1 mg/ml) and siRNA dissolved 
in nuclease-free water was slowly added to it under magnetic stirring. The solution was 
incubated for 30 min at room temperature to facilitate CS-PEG and siRNA complexation 
and nanoparticle self-assembly prior to use. EGFR targeted CS-siRNA nanoparticles were 
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prepared using 1:1 ratio of CS-PEG2000-peptide and mPEG2000-CS by the same procedure 
as described above. 
The formed self-assembled nanoparticles were characterized for size, surface charge, 
morphology, encapsulation efficiency, and stability of the siRNA payload. Particle size, 
surface charge and polydispersity index (PDI) of freshly prepared siRNA loaded chitosan 
(CS-siRNA) nanoparticles were measured using a ZetaSizer Nano ZS (Malvern 
Instruments, Worcestershire, UK). Each sample was analyzed in triplicate at 25°C and the 
size and zeta potential was reported as mean ± SD. The encapsulation efficiency was 
determined using Quant-iT™ Pico-Green reagent (Life Technologies, Carlsbad, CA, USA) 
using a microplate reader (Bio-Tek Instruments, Winooski, VT). A standard curve based on 
fluorescence emission generated from the binding of Pico-Green to known concentration of 
double-stranded siRNA was created and the loading in nanoparticles was determined by 
subtracting the calculated amount of free siRNA from initial amount added. Encapsulation 
efficiency was defined as the ratio percent of siRNA encapsulated in nanoparticles to the 
total siRNA added.  
The morphological characterization of CS-siRNA nanoparticles was carried out under 
transmission electron microscopy (TEM) using JEOL JEM-1000 transmission electron 
microscope (JEOL, Tokyo, Japan). 10µL of nanoparticle was dropped on formvar-coated 
copper grid and allowed to stand for 1 min, excess fluid was drained using a Whatman filter 
paper and the sample was negatively stained with 1.5% uranyl acetate (1 min) prior to its 
visualization. The dark staining of siRNA by uranyl acetate offers a high contrast compared 
to chitosan that can help ascertain loading of genes in polymeric nanosystems. 
2.4 Stability of Chitosan-siRNA Nanoparticles  
Stability of Chitosan-siRNA nanoparticles against RNase digestion was investigated. 
Chitosan-siRNA nanoparticles in an amount equivalent to 2 μg of siRNA we tested. The 
nanoparticles were prepared as previously described, and in a N/P ratio of 50/1. Each set 
of particles was in phosphate buffer at pH 7.4 and was submitted into 4 different conditions: 
no treatment; incubated for 10 min with 5μl heparin (1000 U/ml ) for displacing the siRNA 
from the chitosan nanoparticles; incubated with 4 uL of RNAse A (20ug/ml) for 30 min at 
37°C; and incubation with incubation 4 uL of RNAse A (20ug/ml) for 30 min at 37°C followed 
by heat inactivation of the enzyme and incubation for 10 min with 5μl heparin (1000 U/ml). 
Resulting mixtures were applied to a 4% E-Gel (Invitrogen, Carlsbad, CA), and 
electrophoresis was carried for 15min using E-Gel iBase system. In each gel, free siRNA 
was applied as a reference. The experiments were performed in triplicate. The resulting gel 
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was imaged on ChemiDoc System (Bio Rad, Waltham, MA) using the software Quantity 
One. 
2.5 Cell Culture and Transfection 
A549 human lung carcinoma cell line from the American Type Culture Collection (ATCC, 
Rockville, MD) were cultured at 37°C in 5% CO2 environment in DMEM/F12 medium from 
Life Technologies (Carlsbad, CA). NIH-3T3 mouse embryo fibroblast cell line were also 
purchased from ATCC and cultured in DMEM (Life Technologies, Carlsbad, CA). Both cell 
culture media were supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin (100 U/ml) (Thermo Fisher Scientific, Waltham, MA, USA). Human 
Pulmonary Alveolar Epithelial Cells (HPAEpiC) were purchased from ScienCell Research 
Laboratories and cultured in alveolar epithelial cell medium as recommended by the 
supplier. 
Approximately 80,000 cells per well were seeded in a 6-well plate culture for 24h prior to 
experiments to achieve approximately 75% confluence for transfection and the transfection 
conditions was followed according to the description in Malmo et al (319). Briefly, fresh 
nanoparticles were assembled in water as described above and diluted with an equal 
volume of Opti-MEM Life Technologies (Carlsbad, CA), supplemented with 270 mM 
mannitol (Sigma-Aldrich, St. Louis, MO) and 20 mM HEPES (Sigma-Aldrich, St. Louis, MO). 
Preceding the addition of the nanoparticles, the cells were washed and briefly incubated 
with Hank's balanced salt solution, HBSS (Life Technologies, Carlsbad, CA), at 37°C and 
5% CO2. Next, the HBSS solution was removed and the nanoparticles were added to each 
well. The transfection solution was removed after 6h of incubation at 37°C and 5% CO2 and 
replaced by regular growth media supplemented with 10% FBS and penicillin/streptomycin 
(100 U/ml). 
2.6 Qualitative Analysis of Cellular Trafficking By Confocal Microscopy 
Fluorescence confocal microscopy studies were performed in order to assess the qualitative 
cellular internalization of the nanoparticles. Cells (200,000 cells/well) were seeded on 
coverslips in 6-well plates and were allowed to attach for 24h. After incubation for specific 
periods of time, cells were washed with cold phosphate-buffered saline (PBS, pH 7.4), ﬁxed 
with 4% paraformaldehyde for 20 min, washed with cold PBS and stained with the 
ﬂuorescent DNA-binding dye Hoechst 33342 (Invitrogen, Carlsbad, CA) (1 µg/ml) for 5 min. 
The cells were finally washed with cold PBS and the coverslip was inverted on a glass slide 
in mounting medium. Microscopy images were acquired using LSM 700 confocal 
microscope (Carl Zeiss, Gottingen, Germany) equipped with a 40× and a 63× objectives. 
For each image, representative focus planes were shown. The images were obtained using 
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a 405 nm (5 mW) laser for Hoechst 33258 (417-477 nm emission), 488 nm (10 mW) laser 
for Alexa 488nm-labeled chitosan (500-550 nm emission) and 639 nm (5 mW) laser for Cy5-
siMad2, (600-650 nm). Digital images were analyzed using the NIH Image-J software. All 
setting parameters for ﬂuorescence detection and image analyses were held constant to 
allow consistency in imaging of the sample for comparison.  
2.7 Quantitative Cellular Uptake Studies by Flow Cytometry 
CS was conjugated with amine-reactive dye Alexa Fluor 488 (Life Technologies, Carlsbad, 
CA). In order to achieve this modification, the amine-reactive dye Alexa Fluor 488 was 
dissolved in DMSO (1mg/ml) and added to an aqueous solution of chitosan (1mg/ml) and 
incubated overnight. In the following day, the conjugate was purified by dialysis (molecular 
weight cutoff - 10 kDa) in PBS pH 7.4 and put to freeze-dry. Simultaneously, siRNA against 
Mad2 (siMad2) was labeled with Cy5 dye using the kit Label IT siRNA Tracker Kit (Mirus 
Corporation, Madison, WI) according to the manufacturer’s specifications. For flow 
cytometry, 200,000 cells/well cells were seeded in 6-well plates and left to attach for 24h. 
Cells were then transfected with ﬂuorescently labeled siRNA (Cy5-siMad2) encapsulated in 
Alexa Fluor 488 labeled chitosan. After specific times the transfection solution was 
removed, the cells were washed with PBS and prepared for analysis by flow cytometry. 
Time dependent cellular uptake and EGFR targeting of CS-siRNA nanoparticles was 
quantitatively analyzed using a Becton Dickinson FACS-Calibur® 4 Color Flow Cytometer 
(BD Biosciences, Franklin Lakes, NJ). The obtained data were analyzed and visualized 
using the Cell Quest software (BD Biosciences, Franklin Lakes, NJ). After incubating with 
nanoparticles for specific time periods, the cells were washed with PBS (Life Technologies, 
Carlsbad, CA), trypsinized, re-suspended in ice-cold PBS supplemented with 5% FBS and 
kept on ice until the time of analysis. The relative amounts of intracellular siMad2, was 
evaluated in the FL-2 channel. The percentage of cellular uptake was calculated on the 
basis of the geometric mean (Gm) using the following formula: 
               =  
(     )
(      )
 ×  100 
where GmExp is the Gm of cells in the different experimental conditions and GmCtrl is the Gm 
of cells in the control condition, without treatment. The data presented are the mean 
fluorescent signals from 10,000 events. 
2.8 Assessment of EGFR-Specific Cellular Internalization  
In order to confirm that entry of peptide modified CS-siRNA nanoparticles into cells is 
mediated by EGF receptor targeting, competitive inhibition study was performed in A549 
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cells. The cells were pre-treated for 1h with EGFR binding peptide (50 µg/ml) prior to 
exposure with nanoparticle treatment. Simultaneously, uptake study was also using an 
EGFR non-overexpressing cell line, NIH-3T3. Fluorescently labeled siRNA, purchased from 
Qiagen (Venlo, Neatherlands) was loaded into chitosan nanoparticles and was incubated 
with cells for 15 mins. Cells were washed with 1x PBS and harvested as described 
previously for ﬂow cytometric analysis of cellular uptake. The amount of EGFR on A549 and 
NIH-3T3 was determined by direct immunofluorescence assay via 488nm-labeled EGFR 
antibody. Briefly, cells from both cell lines were harvested and washed with ice cold PBS, 
10% FBS, 1% sodium azide and resuspended in 3% BSA/PBS solution. 488nm-labeled 
EGFR antibody was added to a final concentration of 20 μg/ml. After a 2h incubation, cells 
were washed with ice cold PBS, 10% FBS, 1% sodium azide and resuspended in the same 
solution followed by flow cytometric analysis. 
2.9 In Vitro Gene Silencing Efficiency  
In vitro gene silencing was assessed by qRT-PCR. Cells were transfected with different 
siMad2 concentrations and incubation periods as described above. At the time of analysis, 
cells were collected and total RNA was extracted using GeneJET RNA purification kit 
(Thermo Scientific, Tewksbury, MA) according to the manufacture’s recommendations. 
RNA concentration was determined by spectrophotometry using NanoDrop 2000c (Thermo 
Scientific, Tewksbury, MA). For each sample, 0.5 µg of total RNA was used for cDNA 
synthesis and the reverse transcription reaction was performed with Verso cDNA Synthesis 
kit (Thermo Scientific, Tewksbury, MA) according to the manufacturer’s instructions. 
Real time polymerase chain reaction (qPCR) was performed with the LightCycler 480 SYBR 
Green I Master kit (Roche, Basel, Switzerland) and housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as endogenous control. The sequences of 
the primers used in this work were: Mad2 Forward (GTGGAACAACTGAAAGATTGGT), 
Mad2 Reverse (GTCACACTCAATATCAAACTGC), GAPDH Forward 
(ACAGTCAGCCGCATCTTC) and GAPDH Reverse (GCCCAATACGACCAAATCC). 2 µL 
of the cDNA was used to evaluate Mad2 expression levels. qPCR steps included a pre-
incubation step for 5 min at 95°C, followed by 40 cycles of three steps: 10 sec at 95°C, 20 
sec at 60°C and 30 sec at 72°C. The threshold cycle (Ct) values were generated 
automatically by the LightCycler® 480 Software, Version 1.5 and the comparative method 
for mRNA level quantiﬁcation was calculated according to the following formulas: 
∆   (       ) =   (                      ) −   (                         ) 
∆   (       ) =   (                      ) −   (                         ) 
∆∆   = ∆  (       ) − ∆  (       ) 
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Normalized target gene expression level = 2( ∆∆  ) where Ct is the threshold cycle  
2.10 Determination of Mad2 Protein Expression Levels by Flow Cytometry 
Cells suspensions from different treatments were collected and fixed with 4% formaldehyde 
for 10 min. at RT. After pelleting them, cells were permeabilized with a 0.3% Triton-X 
solution for 7min at RT. After blocking non-specific antigens with a PBS solution containing 
10% FBS, cells were incubated for 2h in the primary antibody solution, mouse anti-Mad2 4 
µg/ml in PBS. After three washing steps with PBS, cells were stained with secondary 
antibody, anti-mouse conjugated with Alexa 568, in a concentration of 2 µg/ml in PBS for 
30 min. After two washing steps, cells were resuspended in 500 µL of PBS and analyzed by 
flow cytometry. 
2.11 Cell Viability Analysis 
The toxicity of the siRNA loaded and blank nanoparticles was assessed using the MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay. Cells were seeded in 96-
well-plates at a density of 2500 cells/well and were allowed to attach overnight. Then, cells 
were washed and 100µL of the nanoparticles solution were added to each well (n=8), 
incubated at 37 °C for 6h following which, the solution was replaced with complete growth 
media. At the specific time points, the media was renewed by fresh complete media 
containing 100 µL of 0.5 mg/ml MTT (Sigma-Aldrich, St. Louis, MO). Two hours after 
incubation, the medium was replaced by dimethyl sulfoxide (DMSO) to stop the reaction 
and lyse the cells. Untreated A549 served as a negative control. Absorbance of the solution 
was measured at 560 nm and the IC50 was calculated using GraphPad Prism Software. 
2.12 Data Analysis 
All data are presented as mean ± SD and are calculated from minimum of three independent 
experiments. Comparisons between two groups were made using Student’s T-test and with 
more than two groups, the ANOVA test was used. A value of p < 0.05 was considered to 
be statistically significant.  
3. RESULTS 
3.1 Characterization of siRNA Encapsulated CS Nanoparticles 
The grafting of Mal-PEG2000-NHS onto chitosan was confirmed by 1H-NMR spectroscopy 
and the degree of PEG modiﬁcation was found to be approximately 10% for both LMW and 
HMW derivatives (Figure 12). NMR spectra of Mal-PEG2000-NHS shows characteristic 
peaks for methylene protons between 3.5 and 3.7 ppm and a distinct peak at 6.9 for the 
protons corresponding to the ring protons of maleimide functional group. The peaks related 
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to the protons on carbon at α position to carboxylic group and NHS group are present 
between 2.5 and 3.0 ppm (Figure 12A). The peaks corresponding to protons on chitosan 
polymer backbone spans between 1.8 and 5.0 ppm and thus several peaks between PEG 
and CS overlap in that region (Figure 12C). Chitosan derivatives were characterized by a 
new signal at δ = 2.40 ppm, which was attributed to the oxyethylene group present in the 
copolymer.  
The unique peak for maleimide group at 6.9 from Mal-PEG-NHS and for CS at 2 ppm was 
used to calculate the total PEG modification on the CS backbone (Figure 12D), which was 
found to be 10%. Further reaction of the PEG-CS derivatives with the EGFR-binding peptide 
leads to disappearance of the maleimide peak at 6.9 and the peaks in the range of 6.8-7.3 
ppm corresponding to the protons from peptide appears (Figure 12B), confirming the 
successful formation of EGFR-binding peptide modified PEG-CS for both low (Figure 12E) 
and high (Figure 12F) molecular weight CS. NMR analysis could not be used for calculating 
the exact concentration for EGFR modification on Mal-PEG-CS. However, since the PEG 
modification was found to be 10% and the concentration of EGFR binding peptide used for 
the grafting to maleimide group was two-fold higher, we assume that 100% of maleimide 
groups were modified. The mPEG and peptide-PEG derivatives of LMW and HMW CS were 
complexed with Mad2 siRNA to form the non-targeted (NT-LMW and NT-HMW) and EGFR-
targeted (T-LMW and T-HMW) nanoparticles respectively. We first optimized the siRNA 
loading efficiency of CS-derivatives as a function of N/P ratio. 
However, the subsequent size and charge analysis of these formulations demonstrated that 
CS-siRNA complexes at a N/P ratio of 50/1 not only give optimum loading but also adequate 
size (< 300 nm) for gene delivery application (Figure 13B,C) and were therefore used for all 
further experiments. The size of the four chitosan/siRNA nanoparticles were measured by 
dynamic light scattering and were found to be in the range of 100-250 nm (Table 4). 
The nanoparticles formed with LMW-CS were characteristically smaller in size compared to 
those formed using corresponding HMW-CS polymer, suggesting that the polymer chain 
length plays a role in the size of the nanoparticle assembly. Most importantly, addition of 
EGFR binding peptide to the polymer leads to a significant increase in the nanoparticles 
size. This could be due to the change in the net positive charge of the chitosan leading to a 
decrease in the particle packing density, although the ability to bind and encapsulate siRNA 
remains the same. That indeed appears to be true since the zeta potential measurement 
for NT-LMW nanoparticle was 33.6 ± 3.5 mV, which decreased to 28.3 ± 2 mV for the T-
LMW nanoparticles suggesting a net decrease in positive charge.  
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Figure 12: 1H-NMR spectrums of (A) NHS-PEG-MAL, (B) EGFR binding peptide, (C) Chitosan, (D) Mal-PEG-
CS, (E) T-LMW and (F) T-HMW. 
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The siRNA loading was found to be nearly 100% for the formulations with N/P ratio of 50/1, 
75/1 and 100/1 (Figure 13).  
 
 
 
Figure 13: Effect of N/P ratio on the siRNA encapsulation efficiency (A), size (B) and charge (C) of nanoparticles 
formulated with targeted and non-targeted LMW and HMW chitosan. A concentration of 50 nM of siMad2 was 
used in a N/P ratio of 50/1. Data are shown as mean ± SD (n = 3). 
The zeta potential of the HMW CS-siRNA nanoparticles also showed a similar trend 
confirming that peptide modification reduces the net positive charge of CS, thereby affecting 
its interaction with negatively charged siRNA and rendering a larger size for targeted 
nanoparticles. The polydispersity index (PDI) values for the chitosan nanoparticles 
decreased with the addition of EGFR peptide for both chitosan molecular weights. In order 
to analyze if the change in the net charge of CS leads to a change in siRNA loading 
efficiency of the targeted formulations, siRNA encapsulation efficiency of all the formulations 
were assessed. The siRNA loading efficiencies of all the nanoparticle systems were found 
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to be 100% irrespective of the difference in CS composition or molecular weight. This 
observation confirmed that even though presence of the peptide affects the assembly of the 
nanoparticle, it does not have any impact on the loading efficiency and that peptide modified 
PEG-CS could still encapsulate siRNA efficiently despite the charge compensation. 
Table 4: Particle size, polydispersity index (PDI), zeta potential and siRNA encapsulation 
efficiency of chitosan/siRNA nanoparticles at a N/P ratio of 50/1. 
Chitosan 
Chitosan 
deacetylation 
degree (%) 
Size (nm) ±SD PDI ±SD 
Zeta potential 
(mV) ±SD 
Encapsulation 
Efficiency (%) 
NT-LMW 75-85 106.8 ± 2.1 0.551 ±0.10 +35.6 ± 3.5 105.1 ± 4 
T-LMW 75-85 227.3 ± 1.8 0.362 ±0.02 +28.3 ± 2.0 99.5 ± 2.4 
NT-HMW 78 173.1 ± 1.3 0.672 ±0.03 +42.8 ± 2.4 101.6 ± 2.3 
T-HMW 78 257.1 ± 3.1 0.421 ±0.01 +13.9 ± 2.9 97.5 ± 3.3 
Transmission electronic microscopy (TEM) was used to examine the morphologies of the 
different CS-siRNA nanoparticles formulations (Figure 14). 
 
Figure 14: TEM image of chitosan/siRNA nanoparticles at a N/P ratio of 50/1 (A) NT-LMW, (B) T-LMW, (C) NT-
HMW and (D) T-HMW. Scale bar in all the images corresponds to 100 nm. 
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The images of non-targeted CS-siRNA nanoparticles demonstrate a more linear, pendant 
like structures showing a compact packing of CS around the siRNA. The negative stain 
used for visualization of the particles seems to intercalate in the siRNA to give a dark 
contrast. On the contrary, the targeted nanoparticles with both type of CS complexed to 
siRNA show larger particle size confirming the observation made from the DLS 
measurement. The particle size from the TEM images corresponded well with the size 
obtained from the DLS measurement for different nanoparticle formulations. 
3.2 Stability against Rnase digestion 
siRNA degradation is one of the most important barriers for siRNA delivery. Considering 
that it is associated with loss of activity and therapeutic effect, we have evaluated the 
protection effect of different siRNA/chitosan derivative complexes against RNase digestion 
(Figure 15). As expected free siRNA was degraded completely in the presence of RNAse 
A while the presence of heparin had no effect on its stability. On the other hand, siRNA, 
which was incorporated in chitosan particles, remained intact. This result clearly showed 
the ability of CS-derivatives to protect siRNA from enzymatic degradation. 
 
Figure 15: RNase stability of siRNA in the CS/PLA/siRNA complexes. Free siMad2 was a negative control. The 
complexes were incubated with RNase A (5 mIU/µg siRNA) at 37°C for 2h. The reaction was inactivated at 70°C 
and was the siRNA released after incubation for 10 min with 5μl heparin (1000 U/ml). Resulting mixtures were 
analyzed by 4% agarose gel electrophoresis. 
3.3 Qualitative analysis of nanoparticle uptake and cellular trafficking 
Fluorescence confocal microscopy was employed to visualize the qualitative intracellular 
uptake of non-targeted and EGFR-targeted CS-siRNA nanoparticles in A549 as a function 
of time. Intracellular uptake was analyzed at 15, 30 and 60 min for the non-targeted and 
targeted CS-siRNA nanoparticles at a siRNA concentration of 50 nM. CS was labeled with 
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green fluorescent Alexa Fluor 488 while siMad2 was labeled with red fluorescent Cy5 dye 
prior to nanoparticle formation. Figure 16 shows the confocal images for uptake of non-
targeted and targeted LMW-CS nanoparticles in A549 cells.  
The images taken after 15 min incubation with the non-targeted and targeted nanoparticles 
clearly show that while targeted nanoparticles show internalization, no evident uptake is 
shown by the non-targeted system. Non-targeted nanoparticles show internalization at 30 
min, which confirms that the EGFR targeting peptide modification of the PEG-CS 
nanoparticles, facilitates an early uptake by receptor-mediated endocytosis. Most 
importantly, in both the cases green and red fluorescence co-localized on some of the 
nanoparticles attached to the cellular membrane and inside the cytoplasm, but the majority 
of red fluorescence (siRNA tag) was rapidly detected in the nucleus. Similar results were 
also obtained for the non-targeted and targeted HMW-CS nanoparticles (data not shown). 
The untreated control cells as well as cell labeled with unlabeled nanoparticle did not show 
any background auto-fluorescence (data not shown).  
3.4 Quantitative cellular uptake by flow cytometry 
In order to ascertain the trend of nanoparticle uptake shown by confocal images and get a 
quantitative estimate of intracellular uptake, A549 cells treated with fluorescently labeled 
non-targeted and targeted nanoparticles in a time dependent manner were also analyzed 
by flow cytometry. The fluorescence intensity for all the samples were normalized to the 
untreated control A549 NSCLC cells. Figure 17 shows the quantitative relative uptake of 
Cy5 labeled siRNA as a function of time for the different samples where the T-LMW and T-
HMW nanoparticles show significantly higher uptake compared to the respective non-
targeted nanoparticles, confirming the trend observed by confocal imaging.  
Besides, cells show nearly 5-fold increase in fluorescence intensity after 15 min of 
incubation with NT-LMW and T-LMW nanoparticles indicating that targeted nanoparticles 
indeed are rapidly internalized by the cells by receptor mediated endocytosis and confirmed 
the much higher uptake show by confocal imaging. We also analyzed uptake after 5 min of 
incubation of nanoparticles to see the targeting efficiency of the EGFR binding peptide and 
the results obtained clearly show that T-LMW nanoparticles give better fluorescence 
intensity after 5 min than NT-LMW nanoparticles after 1h of incubation. Flow cytometry data 
also confirmed that LMW-CS nanoparticles are more readily internalized by the cells in 
comparison to the HMW-CS nanoparticles. T-LMW nanoparticles show a 312% increase in 
the relative fluorescence after 60 min on incubation while the T-HMW nanoparticles show 
176% increase in the fluorescent intensity under similar experiment condition.  
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Figure 16: Cell uptake and intracellular trafficking of siMad2-Cy5 encapsulated in chitosan nanoparticles 
modified with Alexa 488nm. Similar results were obtained for 90kDa chitosan. The concentration of siMad2-Cy5 
was 50 nm. Cell nuclei were counterstained with Hoechst 33258 (blue). The column on the right consists on the 
merge of the fluorescence images and the phase images. Scale bar = 10 µm 
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3.5 Evaluation of targeted receptor internalization 
EGF is internalized by ligand-induced receptor-mediated uptake. (320) In order to confirm 
that higher uptake, better cytotoxicity and enhanced siRNA efficacy of EGFR-targeted 
chitosan nanoparticles is due to receptor-mediated endocytosis, the uptake of fluorescently 
labeled-siRNA-containing nanoparticles was evaluated in a series of experiments. One of 
the strategies adapted was to block the EGFR receptors on the surface of A549 cells by 
exposing to excess of EGFR binding peptide. Cells were pre-incubated with free EGFR 
binding peptide for 1h prior to exposing them to the targeted system and the nanoparticle 
uptake was quantitatively determined by FACS (Figure 18). The uptake of the targeted 
systems significantly decreased when cells were pre-incubation with free EGFR binding 
peptide, suggesting that the targeted nanoparticle indeed show better uptake dues to 
receptor-mediated endocytosis. After 15min of incubation with nanoparticles, A549 showed 
a decreased on the uptake from 47% to 13% for T-LMW and 36% to 11% for T-HMW. 
Concomitantly, we also studied the uptake of targeted siRNA loaded nanoparticles in NIH-
3T3 fibroblast cells, a low-expressing EGFR expressing cell line.(321) To determine the 
expression level of EGFR by A549 and NIH-3T3 cells, the binding of anti-EGFR antibody to 
the cells was quantified using flow cytometry (Figure 19). The variation in the fluorescence 
intensity of A549 after incubation with anti-EGFR antibody was considerably higher than the 
variation in NIH-3T3 cells proving a much higher expression of EGFR on A549 than NIH-
3T3 cells. The nanoparticle uptake by NIH-3T3 cells were found to be roughly the same 
irrespective of the presence or absence of targeting ligand, further cementing that the 
enhanced uptake of targeted particles in A549 cells is due to the receptor-mediated 
endocytosis.  
Receptor-mediated endocytosis is an energy-dependent process and so we also performed 
a nanoparticle uptake study at 4 ˚C where receptor-mediated uptake will be minimum. 
Indeed, the uptake of targeted systems is dramatically low at 4 ˚C compared to that when 
the cells were maintained at 37 ˚C. Nanoparticle uptake was lower for all the treatments at 
4 ˚C, the decrease was however statistically significant only in case of the targeted LMW 
and HMW nanoparticles. It is also noteworthy that the net uptake upon blocking the EGFR, 
using an EGFR non-expressing cell line or performing the study at 4 ˚C is the same 
indicating conclusively that presence of EGFR binding peptide on the nanoparticles indeed 
facilitates receptor-mediated endocytosis. It is important to understand that this data cannot 
be compare to the results represented in Figure 4 since the percent labeling of the siRNA 
was different for that experiment. 
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Figure 17: Quantitative relative intracellular uptake study of non-targeted and targeted siRNA loaded CS 
nanoparticles by flow cytometry in A549 cell line. Data are shown as mean ± SD (n=3). 
 
Figure 18: Quantitative relative intracellular uptake study collected by flow cytometry of non-targeted and 
targeted siRNA loaded CS nanoparticles in A549 and NIH-3T3 cell line, at 37˚C and 4˚C. and a 50nM siRNA 
concentration. Data collected refers to a 15min incubation period. Data are shown as mean ± SD (n=3). 
***P<0.001 
 
 
Figure 19: EGFR expression levels in NIH-3T3 and A549. EGFR expression was evaluated by flow cytometry 
in NIH3T3 (A) and A549 (B) cells using 488nm-labeled EGFR antibody. The grey line corresponds to the 
histograms for untreated cell lines and the red line to cells incubated with anti-EGFR antibody. 
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3.6 Optimization of EGFR peptide density on nanoparticles for specific cellular 
uptake 
The density of EGFR binding peptide on the surface could be a key parameter to impact 
the net uptake of the nanoparticles by the cells. Peptide modified PEG-CS (10% 
modification) was blended at 0, 25, 50, 75 and 100 % (w/w) to the mPEG modified CS to 
vary total peptide content of the nanoparticles and was subsequently tested for uptake in 
A549 cells as a function of incubation time (Figure 20). The cellular uptake profile of 
nanoparticles with EGFR targeting at 50% or higher concentrations showed almost identical 
uptake behavior at all-time points up to 60 min of incubation. A 50-50 blend of peptide 
modified PEG-CS and mPEG modified CS was, therefore, chosen for all subsequent 
experiments with targeted nanoparticles. 
3.7 In vitro Mad2 gene silencing in A459 NSCLC cells 
qRT-PCR was used to evaluate the ability of different formulations to silence the expression 
of Mad2 gene in A549 cells. Mad2 specific mRNA expression was quantified in a dose and 
time-dependent manner after treatment with non-targeted and EGFR targeted CS 
nanoparticles. A N/P ratio of 50/1 was used for all the experiments and lipofectamine, a 
cationic lipid transfection reagent-complexed siRNA, was used as a positive control. The 
dose dependent gene silencing with varying siRNA concentrations ranging from 5 to 50 nM 
were tested after 48 hours of incubation with cells as shown in Figure 21A. Concentrations 
below 20 nM did not show a significant change in the Mad2 expression levels in any of the 
treatment groups. The gene silencing effect was significantly improved at 30 nM dose of 
siRNA where non-targeted LMW and HMW nanoparticles show 73 ± 2% and 74 ± 7% 
decreases in the gene expression. However, the silencing effect was more dramatic with 
EGFR targeted nanoparticles that show 39 ± 6% and 53 ± 4% gene silencing for T-LMW 
and T-HMW nanoparticles respectively. Mad2 expression shows a substantial decrease 
when the A549 cells were treated with 50 nM of siRNA loaded in CS nanoparticles with 4 ± 
2% for NT-LMW, 1 ± 3% for T-LMW, 9 ± 3% for NT-HMW and 1 ± 2% for T-HMW 
nanoparticles.  
Dose dependent study showed an efficient gene silencing at 50 nM concentration of siMad2 
loaded in all the formulations and therefore the same concentration was chosen to evaluate 
a time dependent gene silencing profile of the formulation with lipofectamine as positive 
control (Figure 21B). Lipofectamine loaded siMad2 effectively decreases Mad2 expression 
level to 10 ± 1% within 12h of dosing with a significant and sustained silencing efficiency till 
96h. However, Mad2 expression level starts to revive at later time points of 120 and 144h 
which could be due to the continued growth and proliferation of non-transfected cells leading 
to higher expression level of the gene. On the contrary, treatment with non-targeted and 
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targeted siRNA loaded CS nanoparticles not only showed an efficient silencing effect at 
early time points but also show a sustained silencing effect at the later time periods unlike 
lipofectamine. Mad2 expression levels 144 hours post-transfection were 5 ± 3%, 3 ± 8%, 8 
± 5% and 5 ± 6% for NT-LMW, T-LMW, NT-HMW and T-HMW respectively. In contrast, 
lipofectamine mediated siRNA delivery led to 26 ± 1% and 27 ± 5% expression of the Mad2 
at 120 and 144h respectively, indicating that CS nanoparticles serve as a more potent 
delivery with an efficient and sustained gene silencing effect.  
3.8 Determination of Mad2 protein levels in A549 NSCLC cells 
Flow cytometry was used to further investigate the effect of Mad2 gene silencing on the 
Mad2 protein level in A549 cells after treatment with CS-siMad2 nanoparticles (Figure 22).  
A549 cells were exposed to 50 nM of siMad2 loaded in CS nanoparticles are the protein 
levels were evaluated up to 72h post-transfection. Level of Mad2 protein does not show any 
significant difference after 24h post-transfection and the relative protein content was found 
equivalent to untreated control. Mad2 protein content 48 hours post-transfection however 
shows a dramatic decrease in all the cells treated with CS-siMad2 nanoparticles as well as 
showing 19 ± 4%, 17 ± 5%, 6 ± 2%, 35 ± 1% and 23 ± 4% for Lipofectamine, NT-LMW, T-
LMW, NT-HMW and T-HMW respectively. Incubation for 72h in different formulation further 
led to a decrease in the Mad2 protein level, which is consistent with the Mad2 mRNA 
expression levels observed by qRT-PCR (Figure 21B). 
3.9 cell viability analysis with siRNA-encapsulated CS nanoparticles  
We further conducted cytotoxicity assessment of CS-derivatives alone and loaded with 
siMad2 to study the biocompatibility of the delivery material itself in A549. MTT assay with 
different CS-derivatives revealed that these derivatives by themselves did not show any 
apparent toxicity to both the cell lines even after long periods of incubation at the same 
concentration used for all the in vitro studies (Figure 23).  
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Figure 20: Effect of different percentages of EGFR-P modified chitosan in the targeted formulation, on the 
relative uptake. Uptake values were normalized against the value obtained for the non-targeted system, which 
consists on the 0% of EGFR-P modified chitosan, at 15 min post-transfection. A concentration of 50 nM of 
siMad2 was used in a N/P ratio of 50/1. Data are shown as mean ± SD (n = 3). 
 
 
Figure 21: Down-regulation of Mad2 expression by siMad2 loaded non-targeted and targeted CS nanoparticles 
in A549 cell line (A) dose-dependent gene silencing 48 h post-dosing and (B) time-dependent gene silencing 
with 50 nM siMad2 administration. The N/P ratio for all formulations were 50/1. Data are shown as mean ± SD 
(n=3). **P<0.01; ***P<0.001 
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Figure 22: Mad2 protein levels in A549 cells. A549 cells were incubated with 50nM of siMad2 encapsulated in 
PEG-modified chitosan nanoparticles and EGFR targeting peptide-modified chitosan nanoparticles, using a N/P 
ratio in all of the cases of 50/1. Data are shown as mean ± SD (n=3). 
 
 
Figure 23: Time-dependent cytotoxicity for A549 cells (A) and HPAEpiC (B) upon incubation with 50nM of 
siScramble loaded in CS-derivatives in a N/P ratio of 50/1. Data are shown as mean ± SD (n = 3).  
Previous studies have showed that chitosan is an attractive polymer for gene delivery due 
to several characteristics including its excellent biocompatibility, low toxicity, and low 
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immunogenicity (322). It has been demonstrated that chitosan only exhibited significant 
cytotoxicity at concentrations higher than 0.741 mg/ml, which is 7 times higher than the 
concentration used in this study. (323) SiMad2 loaded CS nanoparticles on the other hand 
showed severe cytotoxicity in A549 after 48h of incubation and kept this trend throughout 
till 120h of the study, where the cell viability for all the nanoparticles was around 25% (Figure 
24A). These results clearly indicate that any cytotoxicity effect elicited by the CS 
nanoparticles is due to the contribution of the siMad2 and that CS-derivatives themselves 
are highly biocompatible and non-toxic. In order to evaluate the cytotoxicity of CS-siMad2 
nanoparticles in EGFR non-expressing, non-cancerous cells, a human lung primary cell 
line, HPAEpiC was used (Figure 24B).  
All the different nanoparticles formulations showed a delayed cytotoxic effect in HPAEpiC 
when compared to A549 cells. Only after 72h post treatment did the chitosan nanoparticles 
triggered a significant change in HPAEpiC cell viability, while in A549 the effect was visible 
after 48h. Interestingly, the cytotoxic effect of the non-targeted and targeted nanoparticles 
is similar in the primary cells indicating a similar uptake level, which would be expected 
since these cells do not over-express EGFR. Besides, the effect of the treatments was much 
milder in the primary cells compared to the tumor cells at the corresponding incubation 
periods.  
3.10 cellular apoptosis studies with siRNA-encapsulated CS nanoparticles 
In order to evaluate the mechanism of siMad2 induced cell toxicity in A549 cells and confirm 
that the observed cell death is through apoptotic pathway, we performed Annexin V-
propidium iodide assay using flow cytometry (Figure 25). Annexin V conjugated to FITC 
specifically stains phosphatidylserine that translocate from the inner side to the outer 
surface of the plasma membrane in apoptotic cells. After 48 hours post-transfection, T-LMW 
nanoparticles loaded with siMad2, 58 ± 5% cells exhibit positive Annexin V staining, 
indicating apoptotic cell population. Treatment with other formulations including 
lipofectamine shows only 35% apoptotic cell population under similar conditions, which 
corroborates well with cytotoxicity results (Figure 24). The apoptotic cell population 
increased further after 72h post-transfection where T-LMW show nearly 87 ± 7% Annexin 
V positive cells while treatment with other formulations showed a lower increase in 
population. This study ascertains that cytotoxicity mediated by siMad2 administration is due 
to induction of apoptotic pathway in the cells. 
Chapter 3 - In vitro Mad2 checkpoint gene silencing using EGFR-targeted chitosan 
nanoparticles in non-small cell lung cancer model  
 
P a g e  71 
 
 
Figure 24: Time-dependent cytotoxicity studies in (A) A549 cells and (B) HPAEpiC upon incubation with 50nM 
of siMad2 loaded in CS-derivatives. Data are shown as mean ± SD (n=3). **P<0.05; **P<0.01; ***P<0.001 
 
Figure 25: Apoptosis assay using Annexin V-PI staining after exposure of A549 cells to 50nM siMad2 loaded in 
CS nanoparticles and lipofectamine as positive control. Data are shown as mean ± SD (n=3). 
  
  
P a g e  72 
4. DISCUSSION 
Mad2 protein is a key component of the mitotic checkpoint and a tumor suppressor gene. 
Its knockdown leads to extensive cell death as a consequence of mitosis failure mainly due 
to premature mitotic exit (131, 191, 221). Therefore, modulating the expression of Mad2 
gene and subsequently reducing the Mad2 protein translation specifically in cancerous cells 
could be a promising anticancer strategy. siRNA therapy particularly has shown tremendous 
promise in selectively down-regulating the activity of a gene of interest.  
In order to enhance siRNA delivery specifically for efficient Mad-2 gene silencing in A549 
NSCLC cells, we have developed EGFR-targeted and non-targeted chitosan nanoparticle 
complex for delivery of siMad2 for application in lung cancer therapy. Cancer cells 
overexpress several receptors on their surface to increase the uptake of nutrients and 
growth factors to meet their incessant demand. EGFR is one such surface receptor that has 
been long known to overexpress on the surface of majority of cancer tumors and has been 
intensively studied and characterized in lung cancer (290, 324, 325). Human lung 
adenocarcinoma A549 cells in particular have been reported to overexpress EGFR receptor 
on their surface and have shown sensitivity to anti-EGFR therapies (326). Targeting EGFR 
therefore serves as a logical approach and to this end, we derivatized the CS backbone 
with heterobifunctional PEG to subsequently bind the EGFR-binding peptide, while the non-
targeted nanoparticles system was developed using methoxy-PEG modification. The use 
of EGFR antibody was avoided due to its larger size compared to EGFR binding peptide, 
which often contributes to steric resistance in conjugating to the nanoparticles surface and 
also due to its limited diffusion in tissues (327). Particle size measurement reveals that m-
PEG modified non-targeted CS-siMad2 nanocomplexes were in the size range of 100-175 
nm depending on the molecular weight of the CS where lower molecular weight CS gives 
smaller average particle size compared to high molecular weight CS (The zeta potential of 
the HMW CS-siRNA nanoparticles also showed a similar trend confirming that peptide 
modification reduces the net positive charge of CS, thereby affecting its interaction with 
negatively charged siRNA and rendering a larger size for targeted nanoparticles. The 
polydispersity index (PDI) values for the chitosan nanoparticles decreased with the addition 
of EGFR peptide for both chitosan molecular weights. In order to analyze if the change in 
the net charge of CS leads to a change in siRNA loading efficiency of the targeted 
formulations, siRNA encapsulation efficiency of all the formulations were assessed. The 
siRNA loading efficiencies of all the nanoparticle systems were found to be 100% 
irrespective of the difference in CS composition or molecular weight. This observation 
confirmed that even though presence of the peptide affects the assembly of the 
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nanoparticle, it does not have any impact on the loading efficiency and that peptide modified 
PEG-CS could still encapsulate siRNA efficiently despite the charge compensation. 
Table 4). Subsequent EGFR binding peptide modification of CS prior to complexation with 
siMad2 leads to an increase in the net average particle size from 106.8 nm to 227.3 nm for 
LMW-CS and 173.1 nm to 257.1 nm for HMW-CS samples. This increase in the particle 
size could be attributed to the peptide modification of CS, which leads to decrease in the 
net positive charge on the polymer thereby affecting the complexation with the negatively 
charged siMad2. Zeta potential measurement indeed confirms that peptide-modified 
nanoparticles show a decrease in the net surface charge for both LMW and HMW 
formulations (The zeta potential of the HMW CS-siRNA nanoparticles also showed a similar 
trend confirming that peptide modification reduces the net positive charge of CS, thereby 
affecting its interaction with negatively charged siRNA and rendering a larger size for 
targeted nanoparticles. The polydispersity index (PDI) values for the chitosan nanoparticles 
decreased with the addition of EGFR peptide for both chitosan molecular weights. In order 
to analyze if the change in the net charge of CS leads to a change in siRNA loading 
efficiency of the targeted formulations, siRNA encapsulation efficiency of all the formulations 
were assessed. The siRNA loading efficiencies of all the nanoparticle systems were found 
to be 100% irrespective of the difference in CS composition or molecular weight. This 
observation confirmed that even though presence of the peptide affects the assembly of the 
nanoparticle, it does not have any impact on the loading efficiency and that peptide modified 
PEG-CS could still encapsulate siRNA efficiently despite the charge compensation. 
Table 4), which would affect the nanoparticle packing in the presence of siRNA even though 
the encapsulation efficiency remains unaltered as demonstrated by similar siRNA loading 
profile. CS nanoparticle size upon condensation with siRNA has been studied as a function 
of the molecular weight of the polymer and the particle size observed by us is well in 
agreement with previously reported literature (268). 
A difference in the nanoparticle size could result in differential uptake characteristics and 
siRNA release profile; especially since the size difference between non-targeted and 
targeted LMW-CS nanoparticles is dramatically large. In this regard, one would expect a 
lower intracellular uptake of large-sized particles due to limited diffusion capability (328) . 
However, on the contrary, all our experiments suggest that targeted nanoparticles, which 
are significantly larger, show greater intracellular uptake suggesting that any size 
dependent limitation in uptake is efficiently overcome by targeting EGFR receptor. Besides, 
the siRNA efficacy of targeted nanoparticles show marked improvement over respective 
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non-targeted nanoparticles at all studied time points indicating that change in nanoparticle 
size does not affect the siRNA release or activity in any manner.  
The siRNA mediated silencing at gene and protein level clearly indicated that the EGFR 
targeted nanoparticles outperformed their corresponding non-targeted systems and that the 
LMW-CS nanoparticles had better activity than the corresponding HMW-CS nanoparticles. 
As with studying any cell-specific targeted system, it is pertinent to establish that the better 
activity of targeted nanoparticles is associated with increased intracellular accumulation due 
to receptor-mediated endocytosis. A series of experiments to study uptake of EGFR-
targeted system in EGFR non-expressing cells, selective blocking of the receptor by target 
peptide and mitigating receptor-mediated endocytosis by performing the study at 4 °C 
conclusively proved that the enhanced intracellular uptake and subsequent great siRNA 
activity shown by targeted system indeed is a result of EGFR targeting.  
Qualitative intracellular uptake studies of all the nanoparticle systems revealed another 
interesting phenomenon that is usually uncommon with siRNA delivery. Confocal images 
indicate that the delivery siRNA localizes in the nucleus of the cells especially at later time 
points while chitosan remains in the cytoplasm throughout the course of our chosen 
experimental time points (Figure 16). Such an observation is unusual especially since RNAi 
mechanism is known to occur in the cytoplasm where mRNA are mostly found; however it 
is not entirely surprising because several other previous studies have reported the same 
behavior of siRNA (329, 330) It has also been shown that by diffusion into the nucleus and 
subsequent export out of the nucleus by Exportin-5, siRNAs can shift between the 
cytoplasm and the nucleus in a sequence-dependent way (329-332). The exact mechanism 
that leads to the localization of siRNA in the nucleus is not well understood but it was 
important to understand whether this property is imparted by the delivery system or is 
governed by the siRNA itself. To discern this rather intriguing observation further, we 
repeated the same study with scrambled siRNA keeping the delivery system unaltered (data 
not shown) and we did not detect localization of the scrambled siRNA in the nucleus. It is 
therefore safe to assume that the nuclear localization of siMad2 is not related to the 
chitosan-based delivery system but is possibly due to the sequence-specific siRNA 
property. 
Several siRNA loaded delivery vectors are efficiently internalized into the tumor cells but do 
not show any activity since they fail to escape endosomes and successfully deliver the 
payload into the cytoplasm. Chitosan as a positively charged biodegradable polymer has 
been extensively studied specifically for nucleic acid delivery since it can complex with these 
negatively charged biomolecules (268). However, several key characteristics of the polymer 
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can influence its in vitro and in vivo performance. Molecular weight of the polymer for 
example can have an impact on the nucleic acid complexation efficiency and subsequent 
protection. Low molecular weight CS (< 10kDa) show poor siRNA condensation while 
intermediate MW CS (<80 kDa) have shown a complete and efficient encapsulation (279, 
333). Thus, MW of CS can greatly impact the size of the nanoparticles (The zeta potential 
of the HMW CS-siRNA nanoparticles also showed a similar trend confirming that peptide 
modification reduces the net positive charge of CS, thereby affecting its interaction with 
negatively charged siRNA and rendering a larger size for targeted nanoparticles. The 
polydispersity index (PDI) values for the chitosan nanoparticles decreased with the addition 
of EGFR peptide for both chitosan molecular weights. In order to analyze if the change in 
the net charge of CS leads to a change in siRNA loading efficiency of the targeted 
formulations, siRNA encapsulation efficiency of all the formulations were assessed. The 
siRNA loading efficiencies of all the nanoparticle systems were found to be 100% 
irrespective of the difference in CS composition or molecular weight. This observation 
confirmed that even though presence of the peptide affects the assembly of the 
nanoparticle, it does not have any impact on the loading efficiency and that peptide modified 
PEG-CS could still encapsulate siRNA efficiently despite the charge compensation. 
Table 4) as well as the stability of the encapsulated siRNA(268). We therefore checked the 
ability of our nanoparticle system to protect the siRNA payload in the presence of RNAse 
and the studies clearly indicate that the 50 kDa and 90 kDa CS polymers could effectively 
shield the siRNA from enzymatic activity (Figure 15).  
Activity of the siRNA can also be influenced by the choice of CS where delivery using higher 
molecular weight polymer tend to show better efficacy of the payload (279). High silencing 
activity of siMad2 at gene and protein level affirmed that CS delivery vector not only protect 
the payload from degradation but are also able to release them timely to show activity in 
vitro. However, molecular weight of the polymer alone cannot entirely govern the 
nanoparticle performance since our results clearly indicate that 50 kDa polymer formulation 
shows better activity compared to 90 kDa polymer formulation. Lipofectamine, a commonly 
used cationic lipid transfection agent, was used as a positive control which generated a 
boost effect on gene silencing but this but failed to provide a sustained silencing effect over 
time (334) CS nanoparticle mediated delivery, on the other hand, serves as a sustained 
source of siMad2 in the cells to achieve effective silencing activity for a significantly longer 
period compared to positive control (Figure 21). Biological activity of any siRNA is directly 
related to its release from the carrier, which in turn can be influenced by nanoparticle carrier 
size, interaction with the payload, stability etc. Kong et al. demonstrated that CS molecular 
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weight can impact the biological activity where changing the polymer from 20 to 40 or 80 
kDa changed the net activity from 60 to 70% (279). 
Reduction in the level of Mad2 protein results in premature mitotic exit, multi-nucleation and 
apoptosis-induced cell death (131, 191, 221). It was therefore relevant to assess if silencing 
of Mad2 gene and subsequent protein expression inflicts any cytotoxic effect on the cells. 
A time-dependent study with 50 nM dose of siMad2 loaded CS-derivatives in A549 cells 
demonstrated higher cytotoxicity as a function of increased incubation time post transfection 
(Figure 23). All formulation loaded with siMad2 start to show cytotoxic effects around 48h 
post transfection, which correlates extremely well with the Mad2 protein levels in A549 cells 
with identical dose of siRNA (Figure 22). Most importantly, blank CS derivatives did not 
cause any toxicity to the cells, thus confirming that the observed cytotoxicity from siMad2 
loaded CS nanoparticles is due to siMad2 activity. It has been well documented that 
depletion of Mad2 protein level leads to apoptosis-mediated cell death (Figure 25) (191, 
221).  
The human lung primary cell line, HPAEpiC was used as an example of non-tumor human 
lung primary cell line to evaluate the toxicity profile of the formulation and assess a 
therapeutic window. The primary alveolar cell line was used to emphasize the two major 
differences between non-tumor cells and the tumor cells: i) non-tumor cells have a much 
lower proliferation rate. Since the mitotic checkpoint proteins such as Mad2 are only needed 
during cell division, its abolition would selectively affect proliferating tissues; therefore 
cancer cells with high cell proliferation rate would be much more prone to anti-Mad2 therapy 
compared to their normal counterpart (131) ii) EGFR is frequently overexpressed in NSCLC 
which would increase the uptake of the EGFR-targeted chitosan nanoparticles when 
compared with non-tumor cells (335). Due to the absence of EGFR overexpression in the 
primary cell line, the targeted and non-targeted particles seem to behave in a similar way 
while in A549 cells the effect of the targeted particles was more pronounced. This further 
confirms that the enhanced toxicity demonstrated by the EGFR targeted nanoparticles is 
indeed due to their targeting effect, which would augment the therapeutic efficacy more 
effectively in the in vivo setting. 
5. CONCLUSIONS 
We have developed an EGFR-targeted chitosan system for silencing Mad2 mitotic 
checkpoint gene in treatment of NSCLC. We showed that this system exhibited higher and 
selective uptake, and efficiently knocked down Mad2, resulting in massive cell death by 
apoptosis. Collectively, our results indicate that the described system can be used as 
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potential therapeutic strategy for cancer treatment. Further studies are needed to validate 
these results in vivo. 
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1. INTRODUCTION 
Lung cancer is one of the deadliest type of malignancy worldwide, accounting for more than 
one quarter of all cancer related deaths with 85% of the cases being NSCLC (336). Most 
cases of lung cancer are diagnosed in their advanced stages, compromising long-term 
survival (1-year survival rate of approximately 10%) (337). Platinum-based therapy is the 
recommended first-line treatment for advanced NSCLC. However, systemic toxicity of 
platinates and development of acquired drug resistance have become an increasing 
problem in clinic, leading to high rate of mortality in NSCLC (338). As such, there is an 
urgent need for development of novel treatment approaches against NSCLC, especially in 
improving clinical outcomes in refractory disease. Some current therapies, such as the use 
of taxanes and vinca alkaloids, take advantage of those neoplastic cells with high 
proliferation rate to inhibit their division through targeting microtubules (339). The 
disadvantage on this strategy is the non-specific toxicity, such as nerve damage, associated 
with these drugs (340, 341). A promising alternative is the use of molecular targeted 
strategies to disrupt mitosis without interfering with microtubule dynamics. As the targeted 
proteins only intervene in actively dividing cells, these strategies would not affect non-
dividing cells thereby decreasing the treatment-related adverse effects (342).  
Mitotic arrest deficient-2 (Mad2) gene is an essential component of the mitotic checkpoint, 
a surveillance mechanism that inhibits the metaphase-to-anaphase transition whenever 
chromosomes are not properly attached to the mitotic spindle (131, 343). Overexpression 
of Mad2 has been observed in several types of cancer including human NSCLC, oral 
cancer, cervical carcinogenesis and urothelial bladder cancer (218, 344-346). Mad2 
depletion disrupts mitotic checkpoint function leading to premature mitotic exit, increased 
chromosome fragmentation and extensive cell death, and also sensitizes cancer cells to 
anticancer drugs. (347-349). We recently used RNA interference (RNAi) approach to 
highlight the potential of Mad2 gene knockdown as antitumor therapeutic strategy (347). A 
major challenge in applying this technology is to effectively deliver the small interfering 
RNAs (siRNAs) to the tumor in vivo. Enzymatic degradation, removal from circulation by 
renal excretion or mononuclear phagocyte system (MPS), poor cellular uptake and 
endosomal release are examples of physiological barriers that siRNAs need to overcome 
(350, 351). Several viral and non-viral delivery vectors, such as adenovirus, polyplexes, 
liposomes, and micelles, amongst others, have been developed to overcome these 
obstacles and improve RNAi therapeutic efficacy in vivo (352-358).  
CS, has gained increasing interest as a safer and more cost-effective vehicle for delivery of 
gene materials. The deacetylated derivative of chitin, is one of the most abundant 
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carbohydrate polymers with several essential features that make it a useful natural material 
for medical and pharmaceutical applications (359). As a random copolymer of poly(D-
glucosamine) and poly(acetyl-D-glucosamine), CS is characterized by the degree of 
deacetylation and primary amine groups which, at low pH, are protonated and afford water 
solubility and cationic properties (271). The presence of positive charges on CS backbone 
is related to its improved mucoadhesive properties and hemostatic activity (360). The 
polymer interacts with membrane negative charges leading to a translocation of tight 
junction proteins from the membrane to the cytoskeleton, resulting in tight junction 
disruption and enhanced permeability (361-363). Many reports have shown that CS can be 
enzymatically degraded in vivo due to the cleavable glycosidic bonds, and has minimal 
toxicity upon systemic administration (359). CS has been widely used as a non-viral gene 
carrier since it can form complexes with nucleic acids by electrostatic interactions (364). 
This way, nucleic acids are protected from nucleases and there is an increased efficiency 
of gene delivery to the cells where these complexes can be released from endosomes to 
enter the nucleus (347, 364).  
Chitosan may be delivered to the tumor tissues by taking advantage of 'leaky' and 
heterogeneous vascularization, which allows the migration of particles with diameter around 
200 nm into the surrounding tumor region. Modifications such as anchoring PEG to the 
nanoparticle surface can be utilized to prolong in vivo circulation and improve tumor 
infiltration. This process refers to the enhanced permeability and retention (EPR) effect that 
allows for passive delivery of long circulating nanoparticle systems to the solid tumor (365, 
366). Other surface alterations, such as the incorporation of targeting moieties (e.g., 
antibodies, proteins, polysaccharides, and small molecules) provide enhanced efficacy and 
selectivity to tumor tissue and cells, thereby enhancing specificity and reducing off-target 
effects. The active targeting approach takes advantage of the overexpression of certain 
ligands and receptors on the tumor cell surfaces that permits a molecular recognition and a 
more efficient uptake of functionalized nanoparticles (367).  
Overexpression and activation of epidermal growth factor receptors (EGFRs) have been 
strongly indicated in tumorigenesis, tumor growth, progression, invasiveness and 
metastasis (324, 368). Due to their high overexpression, they have been extensively used 
as cancer cell selective targeting receptor. We have previously used a synthetic 12 amino 
acids peptide that has demonstrated efficient targeting of EGFR receptor and its targeting 
capability has been successfully validated in vitro as well as in vivo in various EGFR-
overexpressing tumor cells such as A549 (311, 316, 317, 369-371). Most importantly, this 
peptide is capable of inducing nanoparticles cellular uptake without activating EGFR 
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signaling pathway and therefore was included as targeting ligand in our formulation 
approach (318). 
We recently demonstrated efficient in vitro delivery and Mad2 gene silencing by siRNA 
encapsulated in non-targeted (NTG) and EGFR-targeted (TG) CS-based self-assembling 
nanoparticles system, in cisplatin sensitive A549-WT and resistant A549-DDP NSCLC cells 
(347). Here, we have investigated the biodistribution profile of these Mad2 siRNA (siMad2)-
loaded TG and NTG nanoparticles, in mice bearing subcutaneous, cisplatin sensitive or 
resistant, human lung adenocarcinoma xenograft tumors. The differences in the 
biodistribution and pharmacokinetics parameters between TG and NTG nanoparticles has 
been studied qualitatively and quantitatively. 
2. MATERIALS AND METHODS 
2.1 Materials 
CS with a viscosity-average molecular weight of 55 kDa and a degree of deacetylation of 
75-85% was purchased from Sigma-Aldrich Inc. (St. Louis, MO). Fluorescent dye DyLight 
680 NHS-Ester and Pico-Green fluorescence reagent were obtained from Life Technologies 
(Carlsbad, CA, USA). Succinimidyl-([N-maleimidopropionamido]-ethyleneglycol) ester 
(MAL-PEG2000-NHS, MW 2,000 Da) was purchased from JenKem (Allen, TX). EGFR 
specific peptide was synthesized at Tufts University’s Peptide Synthesis Core Facility 
(Boston, MA). SiMad2 and its corresponding scrambled siRNA were obtained from Santa 
Cruz Biotechnology Inc. (Dallas, TX). All primers were ordered from Eurofins Scientific 
(Luxembourg City, Luxembourg). AgPath-ID One step RT-PCR kit was purchased from 
Thermo Scientific (Rockford, IL) to perform RT-PCR. All other reagents were obtained at 
high purity (>99%) from Sigma-Aldrich Inc. (St. Louis, MO) or Thermo Scientific (Rockford, 
IL).  
2.2 Cisplatin sensitive and resistant cell lines and tumor models 
Cisplatin sensitive (parenteral) NSCLC cell line (A549-WT) was obtained from American 
Type Culture Collections (ATCC, Manassas, VA). Cisplatin resistant NSCLC cell line (A549-
DDP) was obtained from our collaborator, Massachusetts General Hospital (Boston, MA). 
Both cell lines were cultured at 37°C in 5% CO2 environment in DMEM/F12 medium from 
Life Technologies (Carlsbad, CA) supplemented with 10% fetal bovine serum and 
penicillin/streptomycin (100 U/mL) (Thermo Fisher Scientific, Waltham, MA, USA). A549-
DDP were cultured in the presence of 2 μg/mL cisplatin to maintain the drug resistance 
phenotype. Three days before use, A549-DDP media was changed to a medium without 
cisplatin. 
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Six weeks old female nu/nu (athymic) mice, strain CrTac:NCr-Foxn1nu from Taconic 
Biosciences, Inc. (Hudson, NY), weighing approximately 20 g, were group-housed upon 
arrival in the Division of Laboratory Animal. The animals were allowed to acclimate for at 
least 72 h prior to any experimentation, raised under specific pathogen-free conditions, kept 
in individually ventilated cage racks and supplied with sterile rodent pellets and water ad 
libitum. Mice were housed under a 12 h light/dark cycle. For A549-WT and A549-DDP tumor 
model development, mice were injected subcutaneously with 3x106 cells in a mixture of 50 
µL DMEM/F12 medium and 50µL Matrigel on the right flank, under mild anesthesia. Tumor 
volume was measured with caliper every 3 days and calculated by the modified ellipsoid 
formula: Tumor volume = ½ (length × width2)  
Each study commenced when the tumors reached an average size of 200 mm3 and the 
animals were randomly assigning to a specific group. The animals were monitored daily for 
food/water intake, body weight and any physical signs of discomfort. In all the experiments 
performed in this study, sample size was determined by power analysis using the software 
G*Power. 
2.3 Synthesis of chitosan derivatives 
For NTG and TG nanoparticles encapsulating Mad2 siRNA, CS derivatives were 
synthesized as previously described (347). Briefly, to a 2mg/mL CS solution in 2% acetic 
acid, a 10% molar equivalent of Mal-PEG2000-NHS was added and left to react overnight at 
room temperature. Dialysis (molecular weight cutoff - 10 kDa) in water was performed in 
order to purify the conjugate. Cysteine was reacted in excess under N2 environment, to 
inactivate the maleimide group to obtain the NTG CS derivative. The synthesis of TG CS 
derivative was achieved by using a 17-amino acid peptide consisting of 12-amino acid 
EGFR recognition peptide, four glycine residues spacer and a terminal cysteine for 
conjugation via the thiol group (i.e., YHWYGYTPQWVI-GGGG-C). The peptide was added 
in a 2-fold molar excess to the CS derivative with a reactive maleimide group and left to 
react overnight at 4°C in nitrogen atmosphere to allow the cysteine group from the peptide 
to react with the maleimide group. NTG and TG derivatives were purified by dialysis 
(molecular weight cutoff - 10 kDa) against water, freeze-dried and stored at -20 °C until their 
use. Degree of PEG substitution on the CS backbone was estimated by NMR analysis in 
D2O using 400 MHz 1H nuclear magnetic resonance (NMR) spectroscopy (Varian Inc., CA). 
2.4 Chitosan labeling with NIR dye for in vivo imaging 
Near-infrared (NIR) labeled CS was obtained by mixing NTG CS derivative with the amine-
reactive dye DyLight 680 NHS-Ester (DL680) in an aqueous solutions at an equivalent 
amount to achieve 5% substitution of the CS amine groups. DL680 is a near-infrared 
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imaging dye with 684/707 nm as Excitation/Emission maxima. After reacting overnight in 
the dark, the NIR derivative was dialyzed overnight using 10 kDa MW cut-off membrane 
(Spectrapore, Spectrum Labs, San Diego, CA) and freeze-dried. The degree of modification 
of the CS backbone with the dye was estimated against a standard curve obtained from the 
absorbance of the known concentrations of the dye measured at 680 nm.  
2.5 siMad2-loaded chitosan nanoparticles 
Both NTG and TG CS nanoparticles were obtained by self-assembly in aqueous solution 
maintaining a N/P ratio (ratio of CS bearing cationic amines to siRNA bearing anionic 
phosphates) of 50. Independent of the desired type of nanoparticles (NTG, TG or NIR-
labeled), CS derivative was dissolved in water (1 mg/mL). SiMad2 was slowly added to this 
solution under magnetic stirring and incubated for 30 min at room temperature. This 
procedure allowed CS and siMad2 complexation and nanoparticles self-assembly prior to 
use. If we intended to produce TG CS nanoparticles, the initial mixture would be a 50 % 
(w/w) mixture of CS-PEG and CS-EGFR (1 mg/mL). In case of NIR-labeled nanoparticles, 
CS-PEG would be substituted by NIR-labeled CS-PEG. For every study, nanoparticles were 
freshly prepared and dissolved in PBS in order to obtain a desired concentration and also 
achieve an osmolarity of 300 mOsm/kg and a pH of 7.2.  
Hydrodynamic diameter (particle size), surface charge and polydispersity index (PDI) of 
freshly prepared siMad2 loaded CS (CS-Mad2) nanoparticles were measured using a 
ZetaSizer Nano ZS (Malvern Instruments, Worcestershire, UK). Each sample was obtained 
from four independent batches in different days. They were diluted in PBS, analyzed in 
triplicate at 25°C and the different parameters reported as mean ± SD. The encapsulation 
efficiency (ratio of encapsulated siRNA over total siRNA added) was determined using 
Quant-iT Pico-Green kit (Life Technologies, Carlsbad, CA, USA).  
2.6 Whole body and ex vivo NIR imaging 
A549-WT and A549-DDP tumor bearing mice were intravenously injected into the 
lateral tail veins with a dose of 3 mg/kg of siMad2 encapsulated in NIR labeled TG and NTG 
CS nanoparticles, (n = 4/group). Intravenous injection was the route of nanoparticles 
administration in all of the experiments in order to avoid an absorption phase which would 
compromise an accurate estimation of distribution and elimination parameters (372). Mice 
were imaged every 24 h until 96 h after the injection, to monitor the distribution of the 
nanoparticles using Xenogen IVIS® Imaging System (Xenogen Corporation, Alameda, CA) 
(Ex: 685 nm, Em: 720 nm). Along with these formulations, free NIR dye in PBS at identical 
concentration was also injected into tumor bearing mice. For ex vivo imaging, the same 
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procedure was adapted but animals were sacrificed at different time points. Tumor and 
major organs (liver, spleen, kidneys, heart and lungs) were collected for imaging purposes. 
2.7 Quantitative analysis of siMad2 in blood and tissues 
siMad2 was encapsulated in NTG and TG CS nanoparticles as described above and 
injected once at time zero into A549-WT and A549-DDP tumor bearing mice at 3 mg/kg (n 
= 5/group). At different time points (12, 24, 48, 72, 96 and 120 h), animals were sacrificed 
and blood samples, the major organs (liver, spleen, lung, heart, kidney), and tumors were 
collected. Blood samples from the facial vein were also collected 6 h after injection. Plasma 
was isolated from the blood samples by centrifugation at 1,200g for 15 min at 4 °C, followed 
by siMad2 quantification. 
Tumor and organs were homogenized in RNALater solution in order to preserve RNA 
integrity and the tissue lysates were diluted at 1:1000 dilution. Mad2 siRNA was then 
quantified in the samples based on an anti-primer quenching PCR method (373). The 
diluted samples were used for subsequent annealing step followed by qRT-PCR. The 
primers used were: Reverse: 5’ GGA AGC CGA TGG CAG T; Forward: /56-FAM/ - 5’ ACT 
CCC TCC CTC GAT TTT CAA TAT CAA AC; and anti-primer: 5’ AAA TCG AGG GAG GGA 
GT /3BHQ_1/. 
The procedure was performed according to the previously optimized protocol published by 
our group (374). Briefly, 6µL of diluted tissue sample was mixed with 18 μl of 100 nM reverse 
primer, and put through a cycle of denaturation by incubating at 95 °C for 5 min and another 
cycle of annealing for 2 min at each temperature of 80, 70, 60 and 45 °C. From this mixture, 
3.5 µl were used and mixed with 8.5 μl from a AgPath-ID One step RT-PCR master mix 
constituted by the following components: RT-PCR buffer (6.25 mL), forward primer (10 
mmol/L, 0.12 mL), reverse primer (10 mmol/L, 0.12 mL), anti-primer (100 mmol/L, 0.12 mL), 
25 U RT-PCR enzyme (0.5 mL), and water (1.5 mL). The PCR conditions were as follows: 
50 °C (10 min), 9 °C (10 min), 40 cycles, 95°C (15 sec), 45 °C (60 sec). Using lysate from 
untreated mouse tissue and spiked with known siRNA concentrations, we were able to do 
a standard curve and quantify. The quantitated siRNA in each tissue was then normalized 
towards the percentage of input dose per volume of plasma or per mass of tissue. 
2.8 Quantitative pharmacokinetic analysis 
SiMad2 plasma pharmacokinetic parameters and organs exposure were determined by 
non-compartmental analysis using Phoenix® WinNonLin® version 1.3 software (Certara, 
St. Louis, MO). Plasma half-life (HL) was calculated by log-linearly fitting the three last time 
points. The maximum observed concentration (Cmax) and the last observed concentration 
(Clast) were calculated as the mean of observed concentrations at the time when the mean 
Chapter 4 - Biodistribution and pharmacokinetics analysis in drug sensitive and resistant non-
small cell lung cancer models 
 
P a g e  87 
concentration was the highest, and at the last time point respectively. Exposure, quantified 
as area under concentrations versus time curve from time zero to the last collection time 
(i.e., AUClast), was calculated using the linear trapezoidal method. AUC extrapolated to 
infinity (AUC∞) was the sum of AUClast and Clast/(ln2/HL). The associated standard error of 
the mean was estimated using equations provided by Nedelman and Jia, and later corrected 
by Holder (375, 376). The mean residence time (MRT) was calculated as the ratio of 
AUMC∞ (Area under the first moment (time * concentration) versus time curve) and AUC∞. 
Clearance (CL) was calculated as the ratio of dose (100%ID) and AUC. The volume of 
distribution at the steady-state (Vss), i.e. at the time when equilibrium is reached for 
exchanges between distribution compartments, was calculated using the formula: Vss = CL 
* MRT. Non-compartmental analysis for sparse data being a naive pooled method, no 
variability could be estimated for pharmacokinetic parameters. Tumor targeting efficiency 
was evaluated by comparing tumor exposure to plasma exposure, and to the sum of other 
organs’ exposure. For each time-point and each condition, five animals were used.  
2.9 Data analysis 
With the exception of the quantitative pharmacokinetic analysis, statistical analyses were 
performed using GraphPad Prism software (San Diego, CA). Paired comparisons were 
performed by Student's t-test. A p value of 0.05 was considered to be statistically significant. 
Data presented are means ± standard deviation. 
3. RESULTS AND DISCUSSION 
In our previous in vitro studies, we designed and prepared EGFR targeted chitosan 
nanoparticles as a delivery system for Mad2 siRNA in lung adenocarcinoma cells (347). 
This nanoparticles were modified with PEG in order to provide a hydrophilic shielding and 
attain passive targeting to tumor site. NTG and TG nanoparticles loaded with siMad2 were 
able to efficiently silence Mad2 gene, leading to increased cytotoxicity by induction of 
apoptosis (347). In the current study, our goal was to evaluate the biodistribution pattern of 
these two types of CS nanoparticles in a subcutaneous xenograft model of human drug 
sensitive A549-WT and platinum resistant A549-DDP tumors. A 3 mg/kg dose of siMad2 
was used for all the experiments to ascertain accurate and consistent quantitative detection 
of the siRNA from various tissues samples.  
3.1 Whole body and ex vivo qualitative biodistribution studies 
Qualitative nanoparticles biodistribution studies were evaluated using an NIR dye, DL680, 
covalently bound to the CS skeleton. Due to the dye’s strong signal, CS was modified in a 
very low percentage (4%) which did not significantly impact the nanoparticles characteristics 
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(Table 5). Both TG and NTG particles were prepared and used to encapsulate siMad2 using 
the same method, independently of the presence or absence of conjugated dye. NIR 
labeled CS/siRNA nanoparticles were intravenously injected via tail vein in A549-WT and 
A549-DDP tumor bearing mice at a single dose of 3 mg/kg of siMad2. Mice were imaged at 
different time points and the NIR signal was measured to capture the whole-body 
distribution pattern. Using the same conditions, a different set of animals were sacrificed 
and their major organs collected and imaged. Although studies were performed in A549-
WT and A549-DDP tumor bearing mice, the results were identical in both models and even 
though we will refer to the results from the A549-WT model, the conclusions apply to both 
tumor models.  
Table 5: NIR dye-loaded CS nanoparticles characterization 
 
Size 
(nm) ±SD 
PDI ±SD 
Zeta potential 
 (mV) ±SD 
siMad2 Encapsulation 
Efficiency (%) 
NTG 106.8 ± 2.1 0.551 ± 0.10 +35.6 ± 3.5 105.1 ± 4 
NTG-DL680 113.1 ± 5.3 0.472 ± 0.53 +32.8 ± 2.4 101.6 ± 2.3 
TG 227.3 ± 1.8 0.362 ± 0.02 +28.3 ± 2.0 99.5 ± 2.4 
TG-DL680 230.1 ± 4.1 0.341 ± 0.21 +29.9 ± 2.9 97.5 ± 3.3 
NTG: Non-targeted; PDI: polydispersity index; SD: standard deviation; TG: Targeted; WT: wild type. 
 
Within the first 12 h post-injection, a very strong NIR signal was observed throughout the 
whole body of animals injected with both systems, and only after 24 h the signal started to 
accumulate in certain areas (Figure 26). The whole body images (Figure 26A) show a strong 
signal at 24h for both TG and NTG nanoparticles in the liver and kidneys, which are the 
significant sites of CS nanoparticles accumulation and metabolism, mainly when using CS 
of low molecular weight (377). Tumors show nanoparticle accumulation, and the signal 
appeared to be stronger for TG nanoparticles compared to the NTG nanoparticles, 
particularly in posterior view images. Due to the limited depth penetration of the optical 
source through the tissue in the whole body imaging, mice were sacrificed and the organs 
were excised for ex vivo imaging. Previous annotations were confirmed by ex vivo 
fluorescent imaging where liver showed a strong signal until 48 h, while kidneys 
demonstrate higher accumulation throughout but mainly within the first 48 h (Figure 26C). 
These results are supported by the fact that CS has been described to have relatively long 
circulation time (377, 378).  
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Figure 26: Whole body and ex vivo optical imaging of near-IR labeled chitosan/siMad2 nanoparticles in mice 
A549-WT tumor bearing mice for up to 96 h. Pre-labeled chitosan with a near-infrared Cy 5.5 dye was used to 
encapsulate siMad2 using a N/P ratio of 50/1. A549 tumor bearing mice were injected once in a concentration 
of 3 mg/kg of siMad2 encapsulated in non-targeted (NTG) or targeted (TG) CS nanoparticles. (A-B) Mice were 
imaged at different time points up to 96h, on their posterior and lateral view using IVIS live imaging system. In 
this images we have two representative animals although a total of four animals per tumor model were used. A 
solution of free dye was also administered at equivalent concentration but it was only detected until 2h after 
injection. Yellow arrow indicates tumor localization. (C) Ex-vivo NIR images of major tissues excised from A549 
tumor bearing mice at different time points post injection. NTG: Non-targeted; TG: Targeted; WT: wild type. 
Contrarily, heart, lungs and spleen did not show any nanoparticles accumulation with the 
only exception being lungs that show low signal with TG nanoparticles at 72h which could 
be due to some contamination during tissue collection, but a very low signal is detected. 
The excised tumors showed a strong signal after 24 h post-injection for both nanoparticles, 
although TG nanoparticles seemed to show a stronger signal at 48h. For the following time 
points, both systems seemed to have similar signal intensity and they reach their maximum 
at 96 h. Although both NTG and TG nanoparticles have shown a high level of signal in the 
  
P a g e  90 
tumor site, the imaging technique is not sensitive enough to discern an improvement in 
tumor accumulation due to the presence of EGFR targeting peptide. In spite of this, both 
nanoparticle systems presented better delivery efficiency compared with free dye, which 
was not detected within the tumor. The body distribution of free NIR dye was monitored in 
order to ensure that the signal seen for NTG and TG nanoparticles was due to intact 
nanoparticles and not due to free dye released from nanoparticles. At 24 h, there was no 
detectable fluorescence signal in any of the mice injected with free dye and therefore mice 
had to be imaged at 1 and 2 h post-injection (Figure 26B). The rapid in vivo signal decrease 
of free NIR imaging dye could be attributed to fluorescence quenching in physiological 
environments and also indicative of a rapid hepatic clearance from the systemic circulation 
(379-381). Nanoparticles allow a long circulation of the dye, providing it with an 
effective shielding and preserving its fluorescence (382). An increased circulation 
associated with small sizes is beneficial since the nanoparticles will be able to extravasate 
across the fenestrated endothelium of the cancer vasculature and accumulate in tumor 
tissue through the EPR effect (366).  
3.2 Plasma pharmacokinetic analysis 
SiMad2 encapsulated in NTG or TG CS nanoparticles were administered by intravenous 
injection at a single dose of 3 mg/kg in mice bearing A549-WT and A549-DDP tumors. Later 
Mad2 siRNA was quantified in different organs, tumor, and plasma, using the anti-primer 
quenching based RT-PCR method (373). Data was processed and expressed as 
percentage of the injected dose per ml of plasma or mg of tissue (% ID/ml or % ID/mg). For 
all conditions, siMad2 was detected in plasma up to 48h after administration. This long 
circulation could be related to the presence of positive charges on CS structure. These 
charges can interact with negative charges on red blood cell membranes and allow the 
nanoparticles to circulate in the bloodstream for long periods of time (383, 384). SiMad2 
concentrations were below the limit of quantification at 72 h post-injection. Regarding siRNA 
concentration in plasma in A549-WT tumor model (Figure 27A), both NTG and TG 
nanoparticles produced similar concentrations after 6 h, but then concentrations decreased 
faster for TG nanoparticles than for NTG nanoparticles, with concentrations at 12 and 24 h 
being significantly lower for TG nanoparticles. A similar trend was obtained in A549-DDP 
tumor model (Figure 27B) where siMad2 being at a similar concentration at 6 h for both type 
of particles and significantly lower for TG nanoparticles at 12 and 48 h.  
 AUClast is an important pharmacokinetic parameter that expresses the concentration of the 
siRNA in the interstitium as a function of time (385). This parameter reflects the tissue 
degree of exposure to siRNA and also its clearance from the body. AUClast was significantly 
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higher in NTG nanoparticles than in TG nanoparticles, independent of the tumor models 
(Figure 28).  
 
Figure 27: Plasma concentrations of siMad2 (%ID/mL) ± SD versus time (h) in A549-WT (A) and A549-DDP (B) 
tumor models, after IV injection of NTG and TG nanoparticles at 3 mg/kg equivalent siRNA. n = 5 mice. * p<0.05, 
** p<0.01, *** p<0.001 (t-test TG vs NTG). DDP: Cisplatin; NTG: Non-targeted; SD: standard deviation; TG: 
Targeted; WT: wild type 
This observation was consistent with the observed kinetics and exposures. The clearance 
of TG nanoparticles was higher than the clearance of NTG nanoparticles for both models 
studied, leading to a shorter mean residence time in the body (Table 6). Accordingly, Clast 
value was lower for TG nanoparticles than for NTG nanoparticles, while Cmax values were 
similar. The volume of distribution appeared reduced by the targeting peptide in the A549-
DDP model only. Surprisingly, half-life calculated from the last three time-points showed no 
clear difference between nanoparticles. This might be ascribed to the small number of time-
  
P a g e  92 
points, which would not enable the characterization of a biphasic kinetics and a relevant 
elimination half-life. Overall, the addition of EGFR targeting peptide induced a significantly 
higher exposure to tumor tissue, which is in line with most published results (317, 386, 387). 
 
Figure 28: Plasma exposure to siMad2 over the duration of the study. AUClast +SE (in h*%ID/mL of plasma) 
for A549-WT and A549-DDP tumor models, after IV injection of NTG and TG nanoparticles at 3 mg/kg equivalent 
siRNA. n = 5 mice. * p<0.05, ** p<0.01, *** p<0.001 (t-test TG vs NTG). AUClast = Area under the concentration 
versus time curve until the last time point; DDP: Cisplatin; NTG: Non-targeted; SE: standard error; TG: Targeted; 
WT: wild type. 
Table 6: Plasma PK parameters calculated by non-compartmental analysis using Phoenix® 
WinNonLin® software. 
 A549-NTG A549-TG A549 DDP-NTG A549 DDP-TG 
HL (h) 19.5 22.6 23.4 24.1 
Cmax (SE) 
(%ID/mL) 
4.73 (0.23) 5.02 (0.10) 6.10 (0.40) 5.25 (0.12) 
Clast  
(%ID/mL) 
0.970 0.588 1.388 0.459 
AUC∞  
(h x %ID/mL) 
168 122 205 143 
MRT (h) 26.1 20.9 30.7 16.0 
CL (mL/h) 0.595 0.817 0.489 0.700 
Vss (mL) 15.5 17.1 15.0 11.2 
AUC∞: Area under the time-concentration curve from time zero to infinity; CL: Total body 
clearance; Clast: concentration at the last time-point; Cmax: maximum observed concentration; 
DDP: Cisplatin; HL: Half-life of the log-linear terminal part of the curve; MRT: Mean residence 
time; NTG: Non-targeted; SE: standard error of the mean; TG: Targeted; Vss: Volume of 
distribution at the steady-state;. 
3.3 Tumor and other tissue pharmacokinetic analysis 
Whole body images were informative regarding the nanoparticles biodistribution and ex vivo 
imaging allowed to identify the most exposed organs, but results needed to be confirmed 
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by quantitative measurements. In A549-WT model treated with NTG nanoparticles, the 
concentrations at 12 h were the highest in kidneys, followed by liver, tumor, heart, spleen 
and lungs (Figure 29A).  
 
 
Figure 29: Biodistribution in tumor and major organs. Organ concentrations of siMad2 (%ID/mg of tissue) ± 
SD at various times after injection (from 12 to 120 hours) in A549-WT (A) and A549-DDP (B) tumor models, 
after IV injection of NTG and TG nanoparticles at 3 mg/kg equivalent siRNA. n = 5 mice. * p<0.05, ** p<0.01, 
*** p<0.001 (t-test TG vs NTG). ID: Injected dose; DDP: Cisplatin; NTG: Non-targeted; TG: Targeted. 
At 24 h, the order was slightly different, with tumor displaying the highest concentration, 
followed by kidneys, spleen, liver, heart, and lungs. The addition of the targeting peptide 
increased siMad2 concentration in tumor (significantly at 24, 72 and 96h), but also in liver 
and kidneys. A significant decrease was seen in spleen and heart at early time points with 
TG nanoparticles, but not maintained later. No significant changes were observed in lungs. 
Interestingly, the quantitative approach allowed to observe differences, for which imaging 
was not sensitive enough. The quantitative approach also showed that tumor 
concentrations were peaking at 24 h and then decreasing, while ex vivo images suggested 
an increase of concentrations until 96 h. It is important to take into account that in one study 
we are quantifying siMad2 while in the imaging studies, we have labeled CS nanoparticles. 
Also, siMad2 is rapidly used by the cellular silencing mechanism once in the cytoplasm 
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while the fate of CS molecule is unsatisfactorily understood (350). In the A549-DDP tumor 
model (Figure 29B), the trends were very similar to the A549-WT model. However, a few 
differences could be observed. First, with NTG nanoparticles, concentration in spleen was 
not lower than in tumor at 12 h, and was higher than in heart. At 24 h, concentration in 
kidney was still higher than in tumor, and spleen was also less exposed than, in A549-WT 
model. When comparing TG to NTG particles, the most striking differences were a much 
higher increase of tumor concentrations, while liver and kidney concentrations were lower 
at 12 h by the addition of the targeted peptide. These results enhance the influence of active 
targeting on increasing target-site accumulation. 
For some of the organs, it was not possible to properly estimate a log-linear terminal phase 
half-life and a mean residence time, due to an unclear decrease slope. For example, due 
to concentrations measurements variability, the spleen concentration at 120 h in the A549-
WT model after NTG nanoparticles administration was higher than earlier concentrations in 
the same conditions. In order to compare the residence times for the different conditions, 
we chose to use an indirect parameter for residence time, which was available for all 
conditions, i.e. the Clast/Cmax ratio (Table 7). 
Table 7: Ratio of the last time-point concentration (Clast) versus the maximum concentration 
reached over the duration of the study (Cmax), expressed in % (SD). n = 5 mice. * p<0.05, ** 
p<0.01, *** p<0.001 (t-test TG vs NTG). 
 
Clast/Cmax (%) (SD) 
A549-WT 
NTG 
A549-WT 
TG 
A549-DDP 
NTG 
A549-DDP 
TG 
Plasma 21.1 (6.4) 11.9 (4.7) 22.7 (0.6) 8.71 (3.11) *** 
Tumor 8.62 (6.73) 0.619 (0.195) 0.452 (0.269) 0.544 (0.346) 
Liver 20.8 (5.4) 15.1 (0.7) 9.07 (3.05) 11.8 (1.1) 
Kidney 11.8 (2.8) 6.92 (1.15) * 7.19 (1.32) 7.11 (0.98) 
Spleen 33.3 (13.5) 1.50 (0.12) ** 11.0 (12.0) 1.84 (0.66) 
Heart 6.89 (6.06) 16.5 (5.5) 19.8 (6.9) 50.3 (16.0) * 
Lung 13.1 (6.7) 15.6 (6.7) 11.4 (5.8) 6.77 (1.73) 
Clast : last time-point concentration; Cmax : maximum concentration reached over the duration of the study; 
DDP: Cisplatin; NTG: Non-targeted; SD: standard deviation; TG: Targeted WT: wild type. 
 
 In plasma, the ratio was lower for TG particles, suggesting a faster elimination and a shorter 
residence time, which is in line with the PK parameters (Table 7). In tumor, the ratio was 
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particularly low compared to other tissues, suggesting a rapid clearance of siMad2 from the 
tumor. This might be due to consumption of the siRNA by its target, leading to a “target-
mediated drug disposition”. The differences were rarely significant between TG and NTG 
particles, except for kidney and spleen in A549 model where the ratio was significantly lower 
for TG particles, and for plasma and heart in A549-DDP model where the ratio was 
significantly lower and higher respectively. The clearest difference between nanoparticle 
types, confirmed in both models, was a decrease of the Clast/Cmax ratio in spleen for TG vs 
NTG nanoparticles, suggesting that the targeting peptide might increase the clearance of 
the siRNA from the spleen. 
Regarding the global exposure of the various tissues to siRNA over the study course 
(estimated as AUClast), it appeared in both tumor models that kidneys were the most 
exposed to siRNA, followed by tumor, liver, spleen, heart, and lungs, when NTG 
nanoparticles were used (Figure 30).  
 
Figure 30: Tissues exposure to siMad2 over the duration of the study. AUClast +SE (in h x %ID/mg of tissue) 
for A549-WT and A549-DDP tumor models, after IV injection of NTG and TG nanoparticles at 3 mg/kg equivalent 
siRNA. n = 5 mice. * p<0.05, ** p<0.01, *** p<0.001 (t-test TG vs NTG). AUClast: Area under the concentration 
versus time curve until the last time point; DDP: Cisplatin; NTG: Non-targeted; TG: Targeted. 
Introduction of the targeting peptide significantly increased exposure of tumor, liver, and 
kidneys for both models, of heart and lungs in A549-DDP model only, and significantly 
decreased spleen exposure in both models. In A549-DDP model, the enhancement of tumor 
exposure was far higher than in A549-WT model and this influence was felt not only in a 
higher tumor accumulation but also in a lower accumulation in other tissues. The difference 
between the tumor models can be ascribed to the slightly higher vascularization that had 
been detected in the A549-DDP model. Indeed, a higher permeability of the tumor allows 
nanoparticles to travel more deeply into the tumor tissues after extravasation (388). Another 
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reason that could contribute to such difference and probably more significantly, is the EGFR 
expression levels in these two models. We have used flow cytometry to measure EGFR) 
cell surface expression levels on A549-WT and A549-DDP and results showed that the 
cisplatin resistant cell line, A549-DDP has a significantly higher expression. This fact is of 
great influence on the amount of nanoparticles being taken up by tumor cells. 
3.4 Evaluation Of The Tumor Targeting Efficiency 
Since not only tumor exposure but also other main organs exposure was increased by the 
presence of targeting peptide, especially in A549-WT; we calculated a new parameter, the 
targeting efficiency (TE). With this parameter we wanted to check if the presence of the 
peptide in the TG nanoparticles was able to increase tumor exposure, i.e. the ability of the 
particle to deliver the siRNA preferably to the tumor than to other tissues. TE was calculated 
as the ratio of tumor exposure versus plasma exposure or non-target organs exposure. In 
all conditions, plasma was far more exposed than tumor, the ratio reaching a maximum of 
3.16% (Figure 31A). However, TE was significantly increased by the targeting strategy in 
both models, a 3.4 fold increase in A549-WT and 5.5 in A549-DDP model. It is apparent 
that the presence of the peptide in the TG nanoparticles has assisted the process of 
concentrating them into the cancer tissue in comparison to the NTG nanoparticles. We 
should also keep in mind that both nanoparticles are PEGylated, which by itself promotes 
tumor accumulation based on the EPR effect (366). Many studies have associated PEG 
with greater tumor uptake and longer circulation time (389, 390). Besides, PEG contributes 
to increased particle hydrophilicity, stability, avoidance of plasma protein identification and 
escape from opsonization and clearance (391). 
When comparing tumor exposure to the sum of other organs exposure (Figure 31B), we 
observed that TE was high, with tumor exposure ranging between 28.3 and 49.0% of the 
global organ exposure. TE was increased by the targeting strategy in both models, 
increasing from 28.3 to 31.0% in A549 model, and from 34.8 to 49.0% in A549-DDP model. 
However, the difference was statistically significant only in the A549-DDP model. These 
results confirm the influence of EGFR-peptide targeted nanoparticles to target the cancer 
cells, which is in agreement with previous studies from our group where the same peptide 
was successfully used (370, 392, 393). 
Based only on the imaging data, the targeting effect could not be clearly detected from the 
whole body and ex-vivo images. These comes from the fact that near-IR images are not 
sensitive enough to allow for visualization of the difference that was later detected from the 
quantitative data. Based on the siMad2 quantification study, we could conclude that the 
presence of the targeting peptide leads to a significant decrease in plasma exposure of 
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targeted nanoparticles and a higher targeting efficiency, i.e. a higher tumor exposure to 
Mad2-siRNA associated to no or a moderate increase of off-target organs exposure. The 
advantage of the targeting strategy was particularly clear for the A549-DDP model, with a 
higher increase of tumor exposure and targeting efficiency, probably due in some part to its 
higher EGFR cell surface expression levels. 
 
 
Figure 31: Targeting efficiency. Ratio (expressed in %) + SE of tumor exposure versus plasma exposure (A) or 
versus the sum of non-target organs exposure (liver, kidney, spleen, heart, lung) for A549-WT and A549-DDP 
tumor models, after IV injection of NTG and TG nanoparticles at 3 mg/kg equivalent siRNA. n = 5 mice. * p< 
0.05, ** p<0.01, ***p<0.001 (t-test TG vs NTG). DDP: Cisplatin; NTG: Non-targeted; SE: standard error; TG: 
Targeted. 
4. CONCLUSIONS 
The imaging and distribution studies together with the pharmacokinetic parameters showed 
that the tested CS formulations were efficient in delivering siMad2 to the tumor tissue in 
both models. In both tumor models, the addition of the targeting peptide resulted in a higher 
clearance, reflecting a faster elimination from the organism, leading to decreased plasma 
concentrations. Since tumor exposure was simultaneously increased, the targeting strategy 
proved efficient in both models to favor the entry of the siRNA inside the tumor. However, 
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the entry of the siRNA was also increased in other tissues. Calculating the ratio of tumor 
exposure versus non-target organs exposure, we proved that the tumor targeting efficiency 
was enhanced by the EGFR peptide, giving a specific advantage for delivery to the tumor 
when compared to other tissues, particularly in A549-DDP model. With an increased tumor 
targeting efficiency demonstrated in vivo and an efficient induction of apoptosis shown in 
vitro, our targeted delivery strategy proved to be a promising approach for NSCLC therapy 
in vivo (347). 
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1. INTRODUCTION 
Lung cancer is the leading cause of cancer related death in both men and women in the 
United States(394).  Non-small cell lung cancer (NSCLC) represents 87% of the cases of 
lung cancer (395). Most of NSCLC patients are frequently diagnosed with advanced-stage 
disease and have a 5-year survival rate of only 17.4%, lower than many other cancer sites 
(394, 395).  
Cisplatin (cis-diamminedichloroplatinum (II)) (DDP) is usually the first-line chemotherapy 
treatment in combination with another drug such as gemcitabine, vinorelbine, docetaxel, or 
paclitaxel (396, 397). In terms of molecular mechanism of action, cisplatin undergoes 
aquation in the cytoplasm and due to the positive charge it is incapable to cross the cell 
membrane (398). 
Cisplatin cytotoxic activity is due to its ability to interact with DNA forming platinum-DNA 
adducts that inhibit DNA replication (398). Cell cycle checkpoints monitor the cell accurate 
order of events, including DNA damage and when an error is detected a delay occurs to 
provide time for the lesion to be repaired (131, 343). It has been reported that cisplatin 
effects causes arrest during the G2/M phase of the cell cycle in cells with an intact DNA 
damage checkpoint(399). In case cells are not able to repair DNA damage caused by 
cisplatin, two different modes of cell death are induced, necrosis and apoptosis (400). If 
G2/M phase checkpoint is defective, the DNA damage might pass unnoticed to the next cell 
cycle phase, the mitotic phase (M phase), where the spindle assembly checkpoint (SAC) 
can be induced and either arrest the cell cycle and initiate DNA repair, or initiate apoptosis 
(401). 
Cisplatin therapy has two major complications, the augmentation of tumor resistance and 
its acute side effects (398). In terms of mechanisms responsible for the acquired resistance 
to cisplatin, several factors have been identified: decreased cytoplasmic accumulation; 
cytoplasmic sequestration; enhanced DNA repair (402, 403). Tumor resistance could be 
circumvented by the use of higher doses but that would aggravate the secondary effects 
(nephrotoxicity, emetogenesis and neurotoxicity), most due to its non- specificity(404). This 
limitations make new approaches urgently needed. 
The demand of new strategies, the constant improved knowledge of cancer molecular 
biology and nanotechnology innovation in the last few decades has made gene therapy a 
novel and attractive treatment modality (405, 406). The addition of gene therapy could 
significantly augment cancer drugs efficacy and allow lower doses, alleviating their 
secondary effects. On the other hand, although gene therapy are more specific, they are 
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not as potent and widespread as chemotherapeutic agents. Gene therapy could also benefit 
and have its efficacy treatment significantly augmented when used together with 
chemotherapy (406). Chemotherapy and gene therapy is a promising combination strategy 
to be applied in the treatment of aggressive tumors such as lung cancer.  
Strategies targeting mitosis in cancer has been an established clinical approach not only 
with classical microtubule-targeting drugs but also with newly proposed small molecules 
targeting Aurora kinases, kinesin spindle proteins, Polo-like kinases, etc. (407, 408). Mitotic 
arrest deficient-2 (Mad2) is an essential component of the mitotic checkpoint that has a 
crucial role in the correct segregation of chromosomes during mitosis (132). Mad2, together 
with other checkpoint proteins, delays anaphase until all chromosomes are attached to the 
mitotic spindle, assuring the fidelity of chromosome segregation in mitosis (131).   
Mad2 is involved both in the SAC and in G2/M phase checkpoint although its role in the 
DNA damage response was only recently described and is still unclear (409). It is suggested 
that Mad2 is involved in the DNA damage response pathway leading to mitotic arrest and 
activation of apoptosis pathway (409, 410). The dual implication of Mad2 on both 
surveillance mechanisms, SAC and G2/M phase checkpoints can explain previous findings 
that showed that Mad2 overexpression conferred sensitivity to DNA-damaging agents, 
especially cisplatin, associated with induction of cell cycle arrest (300).  
The opposite effect can also be used as a therapeutic strategy. Mad2 knockdown leads to 
an early mitosis exit, increased level of severe segregation errors and extensive cell death 
(221, 347, 411). This process is designated by mitotic catastrophe and although a small 
minority of daughter cells could survive, they are condemned to death due to the absence 
of genes coding for essential proteins (412).On the other hand, since Mad2 is a mitotic 
protein, it’s gene silencing will mainly affect cells with increased cell division, one of the 
hallmarks of tumor cells (413). The selectivity and the severe impact of Mad2 silencing on 
cancer cells, makes this approach a very attractive alternative therapy.  
Mad2 silencing is a compelling method that can be achieved by RNA interference (RNAi)-
based therapeutics with small interfering RNAs (siRNAs). RNAi has the potential to become 
a powerful therapeutic approach in many illnesses such as cancer since it allows to 
sequence-specifically target genes involved in the mechanism of proliferation, apoptosis 
evasion, drug resistance, and metastasis (414). The major challenge in RNA-based 
therapeutics in vivo is to ensure siRNAs tumoral delivery (415). Unprotected siRNA present 
a short half-life due to serum nuclease degradation and renal clearance, and are not easily 
taken by the cells (415). These difficulties could be overcome by carefully choosing a 
suitable delivery vector with some particular characteristics such as biocompatible, 
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biodegradable and non-immunogenic (416). Chitosan (CS) is a nonviral vectors extensively 
used for nucleic acid delivery in vitro and in vivo because of its mucosa permeation 
properties, high biocompatibility, low toxicity and biodegradability (377). This natural 
polysaccharide is composed of glucosamine and N-acetylglucosamine residues resulting 
from partial deacetylation of chitin (333). CS is available with different degree of 
deacetylation, molecular weight and depending on the pH, the deacetylated amine groups 
along the CS chain will be protonated and available to interact with the negatively charged 
siRNA (333). CS is capable of protecting siRNA, increasing its stability in the blood stream  
but also, the innumerous chemical modification that can be done to its structure, make it 
capable of enhancing cell specificity and transfection efficiency (417). The addition of 
different groups to CS backbone allows to functional moieties to be added, like cell-targeted 
ligands, making CS an efficient and versatile drug delivery platforms (418, 419). One 
common modification is the anchoring of poly(ethylene glycol) (PEG) chains to the 
nanoparticle surface which is used to improve the circulatory half-lives of therapeutics and 
higher tumor accumulation (420). This effect is associated to the enhanced permeability 
and retention (EPR) effect that describes the preferential accumulation of nanoparticles at 
tumor sites due to leaky vasculature (420)    
In our previous in vitro study, we successfully developed an epidermal growth factor 
receptor (EGFR)-targeted chitosan system capable of silencing Mad2 gene and inducing 
cell death in EGFR overexpressing human A549 cell line (347). Here, we have investigated 
the effects of siRNA targeting Mad2 (siMad2) alone or in combination with cisplatin at sub-
therapeutic dosage. This study was performed in mice bearing subcutaneous, cisplatin 
sensitive or resistant, human lung adenocarcinoma xenograft tumors, with the aim of 
examining its efficacy in the inhibition of tumor growth.   
2. EXPERIMENTAL SECTION 
2.1 Materials 
The following products were purchased from Sigma-Aldrich Inc. (St. Louis, MO): ALT 
Activity Assay Kit (CAT. MAK052); AST Activity Assay Kit (CAT. MAK055); Blood Urea 
Nitrogen Assay Kit (CAT. MAK006); Creatinine Assay Kit (CAT. MAK080); CS (MW = 
55kDa; degree of deacetylation of 75-85%); cisplatin (CAT. P4394). A pool of 3 sequences 
of siRNA duplexes targeted against Mad2 mRNA (CAT. sc-35837) and a non-targeting 
negative control duplexes (CAT. sc-37007) were purchased from Santa Cruz Biotechnology 
Inc. (Dallas, TX). All primers were customized and ordered from Eurofins Scientific 
(Luxembourg City, Luxembourg). EGFR-specific peptide was synthesized at Tufts 
University’s Peptide Synthesis Core Facility (Boston, MA). Succinimidyl-([N-
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maleimidopropionamido]-ethyleneglycol) ester (MAL-PEG2000-NHS, MW 2,000 Da) was 
purchased from JenKem (Allen, TX). All cell culture material was purchased from 
Invitrogen/Life Technologies (Carlsbad, CA). The BMP LeukoChek Test Kit to count white 
blood cells (WBC) and platelets was acquired from Biomedical Polymers, Inc. (Gardner, 
MA). 
2.2 Cell Lines 
A549 human lung adenocarcinoma cells were obtained from American Type Culture 
Collections (Manassas, VA). A cisplatin-resistant version of this cell line (A549-DDP) was 
obtained from Massachusetts General Hospital (Boston, MA). Both cell lines were cultured 
in DMEM/F12 medium from Life Technologies (Carlsbad, CA) supplemented with 10% FBS 
and penicillin/streptomycin (100 U/mL) (Thermo Fisher Scientific, Waltham, MA, USA) and 
grown at 37°C, 5% CO2. A549-DDP cells were cultured with 2 μg/mL (6.7 μM) cisplatin to 
maintain their drug-resistant phenotype. The resistant phenotype of these cells was 
regularly assessed by cytotoxicity analysis to ensure their IC50 (dose that kills 50% of cells) 
values. 
2.3 Synthesis and characterization of pegylated chitosan and epidermal growth 
factor receptor-targeted chitosan derivatives 
PEGylated CS and EGFR-targeted CS derivatives were synthesized according to our 
previously optimized and established protocol reported elsewhere (347, 418). Briefly, to 
obtain both CS derivatives, a 10% molar equivalent of Mal-PEG2000-NHS was added to a 
2mg/mL CS solution in 2% acetic acid and left to react overnight at room temperature. In 
order to purify the conjugate, dialysis was performed in water with a molecular weight cutoff 
of 10 kDa. At this step, to obtain the PEGylated CS, cysteine was added in excess under 
N2 environment to inactivate the maleimide group. The synthesis of EGFR-targeted CS 
derivative was achieved by using a 17-amino acid peptide consisting of 12-amino acid 
EGFR recognition peptide, four glycine residues spacer and a terminal cysteine for 
conjugation via the thiol group (i.e., YHWYGYTPQWVI-GGGG-C). The EGFR-peptide was 
added in a 2-fold molar excess to the PEGylated CS derivative. After reacting overnight at 
4°C in nitrogen atmosphere, cysteine was added in excess. Both derivatives were purified 
by dialysis (molecular weight cutoff - 10 kDa) against water, freeze-dried and stored at -20 
°C. Proton nuclear magnetic resonance (1H-NMR) spectroscopy was employed to 
characterize both derivatives. All NMR samples were prepared by dissolving 2-4 mg of the 
lyophilized product in 0.7 mL of D2O with 0.2% DCl and characterized by 400 MHz 1H NMR 
spectroscopy (Varian, Inc. CA). 
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2.4 Nanoparticle formulation and characterization 
CS nanoparticles encapsulating siRNA were prepared by self-assembly in aqueous solution 
maintaining a N/P ratio (ratio of CS bearing cationic amines to siRNA bearing anionic 
phosphates) of 50. A pool of 3 sequences of siRNA duplexes targeted against the Mad2 
mRNA was used for best knockdown efficiency. This process conditions have been 
developed and optimized in our lab (347, 418). Succinctly, in the interested of getting the 
non-targeted (NTG) nanoparticles, the PEGylated CS is the only CS to be added and after 
dissolving it in water (1 mg/mL), siMad2 was slowly added to this solution under magnetic 
stirring and incubated for 30 min at room temperature. In order to obtain targeted (TG) 
nanoparticles, the initial mixture would be a 50 % (w/w) mixture of PEGylated CS and 
EGFR-targeted CS (1 mg/mL). This procedure allowed CS and siMad2 complexation and 
nanoparticles self-assembly prior to use. As done in the previous in vitro study, the average 
hydrodynamic diameter and the polydispersity index (PDI) of the nanoparticles were 
measured by dynamic light scattering at room temperature and a 90° fixed angle using 
Zetasizer ZS (Malvern, Worcestershire, UK) (347). Similarly, the zeta potential of the 
nanoparticles was measured using an electrophoretic cell. For every study, nanoparticles 
were freshly prepared and dissolved in PBS in order to obtain a desired concentration and 
also achieve an osmolarity of 300 mOsm/kg and a pH of 7.2. 
2.5 In vitro cytotoxicity studies for cisplatin in combination with siRNA therapy 
To measure the cytotoxicity of cisplatin together with siMad2-loaded CS nanoparticles, 
A549 WT and A549-DDP cells were cultured overnight at a cell density of 3000 cells/well in 
a 96-well plate in 200 µl of supplemented culture media. Then, the cells were washed, and 
100 μL of the nanoparticle solution was added to each well (n= 8), incubated at 37°C for 6 
h, and followed by replacement of the solution with complete growth medium. After a 48h 
period, incubation time necessary to produce a satisfactory Mad2 knockdown (ref), growth 
media was replaced with serum-supplemented media containing 0.01 μM-10 000 μM 
cisplatin as free drug. Cell toxicity was assessed 24h later by the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. For that, medium was 
replaced with fresh complete medium containing 100 μL of 0.5 mg/mL MTT (Sigma-Aldrich, 
St. Louis, MO) for two hours Then, medium was replaced by dimethyl sulfoxide (DMSO) to 
stop the reaction and lyse the cells. Absorbance of the solution was measured at 560 nm, 
and the IC50 was calculated using GraphPad Prism software. Untreated cells served as a 
negative control and cells incubated with poly(ethyleneimine) (PEI, MW 10kDa), a known 
cytotoxic cationic polymer, were used as positive control for all cytotoxicity experiments. 
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2.6. Human Lung Adenocarcinoma Xenograft Tumors 
Animal procedures were performed according to a protocol approved by Northeastern 
University, Institutional Animal Care and Use Committee (NUIACUC). Five to six weeks old 
female nu/nu (athymic) mice, strain CrTac:NCr-Foxn1nu, weighing approximately 20 g, 
were purchased from Taconic Biosciences, Inc. (Hudson, NY). The animals were allowed 
to acclimate for at least 72 h prior to any experimentation, raised under specific pathogen-
free conditions, kept in individually ventilated cage racks and supplied with sterile rodent 
pellets and water ad libitum. Mice were housed under a 12 h light/dark cycle. 
 For A549-WT and A549-DDP tumor model development, mice were injected 
subcutaneously under mild anesthesia on the right flank, with 3x106 cells in a mixture of 50 
µL DMEM/F12 medium and 50 µL Matrigel. Tumor volume was calculated by the modified 
ellipsoid formula: tumor volume = 1/2(length × width2). When tumors grew to approximately 
200 ± 20 mm3 in volume the animals were randomized into groups to yield even distribution 
of tumor sizes. Sample size was determined by power analysis using the software 
G*Power. Each animal was identified with an ear tag which allowed us to perform blind 
experiments in order to reduce bias in animal selection and outcome assessment. The 
animals were daily monitored for food/water intake, body weight and any physical signs of 
discomfort.  
2.7 In vivo mad2 gene knockdown in A549 WT and A549-DDP tumor model 
Animals with 200 ± 20 mm3 tumors, A549-WT or A549-DDP, were randomized into groups 
(n = 5) and intravenously injected into the lateral tail veins with one of the treatments (PBS, 
NTG with a scramble sequence siRNA (SCR), TG with SCR, NTG with siMad2 and TG with 
siMad2). At time zero, and based on our recent biodistribution data, mice were given a 
single dose of 3 mg/kg of encapsulated siRNA (either Mad2 siRNA or SCR) and at 24, 48, 
72 and 96 h the animals were euthanized and the tumors excised and Mad2 expression 
evaluated on them. 
Tumors were divided in two sections, one for RNA extraction and another for protein 
extraction. Concerning RNA extraction, tumors were homogenized in RNALater solution in 
order to preserve RNA integrity. Tissue total RNA was extracted using GeneJET RNA 
Purification Kit from Thermo Fisher Scientific (Waltham, MA) and later 0.5 μg of total RNA 
from each sample was used for cDNA synthesis with Verso cDNA synthesis kit (Thermo 
Fisher Scientific, Waltham, MA) according to the manufacturer’s instructions. Finally, Mad2 
siRNA was then quantified by quantitative qPCR with the LightCycler 480 SYBR Green I 
Master kit (Roche, Basel, Switzerland) and primers for 28S ribosomal gene as endogenous 
control in analysis of gene transcription. The sequences of the primers used in this work 
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were as follows: Mad2 forward (GTGGAACAACTGAAAGATTGGT), Mad2 reverse 
(GTCACACTCAATATCAAACTGC), 28S forward (GGGTTTAGACCGTCGTGAGA), 28S 
reverse (TCCTCAGCCAAGCACATACA). All the kits were used accordingly to the 
manufacturer’s instructions. Mad2 gene expression levels were normalized against 28S 
ribosomal expression levels which has shown to have a stable expression throughout the 
tissues. The comparative method for mRNA level quantification was calculated according 
to the following formulas:  
∆   (       ) =   (                      ) −   (                         ) 
∆   (       ) =   (                      ) −   (                         ) 
∆∆   = ∆  (       ) − ∆  (       ) 
Normalized target gene expression level = 2( ∆∆  ) where Ct is the threshold cycle. 
Concerning Western blot analysis, tumors were homogenized in lysis buffer for protein 
extraction. The BCA Protein Assay Kit was utilized to measure the protein concentration. 
Protein were separated on 4-20% gradient SDS-PAGE gels and transferred onto a PVDF 
membrane. The membrane was blocked incubating it for 2 h on blocking buffer (Abcam). 
For antibody staining, the membrane was incubated with primary antibody overnight at 4˚ 
C, washed with TBST and later incubated with HRP secondary antibody for 2 h. The bands 
were visualized after incubation with chemiluminescence detection reagent (Pierce) as 
described in the manufacturer’s instructions. The primary antibodies used were the rabbit 
anti-Mad2 (1:500; Abcam, #ab180579) and the mouse anti-tubulin (1:5000; Abcam, 
#ab80779); the secondary were goat anti-rabbit HRP (horseradish peroxidase) secondary 
antibody (1:5000; SantaCruz, #SC-2054) and goat anti-mouse HRP secondary antibody 
(1:5000; SantaCruz, #SC-2005). Tubulin was used as a protein loading control. 
2.8 In vivo efficacy studies for the combination treatment of Mad2 siRNA/chitosan 
conjugates and cisplatin solution 
Animals bearing A549 WT or A549-DDP tumors with a volume close to 200 ± 20 mm3 were 
randomized into 8 groups (n=8). At day 1, siMad2 (3mg/kg) in NTG or TG nanoparticles 
was administered intravenously via tail vein and 48h later, day 3, cisplatin (1 mg/kg) in 
solution was administered (Figure 34A). This 5-day dosage regimen was repeated for 30 
days. As a negative control, one group was administer with saline solution (Figure 34B). A 
group of animals was only injected with cisplatin (1 mg/kg) and another 2 set of groups were 
given NTG or TG nanoparticles with SCR. Tumor volume was measured daily for the first 
week and every 2 days for the rest of the study. At day 30, animals were sacrificed by 
isoflurane inhalation followed by cervical dislocation. Blood was collected from all groups in 
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order to assess several safety parameters. Liver, kidney, and spleen samples from mice 
were also collected for histopathological analysis. 
2.9 Measuring Body Weight Changes, Liver and Kidney Enzyme Levels 
Quantification, White Blood Cells Count and Platelets 
Mice of different experimental groups were weighed daily till the end of the first week and 
every two days until the end of the experiment. The body weight change was calculated 
and recorded as mean ± standard deviation (SD). Blood was collected in EDTA coated K2 
tubes (Greiner Bio-one, Monroe, NC) from all groups at the end of the study and different 
parameters were measured. Alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels were assessed as indicator of liver damage and serum 
creatinine and blood urea nitrogen as indicators of kidney function. WBC and platelets were 
also counted. All these parameters were measured using the kits mentioned in the materials 
section and used accordingly to the manufacturer’s instructions.  
2.10 Histopathological Analysis 
Liver, kidney, spleen and tumor samples from mice were collected for histopathological 
analysis at the end of the efficacy study. The tissue samples were processed for histological 
sectioning, H&E staining, and analysis at the Veterinary Clinical Laboratory INNO (Braga, 
Portugal). 
2.11 Statistical analysis 
Comparisons between two groups were made using Student’s T-test and with more than 
two groups, the ANOVA test was used. A value of p < 0.05 was considered to be statistically 
significant. Data is presented as means ± standard deviation. 
3. RESULTS AND DISCUSSION 
Improvements in siRNA delivery methods must be made before RNAi can reach its 
maximum therapeutic potential. It is required the development of drug delivery systems that 
are clinically safe, efficient in encapsulating therapeutic siRNAs and can selectively deliver 
them(421). 
3.1 Characterization of chitosan- siRNA nanoparticles 
As previously described, siMad2-loaded NTG and TG nanoparticles were obtained by self-
assembly and their key characteristics are shown on Table 8 (347). The mean particle 
diameters of different nanoparticles ranged between 100-230 nm which are suitable sizes 
for IV administration. Zeta potential were in the range of +28 to +35 and high encapsulation 
efficiencies were obtained for both systems. Earlier, we have extensively studied these 
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particles and validated that the EGFR-targeted CS nanoparticles out-perform the NTG 
nanoparticles by preferred receptor-mediated endocytosis (347). Also, we were able to 
induce apoptotic cell death by depleting Mad2 expression in non-small cell lung cancer cell 
line, A549. 
Table 8: CS nanoparticles characterization (particle size, zeta-potential, and siMad2 
encapsulation efficiency) of CS/siRNA nanoparticles at a N/P ratio of 50/1. 
 
Particle Size 
(nm) ±SD 
Zeta potential 
 (mV) ±SD 
siMad2 Encapsulation 
Efficiency (%) 
NTG 106.8 ± 2.1 +35.6 ± 3.5 105.1 ± 4 
TG 227.3 ± 1.8 +28.3 ± 2.0 99.5 ± 2.4 
 
3.2 Mad2 knockdown potentiates cisplatin effects and sensitizes Cisplatin-Resistant 
Lung Cancer Cells in vitro 
Cancer drugs that includes platinum-based compounds such as cisplatin act against cancer 
cell proliferation by damaging their DNA. As a consequence of this DNA damage, DNA 
replication is prevented before cell division, which usually induces apoptosis. However, 
cancer cells can escape apoptosis through translesion synthesis (TLS), a type of DNA 
replication that is highly prone to errors and, thus, favors drug resistance and tumor 
aggressiveness (422, 423). DNA damage in mitosis activates the spindle assembly 
checkpoint (SAC) which causes cell death after a sustained mitotic arrest (424). However, 
because most cancer cells exhibit a weakly functional SAC, they escape mitosis and 
survive. Complete abrogation of SAC leads to premature cell division with massive 
chromosome segregation errors that are incompatible with life. We thus reasoned that the 
suppression of the SAC component Mad2 by specific siRNA-loaded nanoparticles would 
kill cancer cells that escape cisplatin effect and, consequently, sensitize cancer cells to 
chemotherapy. 
Based on our previous works, we prepared and conducted nanoparticles-mediated gene 
silencing in vitro. Accordingly, down-regulation of Mad2 expression by siMad2-loaded NTG 
and TG CS nanoparticles was efficiently achieved in A549-WT and A549-DDP, with no 
silencing effect in untreated or blank nanoparticles-treated controls, and with TG 
nanoparticles leading to a stronger depletion (Figure 32) (347).  
Before carrying out the Mad2 depletion and cisplatin combination experiments, we first 
assessed the resistance levels of cisplatin in sensitive A549-WT and resistant A549-DDP 
cell lines. The 50% inhibitory concentration (IC50) of cisplatin was more than tenfold higher 
in A549-DDP (IC50=140.73 μM) than in A549-WT (IC50=12.24 μM), confirming the drug-
resistant phenotype of A549-DDP cells (Table 9).  
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Figure 32: In vitro Mad2 expression in the A549 WT and A549 DDP cell line. (A) Mad2 expression comparison 
between the two cell lines. The results are represented as a normalization towards A549 WT expression for an 
easier analysis of the expression differences. (B and C) In vitro down-regulation of Mad2 gene expression by 
siMad2-loaded NTG and TG CS nanoparticles in A549 WT and A549 DDP cell lines. A concentration of 50 nM 
of Mad2 siRNA and a N/P ratio of 50/1 was used in all the cases. Data are shown as mean ± SD (n = 3); *P < 
0.05; **P < 0.01; ***P < 0.001. 
Table 9: IC50 values of free cisplatin treatment, 48h post-transfection with siMad2 
encapsulated in TG or NTG nanoparticles in A549-WT (A) and A549-DDP (B) cells. 
  
Cisplatin IC50  
(± SD) 
Fold change 
A
5
4
9
-W
T
 
DDP 12.24 ± 1.09 — 
Lipofectamine (siMad2 50 nM) 0.306 ± 0.008 40x less 
NTG (siMad2 50 nM) 0.999 ± 0.015 12x less 
TG (siMad2 50 nM) 0.132 ± 0.012 95x less 
A
5
4
9
-D
D
P
 
DDP 142.204 ± 2.156 — 
Lipofectamine (siMad2 5nM) 0.325 ± 0.017 437x less 
NTG (siMad2 1 nM) 0.178 ± 0.021 799x less 
TG (siMad2 1 nM) 0.094 ± 0.023 1513x less 
NTG (siMad2 5 nM) 0.086 ± 0.033 1653x less 
TG (siMad2 5 nM) 0.057 ± 0.031 2495x less 
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For the combination study, cells were incubated for 48h with siMad2-loaded CS 
nanoparticles containing 50 nM siRNA and later 24h with cisplatin at increasing 
concentrations to determining cisplatin IC50. Combination of Mad2 depletion and cisplatin 
treatment leads to a dramatic increase in cytotoxicity in both cell lines, compared to 
individual treatments, with an even stronger effect in the cisplatin-resistant line. Indeed, a 
significant decrease in cisplatin IC50, up to 95-fold in the sensitive cell line and to 2495-fold 
in the resistant cell line, was observed when combined with TG Mad2-siRNA-loaded 
nanoparticles (Table 9). Of note, in the resistant cell line, a strong reduction in cisplatin IC50 
(up to 1513-fold) was still achieved even with reduced amount (50-fold lesser) of Mad2 
siRNA. Interestingly, gene expression analysis by qPCR revealed that Mad2 mRNA levels 
was three times less abundant in A549-DDP compared to A549-WT (Figure 32), which may 
explain why in the resistant line much less siRNA is required to achieve efficient Mad2 
depletion, thereby reducing the toxicity potential associated with high dosage. 
Overall, these results suggest that siRNA-mediated Mad2 downregulation enhances the 
sensitivity of lung cancer cells to cisplatin with a high level of reversal of drug resistance. 
The improvement observed in the in vitro cytotoxicity profile of TG nanoparticles compared 
to the NTG nanoparticles seems mainly due to the EGFR peptide modification triggering 
receptor-mediated endocytosis and this phenomenon has been extensively study in our 
previous work (347). 
Cisplatin, as a crosslinking agent, binds to DNA to form intrastrand and interstrand 
crosslinks and adducts which originates changes in DNA conformation and interferes with 
DNA replication (422, 423). This culminates in G2/M cell cycle arrest that can lead to DNA 
repair, promoting resistance to the drug, or resulting in apoptosis (423). If cells are able to 
escape G2/M arrest and progress to the mitotic phase, since Mad2 is absent, cell will failure 
to arrest and an aberrant chromosome segregation will take place, triggering cell death 
(221, 407). Due to these mechanisms, the combination of CS nanoparticle containing 
siMad2 with cisplatin treatment was found to be more effective when compared with 
cisplatin alone treatment. 
3.3 Mad2 gene silencing in tumor bearing mice  
Using xenograft model of cisplatin-sensitive A549-WT and cisplatin-resistant A549-DDP 
lung cancer, we examined whether nanoparticles formulations were able to silence Mad2 
in tumors. Mad2 silencing was analyzed both at mRNA and protein levels in tumor 
extracts harvested from the mice at the designated time points. As shown in figure 1A, Mad2 
mRNA levels decreased to 20% control levels (i.e. 48h post-treatment in both sensitive and 
resistant tumor models), being TG nanoparticles more efficient in gene silencing than NTG 
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nanoparticles. A similar decrease response was also achieved at protein levels, with a drop 
to 35% Mad2 protein levels relative to the control on A549-WT and 22% on A549-DDP 
(Figure 33). Interestingly, this Mad2 silencing effect upon a single dose of nanoparticles 
was still noticeable at 96h post-treatment, further demonstrating the effectiveness of the 
nanoparticles in inhibiting Mad2 expression in tumors. 
3.4 In vivo efficacy assessment of siMad2/cisplatin combination treatment  
The aim of this study was to determine whether Mad2-siRNA nanoparticles formulations 
would result in increased sensitivity and even reversal of resistance to cisplatin which would 
enhances antitumor activity effects. As could be depicted from Figure 34, this strategy 
resulted in a clear and enhanced antitumor activity. None of the controls had a significant 
effect on tumor growth (Figure 34). Either sensitive or resistant tumors treated with Mad2-
siRNA nanoparticles displayed delayed tumor growth which was more accentuated with TG 
(A549-WT: 45 %; A549-DDP: 51.2 %) than with NTG nanoparticles (A549-WT: 26.2 %; 
A549-DDP: 43 %).  
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Figure 33: Knockdown efficiency of siRNA targeting Mad2 in NSCLC tumor bearing mice. (A) qPCR and (B) 
western blot analysis of Mad2 knockdown efficiency in A549 WT and A549 DDP tumors. A 3 mg/kg single dose 
of siRNA, encapsulated either in TG or NTG NPS, was administered to tumor bearing mice. Tumors were 
collected at different time points for evaluation of the Mad2 gene silencing. (n = 5 animals/group). On qPCR 
data, bars represent the mean ± standard deviation from three independent experiments. *** = p< 0.01. Referring 
to the western data, tubulin protein was used as an internal control. Data represents one of the three 
independent experiments with similar results.  
In contrast, and as expected, cisplatin treatment was more effective in sensitive than in 
resistant tumors. TG siRNA nanoparticles, and to a lesser extent NTG siRNA nanoparticles, 
plus cisplatin resulted in the greatest efficacy in both lung tumor models (NTG (siM2) + 
DDP: 58.9 %; TG (siM2) + DDP: 70.6 %). These results strongly suggests that the 
combinational effects of Mad2-siRNA-loaded nanoparticles and an anticancer drug such as 
cisplatin can be a valuable therapeutic strategy to increase drug sensitivity and overcome 
resistance. 
3.5 In vivo safety profiles 
During this study, to monitor the safety of the formulations, the body weight of each group 
was monitored every two days and the percentage weight change is presented (Figure 
34A). Initially all the groups went through a slight decrease in body weight which is quite 
common due to handling stress but the animals quickly recovered the initial weight.  
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Figure 34: Effect of the combination of cisplatin treatment and Mad2 silencing on growth of sensitive and 
resistant A549 tumor bearing mice. (A) The following dosage regimen was used in order to evaluate the in vivo 
tumor inhibitory effect of the combination therapy. (B) Experimental treatment groups. (C) Tumor volume 
variations for the different treatments intravenously injected in A549 WT (left) and A549 DDP (right) tumor 
bearing mice. (D) A549 WT and A549 DDP xenograft tumors representative of the samples from each treatment 
group. (B) Tumor growth inhibition rates for each treatment group in both tumor models. n = 8 mice. ** p<0.01, 
*** p<0.001 (t-test comparing to PBS treatment). PBS: Phosphate Buffered Saline; NTG: Non-Targeted; TG: 
Targeted; DDP: Cisplatin; SCR: Scramble Sequence siRNA, siM2: small interfering RNA Mad2. 
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Figure 35: Safety profile. (A) Body weight variations mice from different treatment of A549 WT and A549 DDP 
tumor bearing mice. (B) Histograms that show the levels of several safety parameters in the different treatment 
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groups. The parameters tested were: the concentrations of the enzymes aspartate transaminase (AST) and 
alanine transaminase (ALT) that are reasonably sensitive indicators of liver damage; the number of white blood 
cells (WBC); the number of platelets; serum creatinine and blood urea nitrogen as indicators of kidney function. 
In addition to the body weight, some serum safety markers were analyzed in order to 
evaluate the nanoparticles safety. As indicators of liver damage we measured the 
concentrations of the enzymes AST and ALT; serum creatinine and blood urea nitrogen 
were measured as indicators of kidney function; and the number of WBC number of platelets 
were also quantified. During the study period, there was no elevation in liver enzymes levels 
observed (Figure 35B). For both tumor models, AST and ALT levels on the treatment groups 
showed no significant differences from the control group (PBS-treated mice), indicating a 
lack of damage to the liver. Similar results were also obtained for the kidney function 
indicators. Serum creatinine and blood urea nitrogen were unchanged when compared to 
control group demonstrating kidney function did not seemed to be affected. Elevated WBC 
counts is often associated with tissue damage and a decrease in platelet counts are 
indicative of chemotherapy toxicity. WBC and platelets number were found to be consistent 
between the different experimental groups. 
On end of the study, the liver, kidney and spleen of mice from each group, from both tumor 
models were collected and tissue sections were used for hematoxylin and eosin staining 
(Figure 36). For all the groups on both tumor models, the tissues did not show any 
pathological changes in the histology analysis which is in agreement with the serum safety 
markers previously analyzed. We were not expecting toxicity from cisplatin since the dose 
was very low compared to the clinical dose. 
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Figure 36: Histological sections after H&E staining of liver, kidney, and spleen from mice from different treatment 
of (A) A549 WT and (B) A549 DDP tumor bearing mice. Scale bar = 100 μm. 
CONCLUSIONS 
In summary, EGFR-targeted chitosan nanoparticles were employed as a new delivery 
carrier for Mad2 siRNA in combination with cisplatin to achieve maximal therapeutic efficacy 
by overcoming chemo-drug resistance in NCSLC. Both siRNA and cisplatin were used at 
low but effective doses minimizing adverse side effects. In this study, we evaluated two 
formulations that differ on the presence of a target moiety. The targeted delivery showed 
effective and improved tumor growth inhibition when compared to non-targeted and this 
effect was even more pronounced when used in combination with cisplatin. Also, Mad2 
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siRNA results in mitotic failure and extensive cell death but the advantage of such strategy 
is that it preferentially affects mitotic cells, so highly proliferative tumors will be the most 
affected. Collectively, our study validates an effective EGFR-targeted chitosan carrier for 
siRNA, together with a promising therapeutic target, Mad2 and also shows that siRNA can 
be an effective strategy in cancer therapy by itself or in combination with anticancer drugs 
to increase the therapeutic potential of these drugs. 
We have previously reported the development of EGFR targeting CS-based nanoparticles 
for the delivery of Mad2 siRNA (347). Down-regulation of Mad2 expression by siMad2-
loaded NTG and TG CS nanoparticles was observed in A549-WT and A549-DDP, with 
blank nanoparticles showing no toxicity (Figure 32). Similar to our previous reports, TG 
nanoparticles lead to a stronger depletion attesting the advantage of the targeting strategy 
(347).  
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1. INTRODUCTION 
Cancer as a disease shows tremendous ability to adapt to the environment, evolve 
aggressively and metastasize to distant sites, making it a disease replete of complexity and 
heterogeneity (431). First-line therapies often fail, leading to the recurrence of drug resistant 
forms of the disease that are often unresponsive to conventional therapeutic approaches, 
thereby demanding a more ingenious and novel approach. Besides physical and molecular 
factors, complex cellular and extracellular matrix of the tumor microenvironment gravely 
impedes drug penetration to the cancer cells, affecting their activity. The abnormalities 
underlying the processes of oncogenesis, cell survival, apoptosis escape, metastasis and 
drug resistance are almost always multifactorial and rely on redundant mechanisms (432). 
Cancer therapy therefore has become a major challenge in modern medicine and 
development of novel therapeutic approaches to overcome these challenges is urgently 
required. An effective method to fight cancer resistance and improve treatment efficacy will 
be to inhibit multiple targets in a combination therapy regime. When compared to a single-
agent therapy, this strategy will allow the chemotherapeutic drugs to be used in smaller 
doses, decrease their cytotoxic side effects and improve their therapeutic response (433). 
To this end, material science and nanoparticle based drug delivery approach has 
revolutionized the outlook and changed the whole paradigm of cancer therapeutics (433). 
Our improved understanding of materials property and ability to tailor them in order to impart 
them with desired chemical and physical characteristics has become a cornerstone for drug 
delivery.  
The conventional nanoparticle based delivery approach has heavily relied on the properties 
of the host therapeutic molecules to choose the appropriate material to serve as the carrier 
system. The paradigm however severely limit the options available for vectors selection, 
and therefore, while there is a plethora of literature on application of polymeric, lipid and 
inorganic carriers for delivery of therapeutic molecules, more recent advances have focused 
on tailoring the properties of existing materials for such application. Combinatorial design, 
a concept classically and widely used in drug discovery, has been imported in to material 
design where the backbone of a material could be chemically modified to develop a library 
of novel derivatives that can be tailored to achieve the desired final delivery vector. The 
seminal contributions from Langer’s lab introduced this concept to drug delivery and has 
been actively researched since to develop smart materials for cancer imaging, diagnostics 
and therapeutics (304, 314, 434). This approach is particularly powerful since it allows the 
use of simple chemistries and minimal use of organic solvent to generate new, 
biocompatible and biodegradable blocks with desired properties to develop delivery 
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systems capable of carrying combinations of therapeutic payloads such as the most 
conventional chemotherapeutic and molecular anti-cancer agents (e.g. DNA, siRNA and 
miRNA) (304, 314, 434). Each blocks in the delivery system confers a specific advantage 
such as improved circulation time, targeting mechanisms, enhance accumulation at the 
tumor site or versatility of payload (433, 435-437). 
Among the various classes of polymers, polysaccharides stand out as an interesting choice 
of materials since they are natural polymers with high biocompatibility and biodegradability, 
low immunogenicity, widespread availability and low cost. CS, α(1-4)2-amino-2-deoxy-β-D 
glucan, has additional advantages such as pH sensitivity, mucoadhesiveness, relatively 
longer blood circulation times, successful evasion of reticuloendothelial system (RES) as 
well as a high positive charge density(278, 363, 438). Negatively charged nucleotides can 
therefore easily establish electrostatic interaction with positively charged CS and 
spontaneously form nano-size complexes (polyplexes). This feature has made chitosan a 
very attractive and safe alternative. As a gene delivery carrier, it can be controlled based 
on its properties such as degree of deacetylation, molecular weight, ionic strength of the 
solution and pH(268). Not surprisingly, CS has been widely used as nucleic acid carrier but 
it is less amenable for delivery of small chemotherapeutic agents. However, abundance of 
primary amine and hydroxyl groups on the CS backbone makes it an ideal candidate for 
developing combinatorially-designed library of derivatives through specific chemical 
modifications. There have been sporadic attempts to use CS as carrier of small molecules 
but a systematic approach for such delivery application is lacking (439-442).  
In previous studies, CS modified with PEG and EGFR have proven to be an efficient delivery 
system for siRNA into lung cancer cells. In the present manuscript, we have developed a 
lipid chain derivative of CS as the third functional block that allows self-assembly of polymer 
to encapsulate hydrophobic small molecules (Figure 37). Different hydrophobic platinum 
derivatives, starting from cisplatin, have been used as a model system to develop a library 
of cytotoxic drugs that were mixed and matched and the resultant nanoparticles were 
investigated for their size, charge, drug encapsulating capability and subsequent cytotoxic 
effect on drug sensitive A549 and platinum resistant A549-DDP lung adenocarcinoma cells. 
Molecular characterizations of the cells reveal that the combinatorial-designed 
nanoparticles show efficient cell death by inducing apoptotic pathway. This body of work 
cements that application of a combinatorial approach to nanoparticle design can aid in 
developing a customizable small molecule delivery platform using CS, which is otherwise 
popularly used for nucleic acid therapeutics. 
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Figure 37: Schematic diagram 
2. EXPERIMENTAL SECTION 
2.1 Materials 
CS was purchased from Sigma-Aldrich Inc. (St. Louis, MO), with average molecular weight 
of 50 kDa, and the degree of deacetylation between 75 and 85 %. Cis-Pt(NH3)2Cl2 (cisplatin 
or DDP) was purchased from Sigma-Aldrich Inc. (St. Louis, MO). 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC), n-hydroxysuccinimide (NHS), 
succinimidyl-([N-maleimidopropionamido] ethylene glycol) ester (NHS-PEG2000-MAL), 
butanoic anhydride, hexanoic anhydride, octanoic anhydride, decanoic anhydride, 
tetradecanoic anhydride, octadecanoic anhydride, butanoic acid, hexanoic acid, octanoic 
acid and decanoic acid were purchased from Thermo Fisher Scientific (Waltham, MA). The 
EGFR-binding peptide used in this study was custom synthesized at peptide synthesis core 
facility of Tufts University (Boston, MA). This peptide (YHWYGYTPQWVI-), was originally 
synthesized by Li and co-workers and has been proven to be most efficient in targeting the 
EGFR receptor among several tested (311). Chitosanase (Streptomyces) and lysozyme 
were purchased from Sigma Aldrich (St. Louis, MO). 1H, 13C and 195 Pt NMR 
measurements were performed on a 400 MHz 1H NMR spectroscopy (Varian, Inc. CA).  
2.2 A549-WT and A549-DDP resistant NSCLC cell lines 
Human NSCLC cell line A549 was obtained from ATCC (Manassas, VA) and the 
corresponding platinum resistant cell line A549-DDP, was obtained from Massachusetts 
General Hospital, Boston, MA. Both cell lines were subcultured at 37°C in 5% CO2 
environment in DMEM/F12 medium from Life Technologies (Carlsbad, CA) supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin (100 U/mL) (Thermo Fisher 
Scientific, Waltham, MA). A549-DDP were cultured in medium supplemented with cisplatin 
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at a final concentration of 2 μg/mL, to maintain drug resistance. Three days before any 
experiment, A549-DDP media was changed to a media without cisplatin. 
2.3 Synthesis and characterization of CS derivatives 
CS was chemically modified with fatty acids by using a coupling agent, EDC, in the presence 
of NHS, to chemically conjugate the carboxylic group from the fatty acid to the CS free 
amine groups. Fatty acids with a general formula CH3(CH2)nCOOH were used to modified 
CS where n could be 2, 4, 6 and 8. Briefly, 0.62 µmol CS (MW: 50 kDa) was dissolved in 
0.1 M MES, 0.9% sodium chloride, pH 4.7, and 0.18 mmol of fatty acid in 10 mL ethanol, 
respectively. Then, both solution were mixed and an aqueous solution of EDC was added 
into the mixture with continuous stirring. The 1:1 mole ratio of EDC to fatty acid was used 
in all synthesis procedures. After 24 h of reaction, the reaction mixture was dialyzed for 
another 24 h (molecular weight cutoff = 30 kDa) against a 10% ethanol solution with 
frequent exchange of fresh ethanol solution to remove side products. Finally, the reaction 
mixture was dialyzed against deionized water for 6 h to remove any residual solvent and 
the dialyzed product was lyophilized until further use. NMR analysis was performed to 
estimate the degree of substitution of lipids on the CS backbone.. IR spectra of the resulted 
products were measured to attest the chemical interaction between CS and the fatty acid 
chain using FTIR spectrophotometer ABB MB3000 (ABB, Switzerland). 
CS-PEG derivative was independently synthesized as previously described (288). In 
summary, 15% molar equivalent of maleimide-poly (ethylene glycol)-N-hydroxysuccinimide 
(Mal-PEG2000-NHS) was added to a 2 mg/mL solution of CS in 2% acetic acid and left to 
react overnight at room temperature under continuous stirring. Next day, excess of cysteine 
was added to block the reactive maleimide group and the solution was dialyzed (molecular 
weight cutoff= 10 kDa) against 5% acetic acid solution for 24 h. Finally, the dialyzed product 
was lyophilized and the CS-PEG derivative was obtained in powder form. The degree of 
substitution of PEG on chitosan was estimated by NMR analysis.  
For synthesis of CS-PEG-EGFR peptide derivative, the CS-PEG-Mal derivative was reacted 
with EGFR-binding peptide to facilitate the conjugation of thiol group of terminal cysteine on 
the peptide with the maleimide group of PEG. A 2-molar excess of the EGFR-binding 
peptide was added to a 2mg/mL CS-PEG solution to saturate all the maleimide groups. The 
reaction was carried out at 4°C under nitrogen environment overnight. This peptide has 
been successfully used in our lab as a targeting moiety in vitro as well as in vivo (288, 314, 
443). Upon completion of the reaction, excess of cysteine was added to react with any 
unreacted maleimide group and the solution was dialyzed (molecular weight cutoff= 10 kDa) 
against 5% acetic acid solution for 24h, followed by freeze-drying and stored at -20°C until 
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further use. NMR analysis was performed to evaluate the degree of substitution on chitosan. 
All NMR samples of CS were prepared by dissolving 2-4 mg of the lyophilized product in 
0.7 mL of D2O with 0.2% DCl and characterized by 400 MHz 1H NMR spectroscopy (Varian, 
Inc. CA) 
2.4 Synthesis and characterization of lipid-modified platinum derivatives 
The synthesis of c,c,t-Pt(NH3)2Cl2(OH)2 was optimized from previous studies (444, 445). A 
mixture of cisplatin (6.67 mmol) and H2O2 (100.0 mmol) in 90 mL H2O was heated to 80°C 
for 5 h in the dark with vigorous stirring following which, it was allowed to cool down to room 
temperature. The final product was concentrated to 10 mL with rotary evaporator and 
allowed to precipitate at 4°C overnight. The product was collected by vacuum filtration and 
washed with ice-cold water, ethanol, diethyl ether and vacuum dried until a bright yellow 
powder was obtained. An average yield of 83% was obtained. 
Hydrophobic platinum (IV) derivatives have a general formula of c,c,t-
Pt(NH3)2Cl2(OOC(CH2)nCH3)2 and were obtained by covalently modifying c,c,t-
Pt(NH3)2Cl2(OH)2 with fatty acids anhydrides of varying carbon chain length (4, 6, 8, 10, 14 
and 18). DMF was used to dissolve c,c,t-[Pt(NH3)2Cl2(OH)2] (2 mmol) and the solution was 
heated to 70 °C while stirring. The fatty acid anhydride (8 mmol) was added to the mixture 
and let to react while stirring at room temperature for 48 h. The above solution was 
concentrated to a volume of 20 mL and then poured into water. The light yellow precipitate 
was collected by centrifugation and dissolved in acetonitrile. The solvent was evaporated 
by rotary evaporation and the solid was washed several times with diethyl ether and dried. 
An average yield of 74% was usually obtained. LCMS measurements were performed on 
an LCMS-IT-TOF (Shimadzu Corporation, Columbia, MD) with quadrupole ion trap (QIT) 
and electrospray ionization (ESI). The lipid derivatives of DDP samples at a concentration 
of ~100 ppm/mL were prepared in methanol prior to injection onto the LC system coupled 
to IT-TOF and 50:50 methanol-water was used as the mobile phase.  Nanoparticle 
tracking analysis was used to assess the self-assembled nanoparticle forming 
characteristics of the lipid modified DDP derivatives. The DDP derivatives were dispersed 
in water at a concentration of 10 mg/mL and were analyzed by NanoSight NS500 (Malvern 
Instruments, Westborough, MA). The samples were diluted to 30% by water during analysis. 
2.5 Formulation and characterization of control and targeted nanoparticles 
We assessed the ability of the CS derivatives (containing varying lipid content, PEG and 
EGFR) to form self-assembling nanosystems with hydrophobic platinum derivatives. In 
order to do so, the mass ratio between the platinum and the total amount of CS derivatives 
was kept as 1:3. The molar ratio between CS modified with fatty acids (CS-Cn), CS-PEG 
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and CS-EGFR was kept as 2:1:1. Before starting, all the derivatives were dissolved in a 
very small volume of DMF and finally, 20 times deionized water was added to allow self-
assembly of the nanoparticles and cisplatin derivatives. The solution was mixed with a 
vortex mixer for 5 min and probe ultrasonicated for 15 minutes using Vibra-Cell VC 505 
ultrasound instrument (Sonics and Materials, Inc., Newton). The nanoparticles were washed 
using Amicon ultracentrifugation filtration membranes with a molecular mass cutoff of 30 
kDa, allowing any free cisplatin to be removed. Using a ZetaSizer Nano ZS (Malvern 
Instruments, Worcestershire, UK), we were able to obtain information related to particle 
size, surface charge and polydispersity index (PDI). Each sample was analyzed in triplicate 
at 25°C and the result reported as mean ± standard deviation. 
The platinum content in the nanoparticles was measured using a high-performance liquid 
chromatography (HPLC) assay. Two independent methods were used for prodrug 
quantification; the indirect and the direct method and total calculated amount of drug was 
matched to theoretical amount by mass balance. In the indirect method the 
NANOPARTICLEs were centrifuged at 4000 rpm for 10 min and the free platinate were 
quantified in the supernatant by HPLC. In the direct method, CS went through an enzymatic 
digestion with chitosanase and lysozyme in order to disrupt the NANOPARTICLEs and 
release the prodrug. In order to do that, 100 µL of platinate loaded NANOPARTICLEs were 
incubated with 0.02 U chitosanase and 2 U lysozyme in 50 mM of NaAc-HOAc buffer (pH 
5.5) for 4 h at 37°C. The solution was then centrifuged and the supernatant was used for 
cisplatin detection by an RP-HPLC method. The samples were diluted in a solution of 1:1 
methanol/water containing 5% DMF prior to analysis. A Waters LC system (model 2487, 
Waters Corporation, Milford, MA) with a quaternary pump, an autosampler and a UV-
detector was utilized on the analysis. A reverse phase C18 column (4.6 mm x 15 mm, 5mm, 
Hypersil Gold, US) with a C18 pre-column (4 mm x 20 mm, 5mm, Phenomenex, US) was 
used with a mobile phase consisting of 1:1 methanol/water at a flow rate of 0.5 mL/min and 
sample injection volume was 20 µL. A standard curve of each platinum derivative was 
generated with a linear range of detection between 10-250 µg/µl and the elution was 
monitored at 260 nm. Blank CS NANOPARTICLEs were also subjected to the same 
treatment and used as control. Encapsulation efficiency was calculated using the formula: 
Encapsulation efficiency (EE %) = (Wt-Wf)/Wt ×100 where Wt is the total amount of drug 
used during preparation and Wf is the amount of free drug. 
Transmission electron microscopy (TEM) analysis was performed to visualize the 
morphology of the platinum loaded CS nanoparticles. 20 µl of the sample were drop-coated 
on to a Formvar-coated copper grids (Electron Microscopy Science, Hatfield, PA) and 
allowed to stand for 1 min. The excess fluid was gently removed using a Whatman filter 
Chapter 6 - Combinatorial-designed EGFR-targeted chitosan nanoparticles for encapsulation 
and delivery of lipid-modified platinum derivatives in wild-type and resistant NSCLC cancer cells 
 
P a g e  129 
paper and the sample was negatively stained with 1.5% uranyl acetate for 1 min, excess 
stain was removed using a Whatman filter paper and the sample was allowed to air-dry 
prior to imaging. The nanoparticles were finally visualized under a JEOL 100-X transmission 
electron microscope (Peabody, MA) operating at an accelerating voltage of 80 kV. 
2.6 Analysis of cell-kill in wild-type and resistant NSCLC cells 
A549-WTand A549-DDP resistant NSCLC cells were seeded in 96-well plates at a 
concentration of 3,000 cells/well and allowed to adhere overnight. Next day, the media was 
removed from the wells and different nanoparticle formulation was added in 100 µl of fresh 
media. The cells were incubated for 6 h at 37 °C followed by replacement of the solution 
with complete growth medium. The cytotoxic activity of formulations was evaluated after 48 
h by renewing the medium with fresh complete medium containing 100 μL of 0.5 mg/mL (3-
(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) MTT (Sigma-Aldrich, St. Louis, 
MO). After 2 h of incubation at 37 °C, the medium was discarded and 200 µl of dimethyl 
sulfoxide (DMSO) was added to each well to dissolve the formazan crystals. The 
absorbance of the colored solution was measured at 560 nm the IC50 calculated using 
GraphPad Prism® software. All treatments were performed for n=8. 
2.7 Cellular apoptotic response 
A549-WTand A549-DDP resistant were seeded in 6-well plates at a density of 0.2 x 106 
cells per well and incubated overnight at standard conditions (37°C in 5% CO2 
environment). Next day, different formulations were added to the media for 6h of incubation 
after which, the media was removed, the cells were washed twice with warm PBS and fresh 
media was added. After different time periods, total cellular RNA was isolated using the 
PureLink RNA Mini Kit (Ambion, Austin, TX). cDNA synthesis and the reverse transcription 
reaction was performed on 500 ng of total RNA from each sample with Verso cDNA 
Synthesis kit (Thermo Scientific, Tewksbury, MA) according to the manufacturer’s 
instructions. The LightCycler 480 SYBR Green I Master kit (Roche, Basel, Switzerland) was 
used for Real time polymerase chain reaction (qPCR). Regarding the primer sequences, 
the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used 
as endogenous control and the sequences used were: forward 
(ACAGTCAGCCGCATCTTC) and reverse (GCCCAATACGACCAAATCC). Caspase 3 
primer sequences were: forward (GTTTGTGTGCTTCTGAGCC) and reverse 
(CACTGTCTGTCTCAATGCC). qPCR steps included a pre-incubation step for 5 min at 95 
°C, followed by 40 cycles of three steps: 10 sec at 95 °C, 20 sec at 60 °C and 30 sec at 72 
°C. All samples were normalized to the relative levels of GAPDH, and results are expressed 
as the folds increase of levels of caspase-3 relative to non-treated cells. 
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Apoptosis detection using annexin V-FITC apoptosis detection kit I (BD Biosciences, San 
Jose, CA) was performed in order to evaluate the effect of the DDP derivatives, both in 
solution and encapsulated in nanoparticles, at their IC50 concentrations. A549-WTand 
A549-DDP resistant cells (0.2 x 106 cells per well) were seeded in 6-well plates and 
incubated overnight at 37 °C in 5% CO2 environment. Different formulations were seeded 
into the respective wells and after 6 h of incubation, the media was removed, the cells 
washed twice with warmed PBS, and fresh media added. Blank CS nanoparticles served 
as negative control for the experiment. Cells were incubated for 24 h, trypsinized, 
centrifuged and washed twice with PBS and were stained with annexin V-FITC and 
propidium iodide as per manufacturer’s protocol. The stained sample were analyzed by flow 
cytometry (BD Biosciences, San Jose, CA). 
Apoptotic cell death induced after incubation with parent cisplatin and various lipid-modified 
platinum derivatives was examined by microscopic observation of inter-nucleosomal 
fragmentation. In order to do so, we used DeadEnd™ Fluorometric TUNEL (Promega Co., 
Madison, WI, USA). A549-WTand A549-DDP resistant NSCLC were seeded (10,000 
cells/chamber) in a Falcon Lab-Tek 4-grid chamber and after 24 h, the media was removed 
and 0.6 mL of nanoparticle formulation at its corresponding IC50 was dissolved in media and 
added to the chamber. Following incubation at 37°C for 6 h, the solution was removed, the 
cells washed with PBS and new complete cell culture media added. After 24 h since 
nanoparticle treatment, the media was removed, cells were washed three times with 0.6 mL 
of cold PBS and fixed in 0.4 mL of a 3.7% formalin. Manufacturer instructions were followed 
for the remaining steps. Microscopy images were acquired using an LSM 700 confocal 
microscope (Carl Zeiss, Gottingen, Germany) equipped with 40X and 63X objectives. The 
520 and 405 nm lasers were used for the observation of fluorescein and DAPI, respectively. 
2.8 Data analysis 
Statistical analyses were performed using GraphPad Prism software (San Diego, CA). 
Paired comparisons were performed by Student's t-test. A p value of 0.05 was considered 
to be statistically significant. Data presented are means ± standard deviation. 
3. RESULTS AND DISCUSSION 
3.1 Characterization of the CS derivatives 
Control (non-targeted) CS nanoparticles were self-assembled using lipid and PEG 
derivatives of CS (1:1 mole ratio) while the EGFR targeted CS nanoparticles were self-
assembled using lipid, PEG and PEG-EGFR peptide derivatives of CS (1:1:1 mole ratio). 
Each derivative was characterized for its functional modification by 1H-NMR. Fatty acids 
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saturated chains with different number of carbons were tested (n = 4, 6, 8 and 10) in order 
to evaluate its influence on self-assembly, nanoparticle size, charge and encapsulation 
efficiency. The two blocks, CS-PEG and CS-EGFR were used to impart a hydrophilic 
characteristic to the system simultaneously harvest their other impressive features (288). 
PEG is known to confer long-circulating properties and preferential tumor targeting by 
means of the EPR effect and the EGFR peptide has shown to enhance the targeting effect 
in EGFR-overexpressing cells such as NCSLC (288, 290, 446).  
In order to improve the encapsulation of hydrophobic compounds, the third block of 
hydrophobized CS was introduced in to the nanoparticle system and different chain lengths 
tested. The library of lipid modified CS was characterized by 1H-NMR spectroscopy to 
estimate the grafting of the different fatty acids onto the chitosan backbone (Figure 38).  
 
Figure 38: 1H-NMR spectrum for the CS derivatives (CS4, CS6, CS8, CS10) obtained by the modification of 
chitosan (CS) with lipids with different carbon chain lengths. All 1H spectra were obtained in D2O with 0.2% 
DCl, 400 MHz. 
The proton peak corresponding to -CH3 group of the fatty acids was present between 0.85-
0.90 ppm and was used as the signature peak for lipid modification while the acetyl group 
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protons of CS with a peak around 2 ppm were considered the signature peak for all 
calculations. All the four lipid derivatives of CS had nearly similar modifications; CS modified 
with butanoic, hexanoic, octanoic and decanoic acids showed 56, 53, 48 and 45 % 
modification. The IR spectra from these CS derivatives also confirmed the signature 
vibrational stretches from the lipid molecules. The CS spectra showed the characteristic 
peaks for primary amine I and II bending at 1652 cm−1 and 1588 cm−1 respectively. The N-
H stretching vibrational peak that usually appears between 3200-3600 cm−1 could not be 
discerned due to a strong O-H stretching peak in the region. However, the spectra of lipid 
modified CS derivatives showed a very strong signature peaks from amide I and II observed 
at 1652 cm−1 and 1560 cm−1, suggesting formation of new amide peaks during lipid 
conjugation. More conclusively, the strong amide C=O stretching peak at 1714 cm−1 in the 
conjugate was completely absent in CS, confirming the lipid conjugation on the CS 
backbone by amide linkage. The detailed assignment of different peaks has been included 
in the supporting information (Figure 39). 
 
Figure 39: FTIR spectra of CS and CS6: The light (CS) and dark (conjugated CS) gray lines correspond to the 
FTIR spectra of CS before and after conjugation with C6 lipid chain through primary amine conjugation. The 
arrows correspond to the various bond stretches identified. 
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3.2 Characterization of the platinum derivatives 
The parent drug cisplatin was also modified with lipid chain of lengths varying from 4 to 18 
(4, 6, 8, 10, 14 and 18) to impart hydrophobicity and subsequently incorporate them in the 
lipid modified CS CS nanoparticles by virtue of hydrophobic interaction with lipid modified 
CS. All the six cisplatin prodrugs were characterized by 1H NMR, 13C NMR, 195PT NMR 
and LCMS-IT-TOF in order to verify the structural modifications. Similar results were 
obtained for all and the representative spectra are presented. All the 1H NMR spectra 
(Figure 40) contained a broad singlet peak at approximately 6.57 ppm consistent with 
platinum amine proton. 
 
Figure 40: 1H NMR spectrum (DMSO-d6) for cisplatin derivative DDP10. 
 The presence of characteristic peaks for methylene protons at 1.237 ppm substantiated 
the successful synthesis of cisplatin prodrug. The ratio between the integration values for 
the methylene protons and the amine protons indicated the presence of two lipidic ligands 
per platinum center. Despite nearly overlapping signals, the 13C NMR spectra (Figure 41) 
displayed resolved peaks for the expected number of carbon atoms. The 195Pt NMR 
resonance (Figure 42) exhibited a single peak at 1250.5 ppm consistent with other platinum 
(IV)(447, 448). The mass spectrum for individual DDP derivatives further confirms the 
presence of molecular weights corresponding to double substitution of the lipid ligand per 
platinum center. The DDP10 derivative shows a mass of 676.802 corresponding to the 
chlorine adduct [M-1+Cl] of the expected mass of the double lipid substituted DDP (Figure 
43). Lipid modification of cisplatin was efficiently achieved by conjugation of fatty anhydrides 
with varying alkyl chains lengths into the coordination sphere of a cis,cis,trans-
[Pt(NH3)2Cl2L2], platinum(IV) complex, where L represents a hydrophobic axial ligands.  
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Figure 41: 13C NMR spectrum (DMSO-d6) for cisplatin derivative DDP10. 
 
Figure 42: 195Pt NMR spectrum (DMSO-d6) for cisplatin derivative DDP10. 
3.3 Characterization of the platinum encapsulated chitosan nanoparticles  
The graphical abstract shows the general scheme of synthesis of different lipid CS and 
platinum derivatives and their mix and match with PEG and PEG-EGFR derivative of CS to 
combinatorially design drug-encapsulated nanoparticles. In aqueous environment, the lipid-
modified CS could easily self-assemble to form micelles and the micelle core can non-
specifically entrap lipophilic drugs through hydrophobic interactions. To better evaluate the 
nanoparticle self-assembly and drug encapsulation characteristic, the 4 chitosan derivatives 
and six platinum derivatives were used to produce a library of twenty-four drug loaded 
nanoparticles along with 6 self-assembled nanoparticle formulations of lipid modified 
platinum derivatives.  
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Figure 43: Mass spectrum of the DDP10 derivative. The LCMS-IT-TOF analysis of DDP10 derivative in negative 
mode shows the peak at 676.802 corresponding to the chlorine adduct [M-1+Cl] of the derivative with expected 
mass of a double C10 lipid substituted DDP. 
Presence or absence of the EGFR-CS derivatives therefore gives a library of 24 non-
targeted and 24 EGFR-targeted CS nanoparticles that could be evaluated for their anti-
cancer properties. This combinatorial approach towards designing the drug candidate and 
the delivery platform to produce a “mixed and matched library” of nanoparticles, enabling 
us to perform rigorous study of the effect of hydrophobic interactions on the physical 
properties of the nanoparticles, their self-assembling behavior and their drug delivery 
efficacy. The effect of the lipid chain present both on the CS backbone and on encapsulation 
of platinum derivatives was initially studied for the hydrodynamic diameter and 
polydispersity index of the nanoparticles, their zeta potential and their drug encapsulation 
capability (Table 10).  
Nanoparticle tracking analysis confirmed that the lipid-derived DDP could self-assemble to 
form nanoparticles in an aqueous environment (Figure 44). The average particle sizes of 
the different formulations varied from 220 to 365 nm, with the exception of nanoparticles 
obtained from two combinations: cisplatin modified with fourteen (DDP14) and eighteen 
(DDP18) carbon lipid chains encapsulated with CS modified with octanoic acid (CS4), 
designated by CS4-DDP14 and CS4-DDP18, respectively. These two formulations gave 
values much lower than the rest, and we believe that the drug could not be successfully 
encapsulated in these nanoparticles due to the weak hydrophobic interaction between the 
short lipid chain on the CS backbone and the long lipid chain on the DDP. These two 
formulations also show a very low drug encapsulation efficiency (CS4-DDP14 = 36% and 
CS4-DDP18 = 22%) compared to the other formulations (Table 10D), which corroborates 
with our theory. 
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Table 10: Physical Characterization of Combinatorial-Designed Control and Epidermal 
Growth Factor Receptor-Targeted Chitosan Nanoparticlesa 
 
The library of 24 nanoparticles were characterized for the particle size (A), polydispersity Index (B), zeta-
potential (C) and cisplatin encapsulation efficiency (D) variations. All particles had also chitosan-PEG and 
chitosan-PEG-EGFR conjugates in their constitution together with the CS modified with fatty acids. All 
nanoparticles were synthesized with 1:1:1 molar ratio of lipid, PEG and EGFR derivative of CS. Encapsulation 
efficiency was evaluated by HPLC by a direct method. 
 
Figure 44: Nanosight DLS measurement of the DDP8 and DDP10 nanoparticles. The DDP8 (top panel) and 
DDP10 (bottom panel) derivatives were suspended in water to allow the self-assembly, forming nanoparticles. 
The measurement shows the morphology of the particles (left) and their size distribution (right). The average 
particle size for the DDP8 and DDP10 nanoparticles was 130 and 185 nm, consistent with the previously 
measured values. 
In the optimization step, the same results of encapsulation efficiency were obtained for 
several formulations by the indirect and direct methods. Since the direct method is known 
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to give a more realistic result, we decided to use the direct method for all of our samples for 
any further analysis. Table 11 gives the retention times of different lipid derivatives of 
cisplatin. An increase in the retention time of the derivatives as a function of the increasing 
chain length of the lipid was expected due to increased interaction of the platinum 
derivatives with the reverse phase C18 column. A standard curve was generated for each 
derivative to assess the drug encapsulation efficiency of the corresponding nanoparticle. 
HPLC chromatograms used to determine pro-drug encapsulation efficiency have been 
provided in the supporting information (Figure 45). Since the nanoparticles are disrupted 
and there is separation of the CS derivatives from the DDP palatinate derivatives, it makes 
us possible to use HPLC as technique to quantify the drug encapsulation efficiency at the 
260 nm wavelength. The HPLC method is simple, direct, good linear, sensitive, accurate 
and robust for the quality analysis of cisplatin that is pertinent to this study. 
 Table 11: Retention Times of Cisplatin and 
Lipid-Modified Platinum Derivatives 
Compound Retention time (min) 
DDP 5.70 
DDP4 7.82 
DDP6 8.11 
DDP8 8.64 
DDP10 9.70 
DDP14 15.72 
DDP18 28.76 
 
Among the 24 formulations, the ones containing DDP4 and DDP6 showed lower 
encapsulation efficiency and larger hydrodynamic diameter sizes with greater variability in 
the physical properties. This could be probably due to weaker hydrophobic interaction 
between the smaller lipid chains of CS and cisplatin, therefore affecting the self-assembly 
of the lipid derivatives and forming less compact nanoparticles. These nanoparticle 
formulations were therefore eliminated from the further evaluations. 
3.4. In vitro cell-kill efficacy in wild-type and resistant NSCLC cells 
The remaining 16 self-assembled nanoparticles formulations were evaluated for the in vitro 
activity of the encapsulated drug in A549-WT and A549-DDP resistant cells (Table 12) and 
the results were compared with the derivatives in solution as well as unmodified cisplatin. 
The parent cisplatin showed an IC50 of 12.24 µM in A549-WTand 140.73 µM in A549-DDP 
resistant cells, confirming the drug resistant phenotype of A549-DDP cells. The DDP8 and 
  
P a g e  138 
DDP10 derivatives improved the potency of the encapsulated drug and decreased the IC50 
in both the cell lines. However, the same effect was not observed with DDP14 and DDP18 
where the IC50 value increased to 35.8 ± 5.2 µM and 198.3 ± 27.7 µM, respectively in A549-
WTand 453.2 ± 65.4 µM and 954.0 ± 123.5 µM, respectively, in A549-DDP resistant cells.  
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Figure 45: HPLC chromatograms used to determine pro-drug encapsulation efficiency. Spectra A-G refer to 
individual prodrugs while H-N refer to prodrugs extracted from CS nanoparticles. The direct method was used 
to assayed the encapsulation efficiency of palatinate pro-drugs encapsulated in CS nanoparticles. Nanoparticles 
spectra refer to formulations where CS8 was used but similar ones were obtain for CS4, CS6 and CS10 
formulations. Spectra were obtained from the following standard solutions or formulations: (A) DDP standard 
solution, (B) DDP4 standard solution, (C) DDP6 standard solution, (D) DDP8 standard solution, (E) DDP10 
standard solution, (F) DDP14 standard solution, (G) DDP18 standard solution, (H) CS8-DDP4 formulation, (I) CS8-
DDP6 formulation, (J) CS8-DDP8 formulation, (K) CS8-DDP10 formulation, (L) CS8-DDP14 formulation, (M) CS8-
DDP18 formulation, (N) Blank nanoparticles. Chromatographic conditions: reverse phase C18 column with a C18 
pre-column; mobile phase, 1:1 methanol/water (v/v) used at a rate of 0.5 mL/min; detection, 260 nm. 
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This dramatic loss of activity in longer lipid chain platinum derivatives might be related to 
the trapping for the drug in the exoplasmic leaflet bilayer, thereby losing access to the 
cytosolic leaflet (449). The prodrugs were dispersed at a high concentration in DMSO and 
subsequently diluted in culture media for dosing the cells in cytotoxicity studies and the 
effective final DMSO concentration (<0.1%) as control did not show any adverse effects on 
the viability of the cells.  
Table 12: IC50 values of platinum derivatives in solution or encapsulated in EGFR-targeted 
chitosan nanoparticles.  
A 
IC50 (nM)  
± SD 
A549 Wild Type 
(IC50 free cisplatin = 12.24 µM) 
 
No DDP 
Platinum Derivatives 
 DDP8 DDP10 DDP14 DDP18 
In solution - 2.7 ± 1.2 *** 1.3± 0.1 *** 35.8± 5.2*** 198.3± 27.7 
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 CS4 n.o.t 10.0 ±2.4 7.7±1.0 * 4.8±0.6 ** 1.2±0.1 *** 
CS6 n.o.t 1.6 ±0.2 *** 1.4±0.24 *** 6.1±0.8 * 3.0±0.4 ** 
CS8 n.o.t 0.9 ±0.3 *** 0.6±0.1 *** 0.8±0.1 *** 0.8±0.1 *** 
CS10 n.o.t 2.4 ±0.4 *** 1.8 ±0.2 *** 1.6±0.2 *** 6.2±0.8 * 
 
B 
IC50 (nM)  
± SD 
A549-DDP 
(IC50 free cisplatin = 140.73 µM)  
 
No DDP 
Platinum Derivatives 
 DDP8 DDP10 DDP14 DDP18 
In solution n.o.t 70.7±9.8 *** 28.3±3.9 *** 453.2±65.4 954.0 ±123.5 
C
S
 n
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rt
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s
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y
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 CS4 n.o.t 113.8±15.9 ** 87.8±12.8 *** 54.4±7.6 *** 24.8±3.4 *** 
CS6 n.o.t 28.1±3.9 *** 26.5±3.8 *** 69.7±9.7 *** 33.9±4.7 *** 
CS8 n.o.t 20.4±2.8 *** 17.4±2.4 *** 19.1±2.6 *** 19.9±2.7*** 
CS10 n.o.t 27.2±3.8 *** 30.8±3.5 *** 29.2±4.0 *** 71.0±9.7 *** 
IC50 values were obtained by incubating human cancer cell lines A549 wild type (A) and A549-DDP resistant 
(B) with serial dilutions of the different derivatives in solution or encapsulated in CS nanoparticles followed by 
cell viability was assessment using the MTT assay. Values are shown as mean values ± standard deviation for 
three independent determinations. ***p< 0.01, **p< 0.05, *p< 0.1 when compared to IC50 for free cisplatin. n.o.t: 
No observed toxicity. 
The EGFR-targeted hydrophobic derivatives of CS themselves did not show any cytotoxic 
effect of the cells, demonstrating that the derivatized chitosan continues to be a non-toxic 
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material as described in earlier literature(269, 450). All the formulations except DDP8 
encapsulated in CS4 showed a significantly higher cytotoxicity than the respective 
derivatives in solution or parent drug, confirming that the CS derivatives are able to 
efficiently deliver the platinum derivatives to the cancer cells. More importantly, the drug 
activity is improved in the A549-DDP resistant cells, suggesting that the drug encapsulated 
in hydrophobized CS helps overcoming drug resistant property of the A549-DDP cells. We 
also observed that the nanoparticles encapsulating DDP14 and DDP18 showed effective cell 
killing efficiency unlike the corresponding lipid-modified platinum derivatives when 
administered in solution, highlighting the merit of the delivery vector. Most importantly, we 
have demonstrated in our earlier work that these EGFR-targeted CS nanoparticles 
selectively target the overexpressed receptor on the surface of A549 sensitive and resistant 
cells and their improved cytotoxic activity is associated with receptor-mediated 
endocytosis(288).  
The candidate selection from a library of such formulations is a vital parameter to consider 
in eliminating any influence of the physical characteristics of the nanoparticle on its in vitro 
and in vivo activity. All CS8 formulations gave comparable sizes, surface charge, drug 
encapsulation efficiency as well as identical IC50 values for different platinum derivatives in 
both A549-WTand A549-DDP resistant cells and were, therefore, selected for further 
evaluation. Importantly, the preferred nanoparticle size limit to achieve tumor penetration 
by EPR effect has been documented as < 300 nm and all the CS8 formulations show sizes 
between 230 - 270 nm (451). Therefore, they serve as ideal candidates for future animal 
studies and were explored further in this study. 
Nanoparticles obtained by self-assembling CS8 derivative in the presence of DDP8, DDP10, 
DDP14 and DDP18 were negatively stained with 1.5% uranyl acetate and were visualized 
under TEM to observe their morphology (Figure 46). All four nanoparticle systems showed 
a spherical morphology with an average size (obtained from measuring the size of 30 
individual particles across different regions of interest) smaller than that obtained by DLS 
measurement (Table 10). This was expected since TEM images show the actual size of the 
particles unlike DLS measurement that gives the hydrodynamic diameter. The TEM images 
confirm that lipid-modified CS forms self-assembled, micelle like spherical particles in an 
aqueous environment. 
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Figure 46: Transmission electron microscopy images of epidermal growth factor receptor-targeted chitosan 
nanoparticles. The lipid-modified platinum derivatives (C8, C10, C14 and C18) were encapsulated in CS8 
nanoparticles and negatively stained with 1.5% uranyl acetate prior to imaging. The corresponding particle size 
distribution plot as inset in each image has been calculated from a minimum of 30 nanoparticles for the 
respective sample. Scale bar in all images corresponds to 100 nm. 
3.5 Cellular apoptosis studies 
In order to confirm that the cytotoxicity of the parent and the hydrophobic platinum 
derivatives is due to induction and upregulation of apoptotic pathways, quantitative and 
qualitative apoptotic analysis was performed in A549-WTand A549-DDP resistant cells. All 
the formulations were dosed at their corresponding IC50 value to confirm that their in vitro 
cytotoxic activity is mediated by apoptotic pathway and not through any alternate 
mechanism. Since the cytotoxic effect at the corresponding IC50 concentration would be 
uniform across all the samples, any difference in the route of the cytotoxic effect could be 
easily discerned. 
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Caspase-3 is an “effector” caspase associated with the initiation of the apoptotic-signaling 
pathway and thus is used as a marker of the cell’s entry point into the “death cascade” 
(452). Since initiation of caspase-3 activity is an early event in the apoptotic pathway, 
expression levels of the enzyme was measured after 12, 18 and 24 h of incubation with the 
platinum derivatives encapsulated in CS8 nanoparticles and was compared to the activity 
by the corresponding derivative in solution (Figure 47).  
 
Figure 47: Caspase-3 expression level in A549-WT(A) and A549-DDP resistant (B) non-small cell lung cancer 
cells after 24 hours treatment with platinum derivatives, both in solution and encapsulated in CS8 nanoparticles, 
at their IC50 concentrations. Caspase-3 mRNA expression was normalized to GAPDH expression and 
presented as a percentage of the level in untreated cellular controls. Bars represent the mean ± standard 
deviation from three independent experiments. ** = p < 0.01 compared to the untreated group at the 
correspondent time point. 
All the cells were dosed with formulations at their IC50 values to maintain uniformity in the 
drug activity (Table 13). Caspase-3 mRNA expression was normalized to GAPDH 
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expression and presented as a percentage of the level in untreated cellular controls. No 
significant change in the caspase-3 expression level was observed when cells were tested 
with CS8 alone, which indicated its non-cytotoxic nature. The DDP14 and DDP18 in solution 
were omitted from these studies due to their poor in vitro cytotoxic activity. For the parent 
cisplatin in solution as well as for all the lipid-modified platinum derivatives, from 12h to 24h, 
caspase-3 expression levels were significantly higher than in the untreated cells or cells 
treated with CS8 only. This is observed both in A549-WTand A549-DDP resistant cells, 
showing the induction of apoptosis. We confirmed that hydrophobic modifications of 
cisplatin and its encapsulation in hydrophobic CS was able to induce apoptosis even at 
much lower concentrations of the drug, in line with the in vitro cytotoxicity results. 
Table 13: Cell-kill efficacy as measured by IC50 values of values of platinum derivatives 
encapsulated in solution or encapsulated in CS8 nanoparticles that were tested for cellular 
apoptosis studies. 
 A549 Wild-Type A549-DDP 
 
IC50 value 
Fold  
improvement 
IC50 value 
Fold  
improvement 
DDP 12.24 ± 4.2 - 140.73 ± 6.5 - 
DDP8 2.7 ± 1.2 4.5 70.7 ± 9.8 2.0 
DDP10 1.3 ± 0.1 9.4 28.3 ± 3.9 5.0 
DDP14 35.8 ± 5.2 0.3 453.2 ± 65.4 0.3 
DDP18 198.3 ± 27.7 0.1 954 ± 123.5 0.1 
CS8-DDP8 0.9 ± 0.3 13.6 20.4 ± 2.8 6.9 
CS8-DDP10 0.6 ± 0.1 20.4 17.4 ± 2.4 8.1 
CS8-DDP14 0.8 ± 0.1 15.3 19.1 ± 2.6 7.4 
CS8-DDP18 0.8 ± 0.1 15.3 19.9 ± 2.7 7.1 
 
Apoptotic activity was additionally monitored by flow cytometry using annexin V-FITC 
staining to detect translocation of phosphatidylserine to the outer leaflet of cell membrane, 
an event that occurs early in apoptosis (453). A549 and wild-type A549-DDP resistant were 
treated for 24 h with cisplatin in solution, different platinum derivatives in solution or 
encapsulated in CS8 as well as CS8 alone. Cisplatin and its lipid-modified derivatives were 
tested at their determined IC50 concentrations (Table 13). Once again, DDP14 and DDP18 
derivatives in solution were not tested due to their poor in vitro cytotoxic activity. The results 
indicated that control cell samples and cells treated with CS8 had a very low apoptotic index, 
indicating that the hydrophobic chitosan nanoparticles on their own do not show any 
cytotoxic effect (Figure 48 and Figure 49).  
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Figure 48: Analysis of cell death effect of cisplatin and lipid-modified platinum (DDP) derivatives encapsulated 
in CS8 hydrophobic derivative at their IC50 concentration. Apoptosis was determined in A549-WT (A) and A549-
DDP (B) by flow-cytometric detection of annexin V-FITC-positive cells after 24 h of incubation with DDP 
derivatives, both in solution and encapsulated in nanoparticles, at their IC50 concentrations. Cells were also 
incubated with CS8 to check for toxicity coming from the chitosan derivative. Bars represent the mean ± standard 
deviation from three independent experiments. ** = p < 0.01 compared to the untreated group. 
In all the drug treatment groups in both the cell lines, a significant increase in annexin V 
positive cells was observed compared to control cells, being this effect in apoptosis 
induction indistinguishable between the different treatments with cisplatin and lipid-modified 
platinum derivatives in solution or encapsulated in CS8 nanoparticles. This observation 
suggests that the platinum derivatives (DDP8 and DDP10) were able to efficiently trigger cell 
apoptosis even at a lower concentration than the parent cisplatin. Overall, DDP derivatives 
in solution proved to be more potent than cisplatin in eliciting an apoptotic response, and 
when encapsulated in CS8 nanoparticles they are efficient even at lower doses. 
A qualitative assessment of cellular apoptosis using TUNEL assay was performed 
in order to visually detect DNA fragmentation in the apoptotic cells. DNA strand breaks 
during apoptosis, which generates free 3′-OH ends that can be detected by TUNEL assay.  
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Figure 50 shows TUNEL staining images of A549-WTand A549-DDP cells treated with 
cisplatin in solution, and the platinum derivatives in solution, DDPn-CS8 formulations and 
CS8 alone after 24 h of incubation at their corresponding IC50 concentrations (Table 4). Apart 
from control and CS8-treated cells, all other treatment groups exhibited consistent 
accumulation of TUNEL-positive apoptotic population of cells. 
 
Figure 49: Annexin V-PI analysis for Apoptotic population of A549-DDP cells. The two-dimensional plot for 
apoptosis assay using Annexin V−PI staining in A549-DDP cells after treatment with DDP and lipid-modified 
DDP derivatives encapsulated in CS8 derivative at their IC50 concentration. Apoptosis was determined by flow 
cytometry after 24 h of drug treatment. Cells incubated with CS8 empty nanoparticles served as positive control 
to evaluate the toxicity of blank nanoparticles. Total number of events: 10,000. 
Collectively, the data from our cytotoxic assays and evaluation of apoptotic events showed 
that while CS8 alone had no significant toxic effect, a strong apoptotic response was 
achieved by the DDP8 and DDP10 derivatives at very lower concentrations as compared to 
parent cisplatin.  Furthermore, a significant improvement in their activity was achieved when 
encapsulated with hydrophobic CS8, as judged by the significant decrease in their IC50, yet 
Chapter 6 - Combinatorial-designed EGFR-targeted chitosan nanoparticles for encapsulation 
and delivery of lipid-modified platinum derivatives in wild-type and resistant NSCLC cancer cells 
 
P a g e  147 
maintaining the same effects in terms of apoptosis induction. Introduction of a lipid chain 
improved the cisplatin apoptotic efficiency in the case of membrane-permeable DDP8 and 
DDP10, but the same did not apply to DDP14 and DDP18. In case of these last two derivatives, 
the introduction of a long hydrophobic chain has probably produced a compound likely to 
be entrapped in the lipid bilayer membranes, resulting in poor drug transport to the 
intracellular compartment for enhanced efficacy.  
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Figure 50. TUNEL staining images of (A) A549-WTand (B) A549DDP cells treated with lipid-modified 
platinum derivatives CS formulations. Cell’s nucleus was stained with DAPI. In the merge images DAPI is 
shown in blue and the TUNEL staining in green. Images obtained at 10× magnification. Scale bar = 100 
µm 
Encapsulation of the four platinum derivatives with CS8 to form nanoparticles improved the 
cellular uptake, which may be due the specific receptor-mediated endocytosis in both A549-
WT and A549-DDP resistant cells while the parent cisplatin and the derivatives when in 
solution enter the cells via passive permeation (454).  
These results are in agreement with our previous reports as to the potential advantage of 
using EGFR as an active targeting moiety for lung tumor specific drug delivery (288, 290). 
It is noteworthy that CS8 nanoparticles have three blocks in their constitution that can 
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contribute for an enhanced efficacy: an hydrophobic modified block, responsible for 
interacting with hydrophobic modified platinum; a PEG-modified block, highly soluble in 
aqueous solutions; and an EGFR-peptide modified block, as a the targeting modality since 
it is overexpressed in both A549-WT and A549-DDP resistant cell lines (288). 
In this study, we have successfully synthesized CS modified with lipid, PEG and EGFR. 
Together they were able to self-assemble into nanoparticles in water and be utilized to 
deliver a hydrophobic derivative of the antitumor drug cisplatin. Based on a combinatorial 
approach, we evaluated the effect of different lipid chain lengths on nanoparticles 
physicochemical characteristics but also encapsulation efficiency and in vitro cytotoxicity 
studies. These studies indicated that the CS therapeutic platinum nanoformulations were 
more effective for suppressing cellular growth in both sensitive and resistant lung cancer 
cells than the drug solution. The remarkable increase in potency with this combination of 
platinum hydrophobic derivatives in a 3-block CS system can be a benefit to therapy and 
also limit toxic side effects. An especially interesting feature of this nanomedicine design is 
the versatility and customizable method that can be specifically designed to be able to load 
different therapeutic cargos with different hydrophobicities. The multifunctionality of this 
novel CS-targeted platinum loaded formulations holds promising results as it not only 
empowers co-delivery of combinatorial drugs but also has the potential to reduce the toxicity 
associated with these drug by reducing the therapeutic dose 
. 
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General conclusions 
The dismal 15% of 5-year survival rate makes lung cancer as the leading cause of cancer-
related deaths. NSCLC is the leading cause of cancer-related deaths worldwide and 
accounts for 85% of all cases of lung cancer (455). Cancer being a disease of rapidly 
dividing cells, targeting molecular components that act during mitosis has emerged as an 
attractive therapeutic opportunity for new cancer therapies. This approach represents an 
appealing strategy to kill cancer cells, especially those with high rate of proliferation (407).  
In this study, we have developed an EGFR-targeted chitosan nanoparticles for silencing the 
mad2 gene as a strategy to efficiently induce cell death in EGFR overexpressing human 
lung cancer cells. We have chosen the mitotic checkpoint component, Mad2, as the 
molecular target since it is a key cell cycle component that ensures an accurate segregation 
of chromosomes during mitosis by delaying the onset of anaphase until all chromosomes 
are properly attached to a bipolar mitotic spindle. Failure in the mitotic checkpoint leads to 
severe chromosome missegregation and cell death. While a weakened mitotic checkpoint 
is frequently seen in cancer cells and may contribute to tumorigenesis, a severe loss in 
checkpoint signalling is a possible anticancer strategy (189). In order to suppress mad2 
gene, siRNA-mediated knockdown was implemented. Intracellular delivery of highly labile 
biomolecules such as siRNA is a challenging task. CS was explored as siRNA vector due 
to its cationic polyelectrolyte nature, low toxicity, mucoadhesion, biodegradability and 
biocompatibility(456). Furthermore, a EGFR-binding peptide was used as targeting moiety 
that has previously demonstrated efficient targeting of EGFR receptor and its targeting 
capability has been successfully validated in vitro as well as in vivo in various EGFR-
overexpressing tumor cells such as A549 (311, 316, 317, 369-371). 
Initially, CS of two molecular weights (50 and 90 kDa) were tested in the optimization 
process but the one with an average molecular weight of 50 kDa showed better in vitro 
results overall. In order to increase its solubility and achieve longer blood-circulating half-
life, CS was modified with PEG chains prior to the modification with EGFR-binding peptide. 
SiMad2-loaded CS nanoparticles were formed by self-assembly when positively charged 
CS couls electrostatically bind and encapsulate the negatively charged nucleic acids. These 
nanoparticles were characterized for their size, surface charge, morphology, encapsulation 
efficiency and stability. In vitro studies were performed to demonstrate efficient gene 
silencing by both TG and NTG nanoparticles in EGFR overexpressing human A549 NSCLC 
cells. Nevertheless, the EGFR-targeted CS system exhibited higher and selective uptake, 
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indicating that TG nanoparticles are rapidly internalized within the cells by receptor-
mediated endocytosis, culminating into an enhanced apoptotic cell death.  
The in vitro studies also verified that Mad2 knockdown results in massive cell death by 
apoptosis of A549 cells while the cytotoxic impact was significantly less in the non-
cancerous human lung primary cell line; and this helped us assess a therapeutic window. 
Since the mitotic checkpoint protein, Mad2 is only needed during cell division, its depletion 
would selectively affect proliferating tissues; therefore, cancer cells with high cell 
proliferation rate would be much more prone to anti-Mad2 therapy compared to their normal 
counterpart. 
The next step was to assess the pharmacokinetics and biodistribution profile of siMad2 
encapsulated in NTG or TG CS nanoparticles in A549-WT and cisplatin resistant A549-DDP 
tumor-bearing mice via intravenous administration at a dose of 3 mg/kg. The differences in 
the biodistribution were studied qualitatively and quantitatively. Qualitative biodistribution 
profile based on near-IR labeled CS nanoparticles showed a long-lasting exposure of the 
tumor (up to 96 h) to the nanoparticles, independent of the tumor model or targeting 
property. A quantitative pharmacokinetic study was performed based on siMad2 
quantification. Non-compartmental analysis for both tumor models showed that the 
presence of targeting peptide lead to a significant decrease in plasma exposure of targeted 
nanoparticles. The targeting strategy led to a higher targeting efficiency, i.e. a higher tumor 
exposure to Mad2-siRNA. The advantage of the targeting strategy was particularly clear for 
the A549-DDP model, with a higher increase of tumor exposure and targeting efficiency. 
After verifying Mad2 knockdown in the tumors by both NTG and TG formulations, we tested 
their effect on tumor growth inhibition. The antitumor efficacy of TG and NTG nanoparticles 
was tested as a single therapy and in combination with cisplatin in A549-WT and cisplatin-
resistant, A549-DDP subcutaneous tumor models of NSCLC. SiMad2-loaded NTG and TG 
nanoparticles were injected intravenously at a dose of 3 mg/kg of siMad2 and cisplatin was 
used at a dose 1 mg/kg. For both tumor models, the administration of cisplatin in 
combination with Mad2 siRNA-loaded nanoparticles exhibited higher tumor inhibition than 
cisplatin in solution. This fact was even more pronounced in the cisplatin-resistant tumor 
models indicating that Mad2 may be promising in mitigating the molecular mechanisms of 
cisplatin resistance and enhancing therapeutic efficacy.  
Finally, an endeavor was made to develop CS-based platform technology for delivery of 
small molecule along with nucleic acid for such combination therapies. We developed a 
strategy to deliver cisplatin encapsulated in CS nanoparticle in an attempt to improve its 
bioavailability and reduce the associated toxicity by reducing its therapeutic dose and off-
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target effects. In order to achieve this, we synthesized CS modified with lipid chains and 
used it as a 3-block CS system along with CS modified with PEG and EGFR to self-
assemble into nanoparticles. Simultaneously, cisplatin was derivatized with lipid chains to 
impart it a hydrophobic characteristics and allow its encapsulation within the hydrophobic 
pockets of the 3-block nanoparticle system. In the in vitro studies, this system proved to be 
more effective in suppressing cellular growth in both sensitive and resistant lung cancer 
cells compared to the drug solution. This novel EGFR-targeted platinum-loaded CS 
formulation presents with promising opportunity to perform in vivo studies using it as a single 
therapy or in combination with Mad2 siRNA-loaded nanoparticles. 
Collectively, our results indicate that Mad2 has a huge potential as a therapeutic molecular 
target for cancer treatment and that RNAi therapeutics could effective in curbing cancer as 
a disease when delivered through a suitable delivery vector such as CS nanoparticles.  
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